<?xml version="1.0" encoding="utf-8"?>
<Label drug="Nexterone" setid="e9108958-b8d7-4fba-87c3-9a32990de551">
<Text><Section name="DOSAGE &amp; ADMINISTRATION SECTION" id="34068-7">
2 DOSAGE AND ADMINISTRATION 

 Amiodarone shows considerable interindividual variation in response. Although a starting dose adequate to suppress life-threatening arrhythmias is needed, close monitoring with adjustment of dose is essential. The recommended starting dose of NEXTERONE is about 1000 mg over the first 24 hours of therapy, delivered by the following infusion regimen: 

 Table 1: NEXTERONE PREMIXED INJECTION DOSE RECOMMENDATIONS: FIRST 24 HOURS 

 Loading infusions 

 First Rapid: 

 150 mg over the FIRST 10 minutes (15 mg/min). 

 Directly infuse NEXTERONE Premixed Injection (150 mg/100 mL; 1.5 mg/mL) at a rate of 10mL/min. 

 Followed by 

 Slow: 

 360 mg over the NEXT 6 hours (1 mg/min). 

 Directly infuse NEXTERONE Premixed Injection (360 mg/200 mL; 1.8 mg/mL) at a rate of 0.556 mL/min. 

 Maintenance infusion 

 540 mg over the REMAINING 18 hours (0.5 mg/min ). Decrease the rate of the slow loading infusion to 0.5 mg/min. Directly infuse NEXTERONE Premixed Injection (360 mg/200 mL; 1.8 mg/mL) at a rate of 0.278 mL/min. 

 After the first 24 hours , continue the maintenance infusion rate of 0.5 mg/min (720 mg per 24 hours) by directly infusing NEXTERONE Premixed Injection (360 mg/200 mL; 1.8 mg/mL) at a rate of 0.278 mL/min. The rate of the maintenance infusion may be increased to achieve effective arrhythmia suppression. 
 In the event of breakthrough episodes of VF or hemodynamically unstable VT, use 150 mg supplemental infusions of NEXTERONE (infused over 10 minutes to minimize the potential for hypotension). 
 The first 24-hour dose may be individualized for each patient; however, in controlled clinical trials, mean daily doses above 2100 mg were associated with an increased risk of hypotension. Do not exceed an initial infusion rate of 30 mg/min. 
 Based on the experience from clinical studies of intravenous amiodarone, a maintenance infusion of up to 0.5 mg/min can be continued for 2 to 3 weeks regardless of the patient's age, renal function, or left ventricular function. There has been limited experience in patients receiving intravenous amiodarone for longer than 3 weeks. 
 Administer NEXTERONE, whenever possible, through a central venous catheter dedicated to that purpose. Use an in-line filter during administration. 
 Intravenous amiodarone loading infusions at much higher concentrations and rates of infusion much faster than recommended have resulted in hepatocellular necrosis and acute renal failure, leading to death [see Warnings and Precautions (5.3) ]. 
 Intravenous amiodarone concentrations greater than 3 mg/mL have been associated with a high incidence of peripheral vein phlebitis; however, concentrations of 2.5 mg/mL or less appear to be less irritating. Therefore, for infusions longer than 1 hour, do not exceed NEXTERONE concentrations of 2 mg/mL, unless a central venous catheter is used [see Adverse Reactions (6.2) ] . 

 NEXTERONE Premixed Injection is available in GALAXY containers as a single-use, ready-to-use, iso-osmotic solution in dextrose for intravenous administration. No further dilution is required. NEXTERONE Premixed Injection should not be combined with any product in the same intravenous line or premixed container. Do not add supplemental medication. Protect from light until ready to use. 
 NEXTERONE does not need to be protected from light during administration. 
 Since the premixed container is for single-use only, any unused portion should be discarded. 
 NOTE: Inspect parenteral drug products for particulate matter and discoloration prior to administration, whenever solution and container permit, solution should be clear. Visually inspect the container. If the administration port protector is damaged, detached or not present, discard the container as the solution path sterility may be compromised. Check for minute leaks prior to use by squeezing the bag firmly. If leaks are detected, discard solution as sterility may be impaired. 
 CAUTION: Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is complete. 
 Preparation of NEXTERONE Premixed Injection for administration: 

 1. Suspend container from eyelet support. 

 2. Remove protector from outlet port at bottom of container. 

 3. Attach administration set. Refer to complete directions accompanying set. 

 Admixture Incompatibility 
 Amiodarone in D5W Injection forms precipitates with the drugs shown in Table 2. If co-administration of the following drugs is necessary, use separate intravenous administration lines. 

 Table 2: Y-SITE INJECTION INCOMPATIBILITY 

 D5W = Dextrose 5% in Sterile Water, NS = Normal Saline 

 Drug 

 Vehicle 

 Amiodarone Concentration 

 Aminophylline 

 D5W; NS 

 4 mg/mL 

 Amoxicillin Sodium-Clavulanic Acid 

 unknown 

 12.5 mg/mL 

 Ampicillin Sodium-Sulbactam Sodium 

 NS 

 6 mg/mL 

 Argatroban 

 D 5 W 

 1.8 mg/mL 

 Bivalirudin 

 D 5 W 

 4 mg/mL 

 Cefamandole Nafate 

 D 5 W 

 4 mg/mL 

 Cefazolin Sodium 

 D 5 W 

 4 mg/mL 

 Ceftazidime 

 D 5 W 

 6 mg/mL 

 Digoxin 

 D 5 W 

 6 mg/mL 

 Furosemide (10 mg/mL) 

 D 5 W 

 6 mg/mL 

 Mezlocillin Sodium 

 D 5 W 

 4 mg/mL 

 Heparin Sodium 

 D 5 W 

 -- 

 Imipenem-Cilastin Sodium 

 D 5 W 

 6 mg/mL 

 Magnesium Sulfate (500 mg/mL) 

 D 5 W 

 6 mg/mL 

 Micafungin 

 NS 

 4 mg/mL 

 Piperacillin Sodium –Tazobactam Sodium 

 D 5 W 

 6 mg/mL 

 Potassium Phosphates 

 D 5 W 

 6 mg/mL 

 Sodium Bicarbonate 

 D 5 W 

 3 mg/mL 

 Sodium Nitroprusside 

 D 5 W 

 1.5, 6 and 15 mg/mL 

 Sodium Phosphates 

 D 5 W 

 6 mg/mL 

 Intravenous to Oral Transition 
 Patients whose arrhythmias have been suppressed by NEXTERONE may be switched to oral amiodarone. The optimal dose for changing from intravenous to oral administration of amiodarone will depend on the dose of NEXTERONE already administered, as well as the bioavailability of oral amiodarone. When changing to oral amiodarone therapy, clinical monitoring is recommended, particularly for elderly patients. See package insert for oral amiodarone. 
 Since grapefruit juice is known to inhibit CYP3A-mediated metabolism of oral amiodarone in the intestinal mucosa, resulting in increased plasma levels of amiodarone, do not drink grapefruit juice during treatment with oral amiodarone [see Drug Interactions (7) ]. 
 Table 3 provides suggested doses of oral amiodarone to be initiated after varying durations of NEXTERONE administration. These recommendations are made on the basis of a similar total body amount of amiodarone delivered by the intravenous and oral routes, based on 50% bioavailability of oral amiodarone. 

 Table 3: RECOMMENDATIONS FOR ORAL DOSAGE AFTER INTRAVENOUS INFUSION 

 Duration of NEXTERONE Infusion Assuming a 720 mg/day infusion (0.5 mg/min). 

 Initial Daily Dose of Oral Amiodarone 

 &lt; 1 week 

 800-1600 mg 

 1-3 weeks 

 600-800 mg 

 &gt; 3 weeks NEXTERONE is not intended for maintenance treatment. 

 400 mg 

 • The recommended starting dose is about 1000 mg over the first 24 hours of therapy, delivered by the following infusion regimen (2) : 

 o Initial Load: 150 mg in 100 mL infused over 10 minutes 

 o Followed by: 1 mg/min for 6 hours 

 o Followed by: 0.5 mg/min thereafter 

 • For breakthrough episodes of VF or hemodynamically unstable VT , repeat the Initial Load (2)</Section>
<Section name="CONTRAINDICATIONS SECTION" id="34070-3">
4 CONTRAINDICATIONS 

 NEXTERONE is contraindicated in patients with: 

 • Known hypersensitivity to any of the components of NEXTERONE Premixed Injection, including iodine. Hypersensitivity reactions may involve rash, angioedema, cutaneous/mucosal hemorrhage (bleeding), fever, arthralgias (joint pains), eosinophilia (abnormal blood counts), uritcaria (hives), thrombotic thrombocytopenic purpura, or severe periarteritis (inflammation around blood vessels). 

 • Cardiogenic shock. 

 • Marked sinus bradycardia. 

 • Second- or third-degree atrio-ventricular (AV) block unless a functioning pacemaker is available. 

 NEXTERONE is contraindicated in patients with (4) : 

 • Known hypersensitivity to any of the components of NEXTERONE, including iodine 

 • Cardiogenic shock 

 • Marked sinus bradycardia 

 • Second- or third-degree atrio-ventricular (AV) block unless a functioning pacemaker is available.</Section>
<Section name="WARNINGS AND PRECAUTIONS SECTION" id="43685-7">
5 WARNINGS AND PRECAUTIONS 

 NEXTERONE should be administered only by physicians who are experienced in the treatment of life-threatening arrhythmias, who are thoroughly familiar with the risks and benefits of amiodarone therapy, and who have access to facilities adequate for monitoring the effectiveness and side effects of treatment. 
 Because of the long half-life of amiodarone and its metabolite desethylamiodarone, the potential for adverse reactions or interactions, as well as observed adverse effects, can persist following amiodarone withdrawal. 

 • Hypotension: Slow the infusion; as needed, add vasopressor drugs, positive inotropic agents, and volume expansion. (5.1) 

 • Bradycardia and AV block: Slow the infusion or discontinue. ( 5.2 ) 

 5.1 Hypotension 

 Hypotension is the most common adverse reaction seen with intravenous amiodarone. In clinical trials, treatment-emergent, drug-related hypotension was reported as an adverse effect in 288 (16%) of 1836 patients treated with intravenous amiodarone. Clinically significant hypotension during infusions was seen most often in the first several hours of treatment and was not dose related, but appeared to be related to the rate of infusion. Hypotension necessitating alterations in intravenous amiodarone therapy was reported in 3% of patients, with permanent discontinuation required in less than 2% of patients. 
 Treat hypotension initially by slowing the infusion; additional standard therapy may be needed, including the following: vasopressor drugs, positive inotropic agents, and volume expansion. Monitor the initial rate of infusion closely and do not exceed the recommended rate [see Dosage and Administration (2) ]. 
 In some cases, hypotension may be refractory and result in a fatal outcome [see Adverse Reactions (6.2) ]. 

 5.2 Bradycardia and Atrio-ventricular Block 

 In 90 (4.9%) of 1836 patients in clinical trials, drug-related bradycardia that was not dose-related occurred while they were receiving intravenous amiodarone for life-threatening VT/VF. Treat bradycardia by slowing the infusion rate or discontinuing NEXTERONE. In some patients, inserting a pacemaker is required. Despite such measures, bradycardia was progressive and terminal in 1 patient during the controlled trials. Treat patients with a known predisposition to bradycardia or AV block with NEXTERONE in a setting where a temporary pacemaker is available. 

 5.3 Hepatic Injury 

 Elevations of blood hepatic enzyme values [alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT)] are commonly seen in patients with immediately life-threatening VT/VF. Interpreting elevated AST activity can be difficult because the values may be elevated in patients who have had recent myocardial infarction, congestive heart failure, or multiple electrical defibrillations. Approximately 54% of patients receiving intravenous amiodarone in clinical studies had baseline liver enzyme elevations, and 13% had clinically significant elevations. In 81% of patients with both baseline and on-therapy data available, the liver enzyme elevations either improved during therapy or remained at baseline levels. Baseline abnormalities in hepatic enzymes are not a contraindication to treatment. Elevated bilirubin levels have been reported in patients administered intravenous amiodarone. 
 Acute, centrolobular confluent hepatocellular necrosis leading to hepatic coma, acute renal failure, and death has been associated with the administration of intravenous amiodarone [see Dosage and Administration (2) ]. 
 In patients with life-threatening arrhythmias, the potential risk of hepatic injury should be weighed against the potential benefit of NEXTERONE therapy. Carefully monitor patients receiving NEXTERONE for evidence of progressive hepatic injury. In such cases, consider reducing the rate of administration or withdrawing NEXTERONE. 

 5.4 Proarrhythmia 

 Like all antiarrhythmic agents, NEXTERONE may cause a worsening of existing arrhythmias or precipitate a new arrhythmia, sometimes leading to fatal outcomes [see Adverse Reactions (6.2) ]. Proarrhythmia, primarily torsade de pointes (TdP), has been associated with prolongation, by intravenous amiodarone, of the QTc interval to 500 ms or greater. Although QTc prolongation occurred frequently in patients receiving intravenous amiodarone, TdP or new-onset VF occurred infrequently (less than 2%). Monitor patients for QTc prolongation during infusion with NEXTERONE. Reserve the combination of amiodarone with other antiarrhythmic therapies that prolong the QTc to patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent. 
 Correct hypokalemia, hypomagnesemia or hypocalcemia whenever possible before initiating treatment with NEXTERONE, as these disorders can exaggerate the degree of QTc prolongation and increase the potential for TdP. Give special attention to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or in patients receiving concomitant diuretics and laxatives. 
 Amiodarone causes thyroid dysfunction in some patients, which may lead to potentially fatal breakthrough or exacerbated arrhythmias. 

 5.5 Pulmonary Injury 

 Early-onset Pulmonary Toxicity 

 There have been postmarketing reports of acute-onset (days to weeks) pulmonary injury in patients treated with intravenous amiodarone. Findings have included pulmonary infiltrates and masses on X-ray, bronchospasm, wheezing, fever, dyspnea, cough, hemoptysis, and hypoxia. Some cases have progressed to respiratory failure or death. 

 ARDS 

 Two percent (2%) of patients were reported to have adult respiratory distress syndrome (ARDS) during clinical studies involving 48 hours of therapy. 

 Pulmonary Fibrosis 

 There have been reports of early development of pulmonary fibrosis (within 1 to 3 months) following initiation of amiodarone treatment. Only 1 of more than 1000 patients treated with intravenous amiodarone in clinical studies developed pulmonary fibrosis. In that patient, the condition was diagnosed 3 months after treatment with intravenous amiodarone, during which time the patient received oral amiodarone. Pulmonary toxicity is a well-recognized complication of long-term amiodarone use (see package insert for oral amiodarone). 

 5.6 Loss of Vision 

 Cases of optic neuropathy and optic neuritis, usually resulting in visual impairment, have been reported in patients treated with oral amiodarone or intravenous amiodarone. In some cases, visual impairment has progressed to permanent blindness. Optic neuropathy and neuritis may occur at any time following initiation of therapy. A causal relationship to the drug has not been clearly established. Perform an ophthalmic examination if symptoms of visual impairment appear, such as changes in visual acuity and decreases in peripheral vision. Re-evaluate the necessity of amiodarone therapy if optic neuropathy or neuritis is suspected. Perform regular ophthalmic examination, including fundoscopy and slit-lamp examination, during administration of NEXTERONE. 

 5.7 Thyroid Abnormalities 

 Amiodarone inhibits peripheral conversion of thyroxine (T4) to triiodothyronine (T3) and may cause increased T4 levels, decreased T3 levels, and increased levels of inactive reverse T3 (rT3) in clinically euthyroid patients. Amiodarone is also a potential source of large amounts of inorganic iodine and can cause either hypothyroidism or hyperthyroidism. Evaluate thyroid function prior to treatment and periodically thereafter, particularly in elderly patients, and in any patient with a history of thyroid nodules, goiter, or other thyroid dysfunction. Because of the slow elimination of amiodarone and its metabolites, high plasma iodide levels, altered thyroid function, and abnormal thyroid-function tests may persist for several weeks or even months following NEXTERONE withdrawal. 
 There have been postmarketing reports of thyroid nodules/thyroid cancer in patients treated with amiodarone. In some instances hyperthyroidism was also present. 

 Hyperthyroidism and Thyrotoxicosis 

 Amiodarone causes hyperthyroidism in about 2% of patients. Thyrotoxicosis and arrhythmia with fatal outcome has been reported in the presence of pre-existing hyperthyroidism even following a single intravenous amiodarone dose. Consider the possibility of hyperthyroidism if any new signs of arrhythmia appear. 
 Hyperthyroidism may result from iodine load (type 1 amiodarone-induced thyrotoxicosis [type 1 AIT]; in particular in patients with underlying autonomous thyroid nodules or latent Grave’s disease). Hyperthyroidism may also result from direct amiodarone-induced destructive thyroiditis that occurs in individuals with no underlying thyroid disease (type 2 AIT), resulting in the release of preformed thyroid hormone into the bloodstream from damaged thyroid follicular epithelium. Mixed forms of hyperthyroidism as a result of both pathogenic mechanisms (excessive thyroid hormone production and thyroid destruction) can also occur. The risk of hyperthyroidism may be higher among patients with prior inadequate dietary iodine intake. 
 Identify hyperthyroidism by relevant clinical signs and symptoms, subnormal serum levels of thyroid stimulating hormone (TSH), abnormally elevated serum free T4, and elevated or normal serum T3. Since arrhythmia breakthroughs may accompany amiodarone-induced hyperthyroidism, aggressive medical treatment is indicated, including, if possible, dose reduction or withdrawal of amiodarone. Amiodarone hyperthyroidism may be followed by a transient period of hypothyroidism. 
 The institution of antithyroid drugs, β-adrenergic blockers or temporary corticosteroid therapy may be necessary. The action of antithyroid drugs may be especially delayed in amiodarone-induced thyrotoxicosis because of substantial quantities of preformed thyroid hormones stored in the gland. Radioactive iodine therapy is not recommended because of the low radioiodine uptake associated with amiodarone-induced hyperthyroidism. 
 When aggressive treatment of amiodarone-induced thyrotoxicosis has failed or amiodarone cannot be discontinued because it is the only drug effective against the resistant arrhythmia, surgical management may be an option. Experience with thyroidectomy as a treatment for amiodarone-induced thyrotoxicosis is limited, and this form of therapy could induce thyroid storm. Therefore, surgical and anesthetic management require careful planning. 

 Hypothyroidism 

 Hypothyroidism has been reported in 2 to 10% of patients receiving amiodarone and may be primary or subsequent to resolution of preceding amiodarone-induced hyperthyroidism. This condition may be identified by clinical symptoms and elevated serum TSH levels. Cases of severe hypothyroidism and myxedema coma, sometimes fatal, have been reported in association with amiodarone therapy. In some clinically hypothyroid amiodarone-treated patients, free thyroxine index values may be normal. Manage hypothyroidism by reducing the dose of or discontinuing NEXTERONE and considering the need for thyroid hormone supplement. 

 5.8 Neonatal Injury 

 Amiodarone can cause fetal harm when administered to a pregnant woman. Fetal exposure may increase the potential for adverse experiences including cardiac, thyroid, neurodevelopmental, neurological and growth effects in neonate. Inform the patient of the potential hazard to the fetus if NEXTERONE is administered during pregnancy or if the patient becomes pregnant while taking NEXTERONE [See Pregnancy (8.1) ]. 

 5.9 Exaggerated Effects of Perisurgical Therapy 

 Perform close perioperative monitoring in patients undergoing general anesthesia who are on amiodarone therapy as they may be more sensitive to the myocardial depressant and conduction defects of halogenated inhalational anesthetics. 

 5.10 Interference with Corneal Refractive Laser Surgery 

 Advise patients that most manufacturers of corneal refractive laser surgery devices contraindicate corneal refractive laser surgery in patients taking amiodarone. 

 5.11 Hypersensitivity Reactions 

 Anaphylactic/anaphylactoid reactions have been reported with intravenous amiodarone including shock (sometimes fatal), cardiac arrest, and the following manifestations: hypotension, tachycardia, hypoxia, cyanosis, rash, flushing, hyperhidrosis and cold sweat. Since NEXTERONE contains dextrose, patients with allergy to corn or corn products are at risk for allergic reaction.</Section>
<Section name="DRUG INTERACTIONS SECTION" id="34073-7">
7 DRUG INTERACTIONS 

 • Amiodarone is a substrate for CYP3A and CYP2C8, so inhibitors and inducers affect amiodarone exposure ( 7 ) 

 • Amiodarone inhibits p-glycoprotein and CYP1A2, CYP2C9, CYP2D6, and CYP3A, increasing exposure to other drugs ( 7 ) 

 7.1 Pharmacodynamic Interactions 

 Drugs prolonging the QT interval: Co-administration of drugs prolonging the QT interval (such as class I and III antiarrhythmics, lithium, certain phenothiazines, tricyclic antidepressants, certain fluoroquinolone and macrolide antibiotics, azole antifungals, halogenated inhalation anesthetic agents) increases the risk of Torsade de Pointes. In general, avoid concomitant use of drugs that prolong the QT interval [see Warnings and Precautions (5.4) ]. 

 Drugs that slow heart rate : Concomitant use of drugs with depressant effects on the sinus and AV node (e.g., digoxin, beta blockers, verapamil, diltiazem, ivabradine, clonidine) can potentiate the electrophysiologic and hemodynamic effects of amiodarone, resulting in bradycardia, sinus arrest, and AV block. Monitor heart rate in patients on amiodarone and concomitant drugs that slow heart rate. 

 7.2 Pharmacokinetic Interactions 

 Effect of other drugs on amiodarone 

 Amiodarone is metabolized to the active metabolite desethylamiodarone (DEA) by the cytochrome P450 (CYP450) enzyme group, specifically CYP3A and CYP2C8. Amiodarone has the potential for interactions with drugs or substances that may be substrates, inhibitors or inducers of CYP450 enzymes (e.g., inhibitors such as protease inhibitors, grapefruit juice, certain fluoroquinolone and macrolide antibiotics, azole antifungals and inducers such as St. John’s Wort ) or P-glycoprotein. In view of the long and variable half-life of amiodarone, potential for drug interactions exists not only with concomitant medication but also with drugs administered after discontinuation of amiodarone [see Clinical Pharmacology (12.3) ] . 

 Patients should avoid grapefruit juice beverages while taking amiodarone because exposure to amiodarone is significantly increased [see Clinical Pharmacology (12.3) ] . 

 Effect of amiodarone on other drugs 

 Amiodarone and DEA are inhibitors of P-glycoprotein and certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6 and CYP3A [see Clinical Pharmacology (12.3) ]. 

 Antiarrhythmics : The metabolism of quinidine , procainamide , flecainide can be inhibited by amiodarone. In general, initiate any added antiarrhythmic drug at a lower than usual dose and monitor the patient carefully. During transfer to oral amiodarone, reduce the dose levels of previously administered agents by 30 to 50% several days after the addition of oral amiodarone. Review the continued need for the other antiarrhythmic agent after the effects of amiodarone have been established, and attempt discontinuation [see Clinical Pharmacology (12.3) ]. 

 Digoxin : In patients receiving digoxin therapy, administration of oral amiodarone results in an increase in serum digoxin concentration. Reduce dose of digoxin by half or discontinue digoxin. If digitalis treatment is continued, monitor serum levels closely and observe patients for clinical evidence of toxicity [see Clinical Pharmacology (12.3) ]. 

 HMG-CoA Reductase Inhibitors: Limit the dose of simvastatin in patients on amiodarone to 20 mg daily. Limit the daily dose of lovastatin to 40 mg. Lower starting and maintenance doses of other CYP3A4 substrates (e.g., atorvastatin) may be required as amiodarone may increase the plasma concentration of these drugs. 

 Anticoagulants: Potentiation of warfarin -type (CYP2C9 and CYP3A substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding. Since the concomitant administration of warfarin with amiodarone increases the INR by 100% after 3 to 4 days, reduce the dose of the anticoagulant by one-third to one-half, and monitor INR closely. 

 Cyclosporine (CYP3A substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine. Monitor cyclosporine drug levels and renal function in patients taking both drugs. 
 Increased steady-state levels of phenytoin during concomitant therapy with amiodarone have been reported. Monitor phenytoin levels in patients taking both drugs. 

 7.3 Serious Symptomatic Bradycardia When Co-administered with Ledipasvir/Sofosbuvir or with Sofosbuvir with Simeprevir 

 Postmarketing cases of symptomatic bradycardia, some requiring pacemaker insertion and at least one fatal, have been reported when ledipasvir/sofosbuvir or sofosbuvir with simeprevir were initiated in patients on amiodarone. Bradycardia generally occurred within hours to days, but in some cases up to 2 weeks after initiating antiviral treatment. Bradycardia generally resolved after discontinuation of antiviral treatment. The mechanism for this effect is unknown. Monitor heart rate in patients taking or recently discontinuing amiodarone when starting antiviral treatment.</Section>
</Text><Sentences>
<Sentence id="426" LabelDrug="Nexterone" section="34068-7">
<SentenceText>NEXTERONE Premixed Injection is available in GALAXY containers as a single-use , ready-to-use , iso-osmotic solution in dextrose for intravenous administration .</SentenceText>
</Sentence>
<Sentence id="427" LabelDrug="Nexterone" section="34070-3">
<SentenceText>Known hypersensitivity to any of the components of NEXTERONE , including iodine .</SentenceText>
</Sentence>
<Sentence id="428" LabelDrug="Nexterone" section="34070-3">
<SentenceText>Known hypersensitivity to any of the components of NEXTERONE Premixed Injection , including iodine .</SentenceText>
</Sentence>
<Sentence id="429" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Amiodarone and DEA are inhibitors of P-glycoprotein and certain CYP450 enzymes , including CYP1A2 , CYP2C9 , CYP2D6 and CYP3A see Clinical Pharmacology ( 12.3 ) .</SentenceText>
</Sentence>
<Sentence id="430" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Amiodarone has the potential for interactions with drugs or substances that may be substrates , inhibitors or inducers of CYP450 enzymes ( e.g. , inhibitors such as protease inhibitors , grapefruit juice , certain fluoroquinolone and macrolide antibiotics , azole antifungals and inducers such as St.   John s Wort ) or P-glycoprotein .</SentenceText>
<Mention id="M19" type="Trigger" span="19 26" str="potential for interactions"/>
<Mention id="M2" type="Precipitant" span="258 17" str="azole antifungals" code="N0000175487"/>
<Mention id="M4" type="Precipitant" span="214 15;244 11" str="fluoroquinolone | antibiotics" code="N0000011190"/>
<Mention id="M6" type="Precipitant" span="187 16" str="grapefruit juice" code="n0000164879"/>
<Mention id="M8" type="Precipitant" span="110 26" str="inducers of CYP450 enzymes" code="n0000185505"/>
<Mention id="M10" type="Precipitant" span="96 10;119 17" str="inhibitors | of CYP450 enzymes" code="n0000182136"/>
<Mention id="M12" type="Precipitant" span="234 21" str="macrolide antibiotics" code="N0000175431"/>
<Mention id="M14" type="Precipitant" span="320 14" str="P-glycoprotein" code="n0000011430"/>
<Mention id="M16" type="Precipitant" span="165 19" str="protease inhibitors" code="N0000000076"/>
<Mention id="M18" type="Precipitant" span="297 17" str="St.   John s Wort" code="N0000022261"/>
<Mention id="M20" type="Precipitant" span="83 10;119 17" str="substrates | of CYP450 enzymes" code="NO MAP"/>
<Interaction id="I1" type="Unspecified interaction" trigger="M19" precipitant="M2"/>
<Interaction id="I2" type="Unspecified interaction" trigger="M19" precipitant="M4"/>
<Interaction id="I3" type="Unspecified interaction" trigger="M19" precipitant="M6"/>
<Interaction id="I4" type="Unspecified interaction" trigger="M19" precipitant="M8"/>
<Interaction id="I5" type="Unspecified interaction" trigger="M19" precipitant="M10"/>
<Interaction id="I6" type="Unspecified interaction" trigger="M19" precipitant="M12"/>
<Interaction id="I7" type="Unspecified interaction" trigger="M19" precipitant="M14"/>
<Interaction id="I8" type="Unspecified interaction" trigger="M19" precipitant="M16"/>
<Interaction id="I9" type="Unspecified interaction" trigger="M19" precipitant="M18"/>
<Interaction id="I10" type="Unspecified interaction" trigger="M19" precipitant="M20"/>
</Sentence>
<Sentence id="430" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Amiodarone has the potential for interactions with drugs or substances that may be substrates , inhibitors or inducers of CYP450 enzymes ( e.g. , inhibitors such as protease inhibitors , grapefruit juice , certain fluoroquinolone and macrolide antibiotics , azole antifungals and inducers such as St.   John s Wort ) or P-glycoprotein .</SentenceText>
<Mention id="M39" type="Trigger" span="19 26" str="potential for interactions"/>
<Mention id="M22" type="Precipitant" span="258 17" str="azole antifungals" code="N0000175487"/>
<Mention id="M24" type="Precipitant" span="214 15;244 11" str="fluoroquinolone | antibiotics" code="N0000011190"/>
<Mention id="M26" type="Precipitant" span="187 16" str="grapefruit juice" code="n0000164879"/>
<Mention id="M28" type="Precipitant" span="110 26" str="inducers of CYP450 enzymes" code="n0000185505"/>
<Mention id="M30" type="Precipitant" span="96 10;119 17" str="inhibitors | of CYP450 enzymes" code="n0000182136"/>
<Mention id="M32" type="Precipitant" span="234 21" str="macrolide antibiotics" code="N0000175431"/>
<Mention id="M34" type="Precipitant" span="320 14" str="P-glycoprotein" code="n0000011430"/>
<Mention id="M36" type="Precipitant" span="165 19" str="protease inhibitors" code="N0000000076"/>
<Mention id="M38" type="Precipitant" span="297 17" str="St.   John s Wort" code="N0000022261"/>
<Mention id="M40" type="Precipitant" span="83 10;119 17" str="substrates | of CYP450 enzymes" code="NO MAP"/>
<Interaction id="I11" type="Unspecified interaction" trigger="M39" precipitant="M22"/>
<Interaction id="I12" type="Unspecified interaction" trigger="M39" precipitant="M24"/>
<Interaction id="I13" type="Unspecified interaction" trigger="M39" precipitant="M26"/>
<Interaction id="I14" type="Unspecified interaction" trigger="M39" precipitant="M28"/>
<Interaction id="I15" type="Unspecified interaction" trigger="M39" precipitant="M30"/>
<Interaction id="I16" type="Unspecified interaction" trigger="M39" precipitant="M32"/>
<Interaction id="I17" type="Unspecified interaction" trigger="M39" precipitant="M34"/>
<Interaction id="I18" type="Unspecified interaction" trigger="M39" precipitant="M36"/>
<Interaction id="I19" type="Unspecified interaction" trigger="M39" precipitant="M38"/>
<Interaction id="I20" type="Unspecified interaction" trigger="M39" precipitant="M40"/>
</Sentence>
<Sentence id="430" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Amiodarone has the potential for interactions with drugs or substances that may be substrates , inhibitors or inducers of CYP450 enzymes ( e.g. , inhibitors such as protease inhibitors , grapefruit juice , certain fluoroquinolone and macrolide antibiotics , azole antifungals and inducers such as St.   John s Wort ) or P-glycoprotein .</SentenceText>
<Mention id="M59" type="Trigger" span="19 26" str="potential for interactions"/>
<Mention id="M42" type="Precipitant" span="258 17" str="azole antifungals" code="N0000175487"/>
<Mention id="M44" type="Precipitant" span="214 15;244 11" str="fluoroquinolone | antibiotics" code="N0000011190"/>
<Mention id="M46" type="Precipitant" span="187 16" str="grapefruit juice" code="n0000164879"/>
<Mention id="M48" type="Precipitant" span="110 26" str="inducers of CYP450 enzymes" code="n0000185505"/>
<Mention id="M50" type="Precipitant" span="96 10;119 17" str="inhibitors | of CYP450 enzymes" code="n0000182136"/>
<Mention id="M52" type="Precipitant" span="234 21" str="macrolide antibiotics" code="N0000175431"/>
<Mention id="M54" type="Precipitant" span="320 14" str="P-glycoprotein" code="n0000011430"/>
<Mention id="M56" type="Precipitant" span="165 19" str="protease inhibitors" code="N0000000076"/>
<Mention id="M58" type="Precipitant" span="297 17" str="St.   John s Wort" code="N0000022261"/>
<Mention id="M60" type="Precipitant" span="83 10;119 17" str="substrates | of CYP450 enzymes" code="NO MAP"/>
<Interaction id="I21" type="Unspecified interaction" trigger="M59" precipitant="M42"/>
<Interaction id="I22" type="Unspecified interaction" trigger="M59" precipitant="M44"/>
<Interaction id="I23" type="Unspecified interaction" trigger="M59" precipitant="M46"/>
<Interaction id="I24" type="Unspecified interaction" trigger="M59" precipitant="M48"/>
<Interaction id="I25" type="Unspecified interaction" trigger="M59" precipitant="M50"/>
<Interaction id="I26" type="Unspecified interaction" trigger="M59" precipitant="M52"/>
<Interaction id="I27" type="Unspecified interaction" trigger="M59" precipitant="M54"/>
<Interaction id="I28" type="Unspecified interaction" trigger="M59" precipitant="M56"/>
<Interaction id="I29" type="Unspecified interaction" trigger="M59" precipitant="M58"/>
<Interaction id="I30" type="Unspecified interaction" trigger="M59" precipitant="M60"/>
</Sentence>
<Sentence id="430" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Amiodarone has the potential for interactions with drugs or substances that may be substrates , inhibitors or inducers of CYP450 enzymes ( e.g. , inhibitors such as protease inhibitors , grapefruit juice , certain fluoroquinolone and macrolide antibiotics , azole antifungals and inducers such as St.   John s Wort ) or P-glycoprotein .</SentenceText>
<Mention id="M79" type="Trigger" span="19 26" str="potential for interactions"/>
<Mention id="M62" type="Precipitant" span="258 17" str="azole antifungals" code="N0000175487"/>
<Mention id="M64" type="Precipitant" span="214 15;244 11" str="fluoroquinolone | antibiotics" code="N0000011190"/>
<Mention id="M66" type="Precipitant" span="187 16" str="grapefruit juice" code="n0000164879"/>
<Mention id="M68" type="Precipitant" span="110 26" str="inducers of CYP450 enzymes" code="n0000185505"/>
<Mention id="M70" type="Precipitant" span="96 10;119 17" str="inhibitors | of CYP450 enzymes" code="n0000182136"/>
<Mention id="M72" type="Precipitant" span="234 21" str="macrolide antibiotics" code="N0000175431"/>
<Mention id="M74" type="Precipitant" span="320 14" str="P-glycoprotein" code="n0000011430"/>
<Mention id="M76" type="Precipitant" span="165 19" str="protease inhibitors" code="N0000000076"/>
<Mention id="M78" type="Precipitant" span="297 17" str="St.   John s Wort" code="N0000022261"/>
<Mention id="M80" type="Precipitant" span="83 10;119 17" str="substrates | of CYP450 enzymes" code="NO MAP"/>
<Interaction id="I31" type="Unspecified interaction" trigger="M79" precipitant="M62"/>
<Interaction id="I32" type="Unspecified interaction" trigger="M79" precipitant="M64"/>
<Interaction id="I33" type="Unspecified interaction" trigger="M79" precipitant="M66"/>
<Interaction id="I34" type="Unspecified interaction" trigger="M79" precipitant="M68"/>
<Interaction id="I35" type="Unspecified interaction" trigger="M79" precipitant="M70"/>
<Interaction id="I36" type="Unspecified interaction" trigger="M79" precipitant="M72"/>
<Interaction id="I37" type="Unspecified interaction" trigger="M79" precipitant="M74"/>
<Interaction id="I38" type="Unspecified interaction" trigger="M79" precipitant="M76"/>
<Interaction id="I39" type="Unspecified interaction" trigger="M79" precipitant="M78"/>
<Interaction id="I40" type="Unspecified interaction" trigger="M79" precipitant="M80"/>
</Sentence>
<Sentence id="430" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Amiodarone has the potential for interactions with drugs or substances that may be substrates , inhibitors or inducers of CYP450 enzymes ( e.g. , inhibitors such as protease inhibitors , grapefruit juice , certain fluoroquinolone and macrolide antibiotics , azole antifungals and inducers such as St.   John s Wort ) or P-glycoprotein .</SentenceText>
<Mention id="M99" type="Trigger" span="19 26" str="potential for interactions"/>
<Mention id="M82" type="Precipitant" span="258 17" str="azole antifungals" code="N0000175487"/>
<Mention id="M84" type="Precipitant" span="214 15;244 11" str="fluoroquinolone | antibiotics" code="N0000011190"/>
<Mention id="M86" type="Precipitant" span="187 16" str="grapefruit juice" code="n0000164879"/>
<Mention id="M88" type="Precipitant" span="110 26" str="inducers of CYP450 enzymes" code="n0000185505"/>
<Mention id="M90" type="Precipitant" span="96 10;119 17" str="inhibitors | of CYP450 enzymes" code="n0000182136"/>
<Mention id="M92" type="Precipitant" span="234 21" str="macrolide antibiotics" code="N0000175431"/>
<Mention id="M94" type="Precipitant" span="320 14" str="P-glycoprotein" code="n0000011430"/>
<Mention id="M96" type="Precipitant" span="165 19" str="protease inhibitors" code="N0000000076"/>
<Mention id="M98" type="Precipitant" span="297 17" str="St.   John s Wort" code="N0000022261"/>
<Mention id="M100" type="Precipitant" span="83 10;119 17" str="substrates | of CYP450 enzymes" code="NO MAP"/>
<Interaction id="I41" type="Unspecified interaction" trigger="M99" precipitant="M82"/>
<Interaction id="I42" type="Unspecified interaction" trigger="M99" precipitant="M84"/>
<Interaction id="I43" type="Unspecified interaction" trigger="M99" precipitant="M86"/>
<Interaction id="I44" type="Unspecified interaction" trigger="M99" precipitant="M88"/>
<Interaction id="I45" type="Unspecified interaction" trigger="M99" precipitant="M90"/>
<Interaction id="I46" type="Unspecified interaction" trigger="M99" precipitant="M92"/>
<Interaction id="I47" type="Unspecified interaction" trigger="M99" precipitant="M94"/>
<Interaction id="I48" type="Unspecified interaction" trigger="M99" precipitant="M96"/>
<Interaction id="I49" type="Unspecified interaction" trigger="M99" precipitant="M98"/>
<Interaction id="I50" type="Unspecified interaction" trigger="M99" precipitant="M100"/>
</Sentence>
<Sentence id="430" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Amiodarone has the potential for interactions with drugs or substances that may be substrates , inhibitors or inducers of CYP450 enzymes ( e.g. , inhibitors such as protease inhibitors , grapefruit juice , certain fluoroquinolone and macrolide antibiotics , azole antifungals and inducers such as St.   John s Wort ) or P-glycoprotein .</SentenceText>
<Mention id="M119" type="Trigger" span="19 26" str="potential for interactions"/>
<Mention id="M102" type="Precipitant" span="258 17" str="azole antifungals" code="N0000175487"/>
<Mention id="M104" type="Precipitant" span="214 15;244 11" str="fluoroquinolone | antibiotics" code="N0000011190"/>
<Mention id="M106" type="Precipitant" span="187 16" str="grapefruit juice" code="n0000164879"/>
<Mention id="M108" type="Precipitant" span="110 26" str="inducers of CYP450 enzymes" code="n0000185505"/>
<Mention id="M110" type="Precipitant" span="96 10;119 17" str="inhibitors | of CYP450 enzymes" code="n0000182136"/>
<Mention id="M112" type="Precipitant" span="234 21" str="macrolide antibiotics" code="N0000175431"/>
<Mention id="M114" type="Precipitant" span="320 14" str="P-glycoprotein" code="n0000011430"/>
<Mention id="M116" type="Precipitant" span="165 19" str="protease inhibitors" code="N0000000076"/>
<Mention id="M118" type="Precipitant" span="297 17" str="St.   John s Wort" code="N0000022261"/>
<Mention id="M120" type="Precipitant" span="83 10;119 17" str="substrates | of CYP450 enzymes" code="NO MAP"/>
<Interaction id="I51" type="Unspecified interaction" trigger="M119" precipitant="M102"/>
<Interaction id="I52" type="Unspecified interaction" trigger="M119" precipitant="M104"/>
<Interaction id="I53" type="Unspecified interaction" trigger="M119" precipitant="M106"/>
<Interaction id="I54" type="Unspecified interaction" trigger="M119" precipitant="M108"/>
<Interaction id="I55" type="Unspecified interaction" trigger="M119" precipitant="M110"/>
<Interaction id="I56" type="Unspecified interaction" trigger="M119" precipitant="M112"/>
<Interaction id="I57" type="Unspecified interaction" trigger="M119" precipitant="M114"/>
<Interaction id="I58" type="Unspecified interaction" trigger="M119" precipitant="M116"/>
<Interaction id="I59" type="Unspecified interaction" trigger="M119" precipitant="M118"/>
<Interaction id="I60" type="Unspecified interaction" trigger="M119" precipitant="M120"/>
</Sentence>
<Sentence id="430" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Amiodarone has the potential for interactions with drugs or substances that may be substrates , inhibitors or inducers of CYP450 enzymes ( e.g. , inhibitors such as protease inhibitors , grapefruit juice , certain fluoroquinolone and macrolide antibiotics , azole antifungals and inducers such as St.   John s Wort ) or P-glycoprotein .</SentenceText>
<Mention id="M139" type="Trigger" span="19 26" str="potential for interactions"/>
<Mention id="M122" type="Precipitant" span="258 17" str="azole antifungals" code="N0000175487"/>
<Mention id="M124" type="Precipitant" span="214 15;244 11" str="fluoroquinolone | antibiotics" code="N0000011190"/>
<Mention id="M126" type="Precipitant" span="187 16" str="grapefruit juice" code="n0000164879"/>
<Mention id="M128" type="Precipitant" span="110 26" str="inducers of CYP450 enzymes" code="n0000185505"/>
<Mention id="M130" type="Precipitant" span="96 10;119 17" str="inhibitors | of CYP450 enzymes" code="n0000182136"/>
<Mention id="M132" type="Precipitant" span="234 21" str="macrolide antibiotics" code="N0000175431"/>
<Mention id="M134" type="Precipitant" span="320 14" str="P-glycoprotein" code="n0000011430"/>
<Mention id="M136" type="Precipitant" span="165 19" str="protease inhibitors" code="N0000000076"/>
<Mention id="M138" type="Precipitant" span="297 17" str="St.   John s Wort" code="N0000022261"/>
<Mention id="M140" type="Precipitant" span="83 10;119 17" str="substrates | of CYP450 enzymes" code="NO MAP"/>
<Interaction id="I61" type="Unspecified interaction" trigger="M139" precipitant="M122"/>
<Interaction id="I62" type="Unspecified interaction" trigger="M139" precipitant="M124"/>
<Interaction id="I63" type="Unspecified interaction" trigger="M139" precipitant="M126"/>
<Interaction id="I64" type="Unspecified interaction" trigger="M139" precipitant="M128"/>
<Interaction id="I65" type="Unspecified interaction" trigger="M139" precipitant="M130"/>
<Interaction id="I66" type="Unspecified interaction" trigger="M139" precipitant="M132"/>
<Interaction id="I67" type="Unspecified interaction" trigger="M139" precipitant="M134"/>
<Interaction id="I68" type="Unspecified interaction" trigger="M139" precipitant="M136"/>
<Interaction id="I69" type="Unspecified interaction" trigger="M139" precipitant="M138"/>
<Interaction id="I70" type="Unspecified interaction" trigger="M139" precipitant="M140"/>
</Sentence>
<Sentence id="430" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Amiodarone has the potential for interactions with drugs or substances that may be substrates , inhibitors or inducers of CYP450 enzymes ( e.g. , inhibitors such as protease inhibitors , grapefruit juice , certain fluoroquinolone and macrolide antibiotics , azole antifungals and inducers such as St.   John s Wort ) or P-glycoprotein .</SentenceText>
<Mention id="M159" type="Trigger" span="19 26" str="potential for interactions"/>
<Mention id="M142" type="Precipitant" span="258 17" str="azole antifungals" code="N0000175487"/>
<Mention id="M144" type="Precipitant" span="214 15;244 11" str="fluoroquinolone | antibiotics" code="N0000011190"/>
<Mention id="M146" type="Precipitant" span="187 16" str="grapefruit juice" code="n0000164879"/>
<Mention id="M148" type="Precipitant" span="110 26" str="inducers of CYP450 enzymes" code="n0000185505"/>
<Mention id="M150" type="Precipitant" span="96 10;119 17" str="inhibitors | of CYP450 enzymes" code="n0000182136"/>
<Mention id="M152" type="Precipitant" span="234 21" str="macrolide antibiotics" code="N0000175431"/>
<Mention id="M154" type="Precipitant" span="320 14" str="P-glycoprotein" code="n0000011430"/>
<Mention id="M156" type="Precipitant" span="165 19" str="protease inhibitors" code="N0000000076"/>
<Mention id="M158" type="Precipitant" span="297 17" str="St.   John s Wort" code="N0000022261"/>
<Mention id="M160" type="Precipitant" span="83 10;119 17" str="substrates | of CYP450 enzymes" code="NO MAP"/>
<Interaction id="I71" type="Unspecified interaction" trigger="M159" precipitant="M142"/>
<Interaction id="I72" type="Unspecified interaction" trigger="M159" precipitant="M144"/>
<Interaction id="I73" type="Unspecified interaction" trigger="M159" precipitant="M146"/>
<Interaction id="I74" type="Unspecified interaction" trigger="M159" precipitant="M148"/>
<Interaction id="I75" type="Unspecified interaction" trigger="M159" precipitant="M150"/>
<Interaction id="I76" type="Unspecified interaction" trigger="M159" precipitant="M152"/>
<Interaction id="I77" type="Unspecified interaction" trigger="M159" precipitant="M154"/>
<Interaction id="I78" type="Unspecified interaction" trigger="M159" precipitant="M156"/>
<Interaction id="I79" type="Unspecified interaction" trigger="M159" precipitant="M158"/>
<Interaction id="I80" type="Unspecified interaction" trigger="M159" precipitant="M160"/>
</Sentence>
<Sentence id="430" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Amiodarone has the potential for interactions with drugs or substances that may be substrates , inhibitors or inducers of CYP450 enzymes ( e.g. , inhibitors such as protease inhibitors , grapefruit juice , certain fluoroquinolone and macrolide antibiotics , azole antifungals and inducers such as St.   John s Wort ) or P-glycoprotein .</SentenceText>
<Mention id="M179" type="Trigger" span="19 26" str="potential for interactions"/>
<Mention id="M162" type="Precipitant" span="258 17" str="azole antifungals" code="N0000175487"/>
<Mention id="M164" type="Precipitant" span="214 15;244 11" str="fluoroquinolone | antibiotics" code="N0000011190"/>
<Mention id="M166" type="Precipitant" span="187 16" str="grapefruit juice" code="n0000164879"/>
<Mention id="M168" type="Precipitant" span="110 26" str="inducers of CYP450 enzymes" code="n0000185505"/>
<Mention id="M170" type="Precipitant" span="96 10;119 17" str="inhibitors | of CYP450 enzymes" code="n0000182136"/>
<Mention id="M172" type="Precipitant" span="234 21" str="macrolide antibiotics" code="N0000175431"/>
<Mention id="M174" type="Precipitant" span="320 14" str="P-glycoprotein" code="n0000011430"/>
<Mention id="M176" type="Precipitant" span="165 19" str="protease inhibitors" code="N0000000076"/>
<Mention id="M178" type="Precipitant" span="297 17" str="St.   John s Wort" code="N0000022261"/>
<Mention id="M180" type="Precipitant" span="83 10;119 17" str="substrates | of CYP450 enzymes" code="NO MAP"/>
<Interaction id="I81" type="Unspecified interaction" trigger="M179" precipitant="M162"/>
<Interaction id="I82" type="Unspecified interaction" trigger="M179" precipitant="M164"/>
<Interaction id="I83" type="Unspecified interaction" trigger="M179" precipitant="M166"/>
<Interaction id="I84" type="Unspecified interaction" trigger="M179" precipitant="M168"/>
<Interaction id="I85" type="Unspecified interaction" trigger="M179" precipitant="M170"/>
<Interaction id="I86" type="Unspecified interaction" trigger="M179" precipitant="M172"/>
<Interaction id="I87" type="Unspecified interaction" trigger="M179" precipitant="M174"/>
<Interaction id="I88" type="Unspecified interaction" trigger="M179" precipitant="M176"/>
<Interaction id="I89" type="Unspecified interaction" trigger="M179" precipitant="M178"/>
<Interaction id="I90" type="Unspecified interaction" trigger="M179" precipitant="M180"/>
</Sentence>
<Sentence id="430" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Amiodarone has the potential for interactions with drugs or substances that may be substrates , inhibitors or inducers of CYP450 enzymes ( e.g. , inhibitors such as protease inhibitors , grapefruit juice , certain fluoroquinolone and macrolide antibiotics , azole antifungals and inducers such as St.   John s Wort ) or P-glycoprotein .</SentenceText>
<Mention id="M199" type="Trigger" span="19 26" str="potential for interactions"/>
<Mention id="M182" type="Precipitant" span="258 17" str="azole antifungals" code="N0000175487"/>
<Mention id="M184" type="Precipitant" span="214 15;244 11" str="fluoroquinolone | antibiotics" code="N0000011190"/>
<Mention id="M186" type="Precipitant" span="187 16" str="grapefruit juice" code="n0000164879"/>
<Mention id="M188" type="Precipitant" span="110 26" str="inducers of CYP450 enzymes" code="n0000185505"/>
<Mention id="M190" type="Precipitant" span="96 10;119 17" str="inhibitors | of CYP450 enzymes" code="n0000182136"/>
<Mention id="M192" type="Precipitant" span="234 21" str="macrolide antibiotics" code="N0000175431"/>
<Mention id="M194" type="Precipitant" span="320 14" str="P-glycoprotein" code="n0000011430"/>
<Mention id="M196" type="Precipitant" span="165 19" str="protease inhibitors" code="N0000000076"/>
<Mention id="M198" type="Precipitant" span="297 17" str="St.   John s Wort" code="N0000022261"/>
<Mention id="M200" type="Precipitant" span="83 10;119 17" str="substrates | of CYP450 enzymes" code="NO MAP"/>
<Interaction id="I91" type="Unspecified interaction" trigger="M199" precipitant="M182"/>
<Interaction id="I92" type="Unspecified interaction" trigger="M199" precipitant="M184"/>
<Interaction id="I93" type="Unspecified interaction" trigger="M199" precipitant="M186"/>
<Interaction id="I94" type="Unspecified interaction" trigger="M199" precipitant="M188"/>
<Interaction id="I95" type="Unspecified interaction" trigger="M199" precipitant="M190"/>
<Interaction id="I96" type="Unspecified interaction" trigger="M199" precipitant="M192"/>
<Interaction id="I97" type="Unspecified interaction" trigger="M199" precipitant="M194"/>
<Interaction id="I98" type="Unspecified interaction" trigger="M199" precipitant="M196"/>
<Interaction id="I99" type="Unspecified interaction" trigger="M199" precipitant="M198"/>
<Interaction id="I100" type="Unspecified interaction" trigger="M199" precipitant="M200"/>
</Sentence>
<Sentence id="431" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Amiodarone is a substrate for CYP3A and CYP2C8, so inhibitors and inducers affect amiodarone exposure (7) Amiodarone inhibits p-glycoprotein and CYP1A2, CYP2C9, CYP2D6, and CYP3A, increasing exposure to other drugs (7) Drugs prolonging the QT interval: Co-administration of drugs prolonging the QT interval (such as class I and III antiarrhythmics, lithium, certain phenothiazines, tricyclic antidepressants, certain fluoroquinolone and macrolide antibiotics, azole antifungals, halogenated inhalation anesthetic agents) increases the risk of Torsade de Pointes.</SentenceText>
<Mention id="M233" type="Trigger" span="521 18" str="increases the risk"/>
<Mention id="M202" type="Precipitant" span="332 15" str="antiarrhythmics" code="N0000029121"/>
<Mention id="M235" type="SpecificInteraction" span="543 18" str="Torsade de Pointes" code="31722008: Torsades de pointes (disorder)"/>
<Mention id="M205" type="Precipitant" span="460 17" str="azole antifungals" code="N0000175487"/>
<Mention id="M213" type="Trigger" span="75 6;93 8" str="affect | exposure"/>
<Mention id="M208" type="Precipitant" span="40 6;66 8" str="CYP2C8 | inducers" code="n0000187063"/>
<Mention id="M210" type="Precipitant" span="40 6;51 10" str="CYP2C8 | inhibitors" code="n0000187062"/>
<Mention id="M212" type="Precipitant" span="30 5;66 8" str="CYP3A | inducers" code="n0000190118"/>
<Mention id="M214" type="Precipitant" span="30 5;51 10" str="CYP3A | inhibitors" code="n0000191001"/>
<Mention id="M216" type="Precipitant" span="274 32" str="drugs prolonging the QT interval" code="NO MAP"/>
<Mention id="M219" type="Precipitant" span="417 15;447 11" str="fluoroquinolone | antibiotics" code="N0000011190"/>
<Mention id="M222" type="Precipitant" span="479 40" str="halogenated inhalation anesthetic agents" code="N0000029139"/>
<Mention id="M225" type="Precipitant" span="349 7" str="lithium" code="N0000147892"/>
<Mention id="M228" type="Precipitant" span="437 21" str="macrolide antibiotics" code="N0000175431"/>
<Mention id="M231" type="Precipitant" span="366 14" str="phenothiazines" code="N0000175746"/>
<Mention id="M234" type="Precipitant" span="382 25" str="tricyclic antidepressants" code="N0000029148"/>
<Interaction id="I101" type="Pharmacodynamic interaction" trigger="M233" precipitant="M202" effect="M235"/>
<Interaction id="I102" type="Pharmacodynamic interaction" trigger="M233" precipitant="M205" effect="M235"/>
<Interaction id="I103" type="Pharmacokinetic interaction" trigger="M213" precipitant="M208" effect="C54356"/>
<Interaction id="I104" type="Pharmacokinetic interaction" trigger="M213" precipitant="M210" effect="C54355"/>
<Interaction id="I105" type="Pharmacokinetic interaction" trigger="M213" precipitant="M212" effect="C54356"/>
<Interaction id="I106" type="Pharmacokinetic interaction" trigger="M213" precipitant="M214" effect="C54355"/>
<Interaction id="I107" type="Pharmacodynamic interaction" trigger="M233" precipitant="M216" effect="M235"/>
<Interaction id="I108" type="Pharmacodynamic interaction" trigger="M233" precipitant="M219" effect="M235"/>
<Interaction id="I109" type="Pharmacodynamic interaction" trigger="M233" precipitant="M222" effect="M235"/>
<Interaction id="I110" type="Pharmacodynamic interaction" trigger="M233" precipitant="M225" effect="M235"/>
<Interaction id="I111" type="Pharmacodynamic interaction" trigger="M233" precipitant="M228" effect="M235"/>
<Interaction id="I112" type="Pharmacodynamic interaction" trigger="M233" precipitant="M231" effect="M235"/>
<Interaction id="I113" type="Pharmacodynamic interaction" trigger="M233" precipitant="M234" effect="M235"/>
</Sentence>
<Sentence id="431" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Amiodarone is a substrate for CYP3A and CYP2C8, so inhibitors and inducers affect amiodarone exposure (7) Amiodarone inhibits p-glycoprotein and CYP1A2, CYP2C9, CYP2D6, and CYP3A, increasing exposure to other drugs (7) Drugs prolonging the QT interval: Co-administration of drugs prolonging the QT interval (such as class I and III antiarrhythmics, lithium, certain phenothiazines, tricyclic antidepressants, certain fluoroquinolone and macrolide antibiotics, azole antifungals, halogenated inhalation anesthetic agents) increases the risk of Torsade de Pointes.</SentenceText>
<Mention id="M268" type="Trigger" span="521 18" str="increases the risk"/>
<Mention id="M237" type="Precipitant" span="332 15" str="antiarrhythmics" code="N0000029121"/>
<Mention id="M270" type="SpecificInteraction" span="543 18" str="Torsade de Pointes" code="31722008: Torsades de pointes (disorder)"/>
<Mention id="M240" type="Precipitant" span="460 17" str="azole antifungals" code="N0000175487"/>
<Mention id="M248" type="Trigger" span="75 6;93 8" str="affect | exposure"/>
<Mention id="M243" type="Precipitant" span="40 6;66 8" str="CYP2C8 | inducers" code="n0000187063"/>
<Mention id="M245" type="Precipitant" span="40 6;51 10" str="CYP2C8 | inhibitors" code="n0000187062"/>
<Mention id="M247" type="Precipitant" span="30 5;66 8" str="CYP3A | inducers" code="n0000190118"/>
<Mention id="M249" type="Precipitant" span="30 5;51 10" str="CYP3A | inhibitors" code="n0000191001"/>
<Mention id="M251" type="Precipitant" span="274 32" str="drugs prolonging the QT interval" code="NO MAP"/>
<Mention id="M254" type="Precipitant" span="417 15;447 11" str="fluoroquinolone | antibiotics" code="N0000011190"/>
<Mention id="M257" type="Precipitant" span="479 40" str="halogenated inhalation anesthetic agents" code="N0000029139"/>
<Mention id="M260" type="Precipitant" span="349 7" str="lithium" code="N0000147892"/>
<Mention id="M263" type="Precipitant" span="437 21" str="macrolide antibiotics" code="N0000175431"/>
<Mention id="M266" type="Precipitant" span="366 14" str="phenothiazines" code="N0000175746"/>
<Mention id="M269" type="Precipitant" span="382 25" str="tricyclic antidepressants" code="N0000029148"/>
<Interaction id="I114" type="Pharmacodynamic interaction" trigger="M268" precipitant="M237" effect="M270"/>
<Interaction id="I115" type="Pharmacodynamic interaction" trigger="M268" precipitant="M240" effect="M270"/>
<Interaction id="I116" type="Pharmacokinetic interaction" trigger="M248" precipitant="M243" effect="C54356"/>
<Interaction id="I117" type="Pharmacokinetic interaction" trigger="M248" precipitant="M245" effect="C54355"/>
<Interaction id="I118" type="Pharmacokinetic interaction" trigger="M248" precipitant="M247" effect="C54356"/>
<Interaction id="I119" type="Pharmacokinetic interaction" trigger="M248" precipitant="M249" effect="C54355"/>
<Interaction id="I120" type="Pharmacodynamic interaction" trigger="M268" precipitant="M251" effect="M270"/>
<Interaction id="I121" type="Pharmacodynamic interaction" trigger="M268" precipitant="M254" effect="M270"/>
<Interaction id="I122" type="Pharmacodynamic interaction" trigger="M268" precipitant="M257" effect="M270"/>
<Interaction id="I123" type="Pharmacodynamic interaction" trigger="M268" precipitant="M260" effect="M270"/>
<Interaction id="I124" type="Pharmacodynamic interaction" trigger="M268" precipitant="M263" effect="M270"/>
<Interaction id="I125" type="Pharmacodynamic interaction" trigger="M268" precipitant="M266" effect="M270"/>
<Interaction id="I126" type="Pharmacodynamic interaction" trigger="M268" precipitant="M269" effect="M270"/>
</Sentence>
<Sentence id="431" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Amiodarone is a substrate for CYP3A and CYP2C8, so inhibitors and inducers affect amiodarone exposure (7) Amiodarone inhibits p-glycoprotein and CYP1A2, CYP2C9, CYP2D6, and CYP3A, increasing exposure to other drugs (7) Drugs prolonging the QT interval: Co-administration of drugs prolonging the QT interval (such as class I and III antiarrhythmics, lithium, certain phenothiazines, tricyclic antidepressants, certain fluoroquinolone and macrolide antibiotics, azole antifungals, halogenated inhalation anesthetic agents) increases the risk of Torsade de Pointes.</SentenceText>
<Mention id="M303" type="Trigger" span="521 18" str="increases the risk"/>
<Mention id="M272" type="Precipitant" span="332 15" str="antiarrhythmics" code="N0000029121"/>
<Mention id="M305" type="SpecificInteraction" span="543 18" str="Torsade de Pointes" code="31722008: Torsades de pointes (disorder)"/>
<Mention id="M275" type="Precipitant" span="460 17" str="azole antifungals" code="N0000175487"/>
<Mention id="M283" type="Trigger" span="75 6;93 8" str="affect | exposure"/>
<Mention id="M278" type="Precipitant" span="40 6;66 8" str="CYP2C8 | inducers" code="n0000187063"/>
<Mention id="M280" type="Precipitant" span="40 6;51 10" str="CYP2C8 | inhibitors" code="n0000187062"/>
<Mention id="M282" type="Precipitant" span="30 5;66 8" str="CYP3A | inducers" code="n0000190118"/>
<Mention id="M284" type="Precipitant" span="30 5;51 10" str="CYP3A | inhibitors" code="n0000191001"/>
<Mention id="M286" type="Precipitant" span="274 32" str="drugs prolonging the QT interval" code="NO MAP"/>
<Mention id="M289" type="Precipitant" span="417 15;447 11" str="fluoroquinolone | antibiotics" code="N0000011190"/>
<Mention id="M292" type="Precipitant" span="479 40" str="halogenated inhalation anesthetic agents" code="N0000029139"/>
<Mention id="M295" type="Precipitant" span="349 7" str="lithium" code="N0000147892"/>
<Mention id="M298" type="Precipitant" span="437 21" str="macrolide antibiotics" code="N0000175431"/>
<Mention id="M301" type="Precipitant" span="366 14" str="phenothiazines" code="N0000175746"/>
<Mention id="M304" type="Precipitant" span="382 25" str="tricyclic antidepressants" code="N0000029148"/>
<Interaction id="I127" type="Pharmacodynamic interaction" trigger="M303" precipitant="M272" effect="M305"/>
<Interaction id="I128" type="Pharmacodynamic interaction" trigger="M303" precipitant="M275" effect="M305"/>
<Interaction id="I129" type="Pharmacokinetic interaction" trigger="M283" precipitant="M278" effect="C54356"/>
<Interaction id="I130" type="Pharmacokinetic interaction" trigger="M283" precipitant="M280" effect="C54355"/>
<Interaction id="I131" type="Pharmacokinetic interaction" trigger="M283" precipitant="M282" effect="C54356"/>
<Interaction id="I132" type="Pharmacokinetic interaction" trigger="M283" precipitant="M284" effect="C54355"/>
<Interaction id="I133" type="Pharmacodynamic interaction" trigger="M303" precipitant="M286" effect="M305"/>
<Interaction id="I134" type="Pharmacodynamic interaction" trigger="M303" precipitant="M289" effect="M305"/>
<Interaction id="I135" type="Pharmacodynamic interaction" trigger="M303" precipitant="M292" effect="M305"/>
<Interaction id="I136" type="Pharmacodynamic interaction" trigger="M303" precipitant="M295" effect="M305"/>
<Interaction id="I137" type="Pharmacodynamic interaction" trigger="M303" precipitant="M298" effect="M305"/>
<Interaction id="I138" type="Pharmacodynamic interaction" trigger="M303" precipitant="M301" effect="M305"/>
<Interaction id="I139" type="Pharmacodynamic interaction" trigger="M303" precipitant="M304" effect="M305"/>
</Sentence>
<Sentence id="431" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Amiodarone is a substrate for CYP3A and CYP2C8, so inhibitors and inducers affect amiodarone exposure (7) Amiodarone inhibits p-glycoprotein and CYP1A2, CYP2C9, CYP2D6, and CYP3A, increasing exposure to other drugs (7) Drugs prolonging the QT interval: Co-administration of drugs prolonging the QT interval (such as class I and III antiarrhythmics, lithium, certain phenothiazines, tricyclic antidepressants, certain fluoroquinolone and macrolide antibiotics, azole antifungals, halogenated inhalation anesthetic agents) increases the risk of Torsade de Pointes.</SentenceText>
<Mention id="M338" type="Trigger" span="521 18" str="increases the risk"/>
<Mention id="M307" type="Precipitant" span="332 15" str="antiarrhythmics" code="N0000029121"/>
<Mention id="M340" type="SpecificInteraction" span="543 18" str="Torsade de Pointes" code="31722008: Torsades de pointes (disorder)"/>
<Mention id="M310" type="Precipitant" span="460 17" str="azole antifungals" code="N0000175487"/>
<Mention id="M318" type="Trigger" span="75 6;93 8" str="affect | exposure"/>
<Mention id="M313" type="Precipitant" span="40 6;66 8" str="CYP2C8 | inducers" code="n0000187063"/>
<Mention id="M315" type="Precipitant" span="40 6;51 10" str="CYP2C8 | inhibitors" code="n0000187062"/>
<Mention id="M317" type="Precipitant" span="30 5;66 8" str="CYP3A | inducers" code="n0000190118"/>
<Mention id="M319" type="Precipitant" span="30 5;51 10" str="CYP3A | inhibitors" code="n0000191001"/>
<Mention id="M321" type="Precipitant" span="274 32" str="drugs prolonging the QT interval" code="NO MAP"/>
<Mention id="M324" type="Precipitant" span="417 15;447 11" str="fluoroquinolone | antibiotics" code="N0000011190"/>
<Mention id="M327" type="Precipitant" span="479 40" str="halogenated inhalation anesthetic agents" code="N0000029139"/>
<Mention id="M330" type="Precipitant" span="349 7" str="lithium" code="N0000147892"/>
<Mention id="M333" type="Precipitant" span="437 21" str="macrolide antibiotics" code="N0000175431"/>
<Mention id="M336" type="Precipitant" span="366 14" str="phenothiazines" code="N0000175746"/>
<Mention id="M339" type="Precipitant" span="382 25" str="tricyclic antidepressants" code="N0000029148"/>
<Interaction id="I140" type="Pharmacodynamic interaction" trigger="M338" precipitant="M307" effect="M340"/>
<Interaction id="I141" type="Pharmacodynamic interaction" trigger="M338" precipitant="M310" effect="M340"/>
<Interaction id="I142" type="Pharmacokinetic interaction" trigger="M318" precipitant="M313" effect="C54356"/>
<Interaction id="I143" type="Pharmacokinetic interaction" trigger="M318" precipitant="M315" effect="C54355"/>
<Interaction id="I144" type="Pharmacokinetic interaction" trigger="M318" precipitant="M317" effect="C54356"/>
<Interaction id="I145" type="Pharmacokinetic interaction" trigger="M318" precipitant="M319" effect="C54355"/>
<Interaction id="I146" type="Pharmacodynamic interaction" trigger="M338" precipitant="M321" effect="M340"/>
<Interaction id="I147" type="Pharmacodynamic interaction" trigger="M338" precipitant="M324" effect="M340"/>
<Interaction id="I148" type="Pharmacodynamic interaction" trigger="M338" precipitant="M327" effect="M340"/>
<Interaction id="I149" type="Pharmacodynamic interaction" trigger="M338" precipitant="M330" effect="M340"/>
<Interaction id="I150" type="Pharmacodynamic interaction" trigger="M338" precipitant="M333" effect="M340"/>
<Interaction id="I151" type="Pharmacodynamic interaction" trigger="M338" precipitant="M336" effect="M340"/>
<Interaction id="I152" type="Pharmacodynamic interaction" trigger="M338" precipitant="M339" effect="M340"/>
</Sentence>
<Sentence id="431" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Amiodarone is a substrate for CYP3A and CYP2C8, so inhibitors and inducers affect amiodarone exposure (7) Amiodarone inhibits p-glycoprotein and CYP1A2, CYP2C9, CYP2D6, and CYP3A, increasing exposure to other drugs (7) Drugs prolonging the QT interval: Co-administration of drugs prolonging the QT interval (such as class I and III antiarrhythmics, lithium, certain phenothiazines, tricyclic antidepressants, certain fluoroquinolone and macrolide antibiotics, azole antifungals, halogenated inhalation anesthetic agents) increases the risk of Torsade de Pointes.</SentenceText>
<Mention id="M373" type="Trigger" span="521 18" str="increases the risk"/>
<Mention id="M342" type="Precipitant" span="332 15" str="antiarrhythmics" code="N0000029121"/>
<Mention id="M375" type="SpecificInteraction" span="543 18" str="Torsade de Pointes" code="31722008: Torsades de pointes (disorder)"/>
<Mention id="M345" type="Precipitant" span="460 17" str="azole antifungals" code="N0000175487"/>
<Mention id="M353" type="Trigger" span="75 6;93 8" str="affect | exposure"/>
<Mention id="M348" type="Precipitant" span="40 6;66 8" str="CYP2C8 | inducers" code="n0000187063"/>
<Mention id="M350" type="Precipitant" span="40 6;51 10" str="CYP2C8 | inhibitors" code="n0000187062"/>
<Mention id="M352" type="Precipitant" span="30 5;66 8" str="CYP3A | inducers" code="n0000190118"/>
<Mention id="M354" type="Precipitant" span="30 5;51 10" str="CYP3A | inhibitors" code="n0000191001"/>
<Mention id="M356" type="Precipitant" span="274 32" str="drugs prolonging the QT interval" code="NO MAP"/>
<Mention id="M359" type="Precipitant" span="417 15;447 11" str="fluoroquinolone | antibiotics" code="N0000011190"/>
<Mention id="M362" type="Precipitant" span="479 40" str="halogenated inhalation anesthetic agents" code="N0000029139"/>
<Mention id="M365" type="Precipitant" span="349 7" str="lithium" code="N0000147892"/>
<Mention id="M368" type="Precipitant" span="437 21" str="macrolide antibiotics" code="N0000175431"/>
<Mention id="M371" type="Precipitant" span="366 14" str="phenothiazines" code="N0000175746"/>
<Mention id="M374" type="Precipitant" span="382 25" str="tricyclic antidepressants" code="N0000029148"/>
<Interaction id="I153" type="Pharmacodynamic interaction" trigger="M373" precipitant="M342" effect="M375"/>
<Interaction id="I154" type="Pharmacodynamic interaction" trigger="M373" precipitant="M345" effect="M375"/>
<Interaction id="I155" type="Pharmacokinetic interaction" trigger="M353" precipitant="M348" effect="C54356"/>
<Interaction id="I156" type="Pharmacokinetic interaction" trigger="M353" precipitant="M350" effect="C54355"/>
<Interaction id="I157" type="Pharmacokinetic interaction" trigger="M353" precipitant="M352" effect="C54356"/>
<Interaction id="I158" type="Pharmacokinetic interaction" trigger="M353" precipitant="M354" effect="C54355"/>
<Interaction id="I159" type="Pharmacodynamic interaction" trigger="M373" precipitant="M356" effect="M375"/>
<Interaction id="I160" type="Pharmacodynamic interaction" trigger="M373" precipitant="M359" effect="M375"/>
<Interaction id="I161" type="Pharmacodynamic interaction" trigger="M373" precipitant="M362" effect="M375"/>
<Interaction id="I162" type="Pharmacodynamic interaction" trigger="M373" precipitant="M365" effect="M375"/>
<Interaction id="I163" type="Pharmacodynamic interaction" trigger="M373" precipitant="M368" effect="M375"/>
<Interaction id="I164" type="Pharmacodynamic interaction" trigger="M373" precipitant="M371" effect="M375"/>
<Interaction id="I165" type="Pharmacodynamic interaction" trigger="M373" precipitant="M374" effect="M375"/>
</Sentence>
<Sentence id="431" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Amiodarone is a substrate for CYP3A and CYP2C8, so inhibitors and inducers affect amiodarone exposure (7) Amiodarone inhibits p-glycoprotein and CYP1A2, CYP2C9, CYP2D6, and CYP3A, increasing exposure to other drugs (7) Drugs prolonging the QT interval: Co-administration of drugs prolonging the QT interval (such as class I and III antiarrhythmics, lithium, certain phenothiazines, tricyclic antidepressants, certain fluoroquinolone and macrolide antibiotics, azole antifungals, halogenated inhalation anesthetic agents) increases the risk of Torsade de Pointes.</SentenceText>
<Mention id="M408" type="Trigger" span="521 18" str="increases the risk"/>
<Mention id="M377" type="Precipitant" span="332 15" str="antiarrhythmics" code="N0000029121"/>
<Mention id="M410" type="SpecificInteraction" span="543 18" str="Torsade de Pointes" code="31722008: Torsades de pointes (disorder)"/>
<Mention id="M380" type="Precipitant" span="460 17" str="azole antifungals" code="N0000175487"/>
<Mention id="M388" type="Trigger" span="75 6;93 8" str="affect | exposure"/>
<Mention id="M383" type="Precipitant" span="40 6;66 8" str="CYP2C8 | inducers" code="n0000187063"/>
<Mention id="M385" type="Precipitant" span="40 6;51 10" str="CYP2C8 | inhibitors" code="n0000187062"/>
<Mention id="M387" type="Precipitant" span="30 5;66 8" str="CYP3A | inducers" code="n0000190118"/>
<Mention id="M389" type="Precipitant" span="30 5;51 10" str="CYP3A | inhibitors" code="n0000191001"/>
<Mention id="M391" type="Precipitant" span="274 32" str="drugs prolonging the QT interval" code="NO MAP"/>
<Mention id="M394" type="Precipitant" span="417 15;447 11" str="fluoroquinolone | antibiotics" code="N0000011190"/>
<Mention id="M397" type="Precipitant" span="479 40" str="halogenated inhalation anesthetic agents" code="N0000029139"/>
<Mention id="M400" type="Precipitant" span="349 7" str="lithium" code="N0000147892"/>
<Mention id="M403" type="Precipitant" span="437 21" str="macrolide antibiotics" code="N0000175431"/>
<Mention id="M406" type="Precipitant" span="366 14" str="phenothiazines" code="N0000175746"/>
<Mention id="M409" type="Precipitant" span="382 25" str="tricyclic antidepressants" code="N0000029148"/>
<Interaction id="I166" type="Pharmacodynamic interaction" trigger="M408" precipitant="M377" effect="M410"/>
<Interaction id="I167" type="Pharmacodynamic interaction" trigger="M408" precipitant="M380" effect="M410"/>
<Interaction id="I168" type="Pharmacokinetic interaction" trigger="M388" precipitant="M383" effect="C54356"/>
<Interaction id="I169" type="Pharmacokinetic interaction" trigger="M388" precipitant="M385" effect="C54355"/>
<Interaction id="I170" type="Pharmacokinetic interaction" trigger="M388" precipitant="M387" effect="C54356"/>
<Interaction id="I171" type="Pharmacokinetic interaction" trigger="M388" precipitant="M389" effect="C54355"/>
<Interaction id="I172" type="Pharmacodynamic interaction" trigger="M408" precipitant="M391" effect="M410"/>
<Interaction id="I173" type="Pharmacodynamic interaction" trigger="M408" precipitant="M394" effect="M410"/>
<Interaction id="I174" type="Pharmacodynamic interaction" trigger="M408" precipitant="M397" effect="M410"/>
<Interaction id="I175" type="Pharmacodynamic interaction" trigger="M408" precipitant="M400" effect="M410"/>
<Interaction id="I176" type="Pharmacodynamic interaction" trigger="M408" precipitant="M403" effect="M410"/>
<Interaction id="I177" type="Pharmacodynamic interaction" trigger="M408" precipitant="M406" effect="M410"/>
<Interaction id="I178" type="Pharmacodynamic interaction" trigger="M408" precipitant="M409" effect="M410"/>
</Sentence>
<Sentence id="431" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Amiodarone is a substrate for CYP3A and CYP2C8, so inhibitors and inducers affect amiodarone exposure (7) Amiodarone inhibits p-glycoprotein and CYP1A2, CYP2C9, CYP2D6, and CYP3A, increasing exposure to other drugs (7) Drugs prolonging the QT interval: Co-administration of drugs prolonging the QT interval (such as class I and III antiarrhythmics, lithium, certain phenothiazines, tricyclic antidepressants, certain fluoroquinolone and macrolide antibiotics, azole antifungals, halogenated inhalation anesthetic agents) increases the risk of Torsade de Pointes.</SentenceText>
<Mention id="M443" type="Trigger" span="521 18" str="increases the risk"/>
<Mention id="M412" type="Precipitant" span="332 15" str="antiarrhythmics" code="N0000029121"/>
<Mention id="M445" type="SpecificInteraction" span="543 18" str="Torsade de Pointes" code="31722008: Torsades de pointes (disorder)"/>
<Mention id="M415" type="Precipitant" span="460 17" str="azole antifungals" code="N0000175487"/>
<Mention id="M423" type="Trigger" span="75 6;93 8" str="affect | exposure"/>
<Mention id="M418" type="Precipitant" span="40 6;66 8" str="CYP2C8 | inducers" code="n0000187063"/>
<Mention id="M420" type="Precipitant" span="40 6;51 10" str="CYP2C8 | inhibitors" code="n0000187062"/>
<Mention id="M422" type="Precipitant" span="30 5;66 8" str="CYP3A | inducers" code="n0000190118"/>
<Mention id="M424" type="Precipitant" span="30 5;51 10" str="CYP3A | inhibitors" code="n0000191001"/>
<Mention id="M426" type="Precipitant" span="274 32" str="drugs prolonging the QT interval" code="NO MAP"/>
<Mention id="M429" type="Precipitant" span="417 15;447 11" str="fluoroquinolone | antibiotics" code="N0000011190"/>
<Mention id="M432" type="Precipitant" span="479 40" str="halogenated inhalation anesthetic agents" code="N0000029139"/>
<Mention id="M435" type="Precipitant" span="349 7" str="lithium" code="N0000147892"/>
<Mention id="M438" type="Precipitant" span="437 21" str="macrolide antibiotics" code="N0000175431"/>
<Mention id="M441" type="Precipitant" span="366 14" str="phenothiazines" code="N0000175746"/>
<Mention id="M444" type="Precipitant" span="382 25" str="tricyclic antidepressants" code="N0000029148"/>
<Interaction id="I179" type="Pharmacodynamic interaction" trigger="M443" precipitant="M412" effect="M445"/>
<Interaction id="I180" type="Pharmacodynamic interaction" trigger="M443" precipitant="M415" effect="M445"/>
<Interaction id="I181" type="Pharmacokinetic interaction" trigger="M423" precipitant="M418" effect="C54356"/>
<Interaction id="I182" type="Pharmacokinetic interaction" trigger="M423" precipitant="M420" effect="C54355"/>
<Interaction id="I183" type="Pharmacokinetic interaction" trigger="M423" precipitant="M422" effect="C54356"/>
<Interaction id="I184" type="Pharmacokinetic interaction" trigger="M423" precipitant="M424" effect="C54355"/>
<Interaction id="I185" type="Pharmacodynamic interaction" trigger="M443" precipitant="M426" effect="M445"/>
<Interaction id="I186" type="Pharmacodynamic interaction" trigger="M443" precipitant="M429" effect="M445"/>
<Interaction id="I187" type="Pharmacodynamic interaction" trigger="M443" precipitant="M432" effect="M445"/>
<Interaction id="I188" type="Pharmacodynamic interaction" trigger="M443" precipitant="M435" effect="M445"/>
<Interaction id="I189" type="Pharmacodynamic interaction" trigger="M443" precipitant="M438" effect="M445"/>
<Interaction id="I190" type="Pharmacodynamic interaction" trigger="M443" precipitant="M441" effect="M445"/>
<Interaction id="I191" type="Pharmacodynamic interaction" trigger="M443" precipitant="M444" effect="M445"/>
</Sentence>
<Sentence id="431" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Amiodarone is a substrate for CYP3A and CYP2C8, so inhibitors and inducers affect amiodarone exposure (7) Amiodarone inhibits p-glycoprotein and CYP1A2, CYP2C9, CYP2D6, and CYP3A, increasing exposure to other drugs (7) Drugs prolonging the QT interval: Co-administration of drugs prolonging the QT interval (such as class I and III antiarrhythmics, lithium, certain phenothiazines, tricyclic antidepressants, certain fluoroquinolone and macrolide antibiotics, azole antifungals, halogenated inhalation anesthetic agents) increases the risk of Torsade de Pointes.</SentenceText>
<Mention id="M478" type="Trigger" span="521 18" str="increases the risk"/>
<Mention id="M447" type="Precipitant" span="332 15" str="antiarrhythmics" code="N0000029121"/>
<Mention id="M480" type="SpecificInteraction" span="543 18" str="Torsade de Pointes" code="31722008: Torsades de pointes (disorder)"/>
<Mention id="M450" type="Precipitant" span="460 17" str="azole antifungals" code="N0000175487"/>
<Mention id="M458" type="Trigger" span="75 6;93 8" str="affect | exposure"/>
<Mention id="M453" type="Precipitant" span="40 6;66 8" str="CYP2C8 | inducers" code="n0000187063"/>
<Mention id="M455" type="Precipitant" span="40 6;51 10" str="CYP2C8 | inhibitors" code="n0000187062"/>
<Mention id="M457" type="Precipitant" span="30 5;66 8" str="CYP3A | inducers" code="n0000190118"/>
<Mention id="M459" type="Precipitant" span="30 5;51 10" str="CYP3A | inhibitors" code="n0000191001"/>
<Mention id="M461" type="Precipitant" span="274 32" str="drugs prolonging the QT interval" code="NO MAP"/>
<Mention id="M464" type="Precipitant" span="417 15;447 11" str="fluoroquinolone | antibiotics" code="N0000011190"/>
<Mention id="M467" type="Precipitant" span="479 40" str="halogenated inhalation anesthetic agents" code="N0000029139"/>
<Mention id="M470" type="Precipitant" span="349 7" str="lithium" code="N0000147892"/>
<Mention id="M473" type="Precipitant" span="437 21" str="macrolide antibiotics" code="N0000175431"/>
<Mention id="M476" type="Precipitant" span="366 14" str="phenothiazines" code="N0000175746"/>
<Mention id="M479" type="Precipitant" span="382 25" str="tricyclic antidepressants" code="N0000029148"/>
<Interaction id="I192" type="Pharmacodynamic interaction" trigger="M478" precipitant="M447" effect="M480"/>
<Interaction id="I193" type="Pharmacodynamic interaction" trigger="M478" precipitant="M450" effect="M480"/>
<Interaction id="I194" type="Pharmacokinetic interaction" trigger="M458" precipitant="M453" effect="C54356"/>
<Interaction id="I195" type="Pharmacokinetic interaction" trigger="M458" precipitant="M455" effect="C54355"/>
<Interaction id="I196" type="Pharmacokinetic interaction" trigger="M458" precipitant="M457" effect="C54356"/>
<Interaction id="I197" type="Pharmacokinetic interaction" trigger="M458" precipitant="M459" effect="C54355"/>
<Interaction id="I198" type="Pharmacodynamic interaction" trigger="M478" precipitant="M461" effect="M480"/>
<Interaction id="I199" type="Pharmacodynamic interaction" trigger="M478" precipitant="M464" effect="M480"/>
<Interaction id="I200" type="Pharmacodynamic interaction" trigger="M478" precipitant="M467" effect="M480"/>
<Interaction id="I201" type="Pharmacodynamic interaction" trigger="M478" precipitant="M470" effect="M480"/>
<Interaction id="I202" type="Pharmacodynamic interaction" trigger="M478" precipitant="M473" effect="M480"/>
<Interaction id="I203" type="Pharmacodynamic interaction" trigger="M478" precipitant="M476" effect="M480"/>
<Interaction id="I204" type="Pharmacodynamic interaction" trigger="M478" precipitant="M479" effect="M480"/>
</Sentence>
<Sentence id="431" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Amiodarone is a substrate for CYP3A and CYP2C8, so inhibitors and inducers affect amiodarone exposure (7) Amiodarone inhibits p-glycoprotein and CYP1A2, CYP2C9, CYP2D6, and CYP3A, increasing exposure to other drugs (7) Drugs prolonging the QT interval: Co-administration of drugs prolonging the QT interval (such as class I and III antiarrhythmics, lithium, certain phenothiazines, tricyclic antidepressants, certain fluoroquinolone and macrolide antibiotics, azole antifungals, halogenated inhalation anesthetic agents) increases the risk of Torsade de Pointes.</SentenceText>
<Mention id="M513" type="Trigger" span="521 18" str="increases the risk"/>
<Mention id="M482" type="Precipitant" span="332 15" str="antiarrhythmics" code="N0000029121"/>
<Mention id="M515" type="SpecificInteraction" span="543 18" str="Torsade de Pointes" code="31722008: Torsades de pointes (disorder)"/>
<Mention id="M485" type="Precipitant" span="460 17" str="azole antifungals" code="N0000175487"/>
<Mention id="M493" type="Trigger" span="75 6;93 8" str="affect | exposure"/>
<Mention id="M488" type="Precipitant" span="40 6;66 8" str="CYP2C8 | inducers" code="n0000187063"/>
<Mention id="M490" type="Precipitant" span="40 6;51 10" str="CYP2C8 | inhibitors" code="n0000187062"/>
<Mention id="M492" type="Precipitant" span="30 5;66 8" str="CYP3A | inducers" code="n0000190118"/>
<Mention id="M494" type="Precipitant" span="30 5;51 10" str="CYP3A | inhibitors" code="n0000191001"/>
<Mention id="M496" type="Precipitant" span="274 32" str="drugs prolonging the QT interval" code="NO MAP"/>
<Mention id="M499" type="Precipitant" span="417 15;447 11" str="fluoroquinolone | antibiotics" code="N0000011190"/>
<Mention id="M502" type="Precipitant" span="479 40" str="halogenated inhalation anesthetic agents" code="N0000029139"/>
<Mention id="M505" type="Precipitant" span="349 7" str="lithium" code="N0000147892"/>
<Mention id="M508" type="Precipitant" span="437 21" str="macrolide antibiotics" code="N0000175431"/>
<Mention id="M511" type="Precipitant" span="366 14" str="phenothiazines" code="N0000175746"/>
<Mention id="M514" type="Precipitant" span="382 25" str="tricyclic antidepressants" code="N0000029148"/>
<Interaction id="I205" type="Pharmacodynamic interaction" trigger="M513" precipitant="M482" effect="M515"/>
<Interaction id="I206" type="Pharmacodynamic interaction" trigger="M513" precipitant="M485" effect="M515"/>
<Interaction id="I207" type="Pharmacokinetic interaction" trigger="M493" precipitant="M488" effect="C54356"/>
<Interaction id="I208" type="Pharmacokinetic interaction" trigger="M493" precipitant="M490" effect="C54355"/>
<Interaction id="I209" type="Pharmacokinetic interaction" trigger="M493" precipitant="M492" effect="C54356"/>
<Interaction id="I210" type="Pharmacokinetic interaction" trigger="M493" precipitant="M494" effect="C54355"/>
<Interaction id="I211" type="Pharmacodynamic interaction" trigger="M513" precipitant="M496" effect="M515"/>
<Interaction id="I212" type="Pharmacodynamic interaction" trigger="M513" precipitant="M499" effect="M515"/>
<Interaction id="I213" type="Pharmacodynamic interaction" trigger="M513" precipitant="M502" effect="M515"/>
<Interaction id="I214" type="Pharmacodynamic interaction" trigger="M513" precipitant="M505" effect="M515"/>
<Interaction id="I215" type="Pharmacodynamic interaction" trigger="M513" precipitant="M508" effect="M515"/>
<Interaction id="I216" type="Pharmacodynamic interaction" trigger="M513" precipitant="M511" effect="M515"/>
<Interaction id="I217" type="Pharmacodynamic interaction" trigger="M513" precipitant="M514" effect="M515"/>
</Sentence>
<Sentence id="431" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Amiodarone is a substrate for CYP3A and CYP2C8, so inhibitors and inducers affect amiodarone exposure (7) Amiodarone inhibits p-glycoprotein and CYP1A2, CYP2C9, CYP2D6, and CYP3A, increasing exposure to other drugs (7) Drugs prolonging the QT interval: Co-administration of drugs prolonging the QT interval (such as class I and III antiarrhythmics, lithium, certain phenothiazines, tricyclic antidepressants, certain fluoroquinolone and macrolide antibiotics, azole antifungals, halogenated inhalation anesthetic agents) increases the risk of Torsade de Pointes.</SentenceText>
<Mention id="M548" type="Trigger" span="521 18" str="increases the risk"/>
<Mention id="M517" type="Precipitant" span="332 15" str="antiarrhythmics" code="N0000029121"/>
<Mention id="M550" type="SpecificInteraction" span="543 18" str="Torsade de Pointes" code="31722008: Torsades de pointes (disorder)"/>
<Mention id="M520" type="Precipitant" span="460 17" str="azole antifungals" code="N0000175487"/>
<Mention id="M528" type="Trigger" span="75 6;93 8" str="affect | exposure"/>
<Mention id="M523" type="Precipitant" span="40 6;66 8" str="CYP2C8 | inducers" code="n0000187063"/>
<Mention id="M525" type="Precipitant" span="40 6;51 10" str="CYP2C8 | inhibitors" code="n0000187062"/>
<Mention id="M527" type="Precipitant" span="30 5;66 8" str="CYP3A | inducers" code="n0000190118"/>
<Mention id="M529" type="Precipitant" span="30 5;51 10" str="CYP3A | inhibitors" code="n0000191001"/>
<Mention id="M531" type="Precipitant" span="274 32" str="drugs prolonging the QT interval" code="NO MAP"/>
<Mention id="M534" type="Precipitant" span="417 15;447 11" str="fluoroquinolone | antibiotics" code="N0000011190"/>
<Mention id="M537" type="Precipitant" span="479 40" str="halogenated inhalation anesthetic agents" code="N0000029139"/>
<Mention id="M540" type="Precipitant" span="349 7" str="lithium" code="N0000147892"/>
<Mention id="M543" type="Precipitant" span="437 21" str="macrolide antibiotics" code="N0000175431"/>
<Mention id="M546" type="Precipitant" span="366 14" str="phenothiazines" code="N0000175746"/>
<Mention id="M549" type="Precipitant" span="382 25" str="tricyclic antidepressants" code="N0000029148"/>
<Interaction id="I218" type="Pharmacodynamic interaction" trigger="M548" precipitant="M517" effect="M550"/>
<Interaction id="I219" type="Pharmacodynamic interaction" trigger="M548" precipitant="M520" effect="M550"/>
<Interaction id="I220" type="Pharmacokinetic interaction" trigger="M528" precipitant="M523" effect="C54356"/>
<Interaction id="I221" type="Pharmacokinetic interaction" trigger="M528" precipitant="M525" effect="C54355"/>
<Interaction id="I222" type="Pharmacokinetic interaction" trigger="M528" precipitant="M527" effect="C54356"/>
<Interaction id="I223" type="Pharmacokinetic interaction" trigger="M528" precipitant="M529" effect="C54355"/>
<Interaction id="I224" type="Pharmacodynamic interaction" trigger="M548" precipitant="M531" effect="M550"/>
<Interaction id="I225" type="Pharmacodynamic interaction" trigger="M548" precipitant="M534" effect="M550"/>
<Interaction id="I226" type="Pharmacodynamic interaction" trigger="M548" precipitant="M537" effect="M550"/>
<Interaction id="I227" type="Pharmacodynamic interaction" trigger="M548" precipitant="M540" effect="M550"/>
<Interaction id="I228" type="Pharmacodynamic interaction" trigger="M548" precipitant="M543" effect="M550"/>
<Interaction id="I229" type="Pharmacodynamic interaction" trigger="M548" precipitant="M546" effect="M550"/>
<Interaction id="I230" type="Pharmacodynamic interaction" trigger="M548" precipitant="M549" effect="M550"/>
</Sentence>
<Sentence id="431" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Amiodarone is a substrate for CYP3A and CYP2C8, so inhibitors and inducers affect amiodarone exposure (7) Amiodarone inhibits p-glycoprotein and CYP1A2, CYP2C9, CYP2D6, and CYP3A, increasing exposure to other drugs (7) Drugs prolonging the QT interval: Co-administration of drugs prolonging the QT interval (such as class I and III antiarrhythmics, lithium, certain phenothiazines, tricyclic antidepressants, certain fluoroquinolone and macrolide antibiotics, azole antifungals, halogenated inhalation anesthetic agents) increases the risk of Torsade de Pointes.</SentenceText>
<Mention id="M583" type="Trigger" span="521 18" str="increases the risk"/>
<Mention id="M552" type="Precipitant" span="332 15" str="antiarrhythmics" code="N0000029121"/>
<Mention id="M585" type="SpecificInteraction" span="543 18" str="Torsade de Pointes" code="31722008: Torsades de pointes (disorder)"/>
<Mention id="M555" type="Precipitant" span="460 17" str="azole antifungals" code="N0000175487"/>
<Mention id="M563" type="Trigger" span="75 6;93 8" str="affect | exposure"/>
<Mention id="M558" type="Precipitant" span="40 6;66 8" str="CYP2C8 | inducers" code="n0000187063"/>
<Mention id="M560" type="Precipitant" span="40 6;51 10" str="CYP2C8 | inhibitors" code="n0000187062"/>
<Mention id="M562" type="Precipitant" span="30 5;66 8" str="CYP3A | inducers" code="n0000190118"/>
<Mention id="M564" type="Precipitant" span="30 5;51 10" str="CYP3A | inhibitors" code="n0000191001"/>
<Mention id="M566" type="Precipitant" span="274 32" str="drugs prolonging the QT interval" code="NO MAP"/>
<Mention id="M569" type="Precipitant" span="417 15;447 11" str="fluoroquinolone | antibiotics" code="N0000011190"/>
<Mention id="M572" type="Precipitant" span="479 40" str="halogenated inhalation anesthetic agents" code="N0000029139"/>
<Mention id="M575" type="Precipitant" span="349 7" str="lithium" code="N0000147892"/>
<Mention id="M578" type="Precipitant" span="437 21" str="macrolide antibiotics" code="N0000175431"/>
<Mention id="M581" type="Precipitant" span="366 14" str="phenothiazines" code="N0000175746"/>
<Mention id="M584" type="Precipitant" span="382 25" str="tricyclic antidepressants" code="N0000029148"/>
<Interaction id="I231" type="Pharmacodynamic interaction" trigger="M583" precipitant="M552" effect="M585"/>
<Interaction id="I232" type="Pharmacodynamic interaction" trigger="M583" precipitant="M555" effect="M585"/>
<Interaction id="I233" type="Pharmacokinetic interaction" trigger="M563" precipitant="M558" effect="C54356"/>
<Interaction id="I234" type="Pharmacokinetic interaction" trigger="M563" precipitant="M560" effect="C54355"/>
<Interaction id="I235" type="Pharmacokinetic interaction" trigger="M563" precipitant="M562" effect="C54356"/>
<Interaction id="I236" type="Pharmacokinetic interaction" trigger="M563" precipitant="M564" effect="C54355"/>
<Interaction id="I237" type="Pharmacodynamic interaction" trigger="M583" precipitant="M566" effect="M585"/>
<Interaction id="I238" type="Pharmacodynamic interaction" trigger="M583" precipitant="M569" effect="M585"/>
<Interaction id="I239" type="Pharmacodynamic interaction" trigger="M583" precipitant="M572" effect="M585"/>
<Interaction id="I240" type="Pharmacodynamic interaction" trigger="M583" precipitant="M575" effect="M585"/>
<Interaction id="I241" type="Pharmacodynamic interaction" trigger="M583" precipitant="M578" effect="M585"/>
<Interaction id="I242" type="Pharmacodynamic interaction" trigger="M583" precipitant="M581" effect="M585"/>
<Interaction id="I243" type="Pharmacodynamic interaction" trigger="M583" precipitant="M584" effect="M585"/>
</Sentence>
<Sentence id="431" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Amiodarone is a substrate for CYP3A and CYP2C8, so inhibitors and inducers affect amiodarone exposure (7) Amiodarone inhibits p-glycoprotein and CYP1A2, CYP2C9, CYP2D6, and CYP3A, increasing exposure to other drugs (7) Drugs prolonging the QT interval: Co-administration of drugs prolonging the QT interval (such as class I and III antiarrhythmics, lithium, certain phenothiazines, tricyclic antidepressants, certain fluoroquinolone and macrolide antibiotics, azole antifungals, halogenated inhalation anesthetic agents) increases the risk of Torsade de Pointes.</SentenceText>
<Mention id="M618" type="Trigger" span="521 18" str="increases the risk"/>
<Mention id="M587" type="Precipitant" span="332 15" str="antiarrhythmics" code="N0000029121"/>
<Mention id="M620" type="SpecificInteraction" span="543 18" str="Torsade de Pointes" code="31722008: Torsades de pointes (disorder)"/>
<Mention id="M590" type="Precipitant" span="460 17" str="azole antifungals" code="N0000175487"/>
<Mention id="M598" type="Trigger" span="75 6;93 8" str="affect | exposure"/>
<Mention id="M593" type="Precipitant" span="40 6;66 8" str="CYP2C8 | inducers" code="n0000187063"/>
<Mention id="M595" type="Precipitant" span="40 6;51 10" str="CYP2C8 | inhibitors" code="n0000187062"/>
<Mention id="M597" type="Precipitant" span="30 5;66 8" str="CYP3A | inducers" code="n0000190118"/>
<Mention id="M599" type="Precipitant" span="30 5;51 10" str="CYP3A | inhibitors" code="n0000191001"/>
<Mention id="M601" type="Precipitant" span="274 32" str="drugs prolonging the QT interval" code="NO MAP"/>
<Mention id="M604" type="Precipitant" span="417 15;447 11" str="fluoroquinolone | antibiotics" code="N0000011190"/>
<Mention id="M607" type="Precipitant" span="479 40" str="halogenated inhalation anesthetic agents" code="N0000029139"/>
<Mention id="M610" type="Precipitant" span="349 7" str="lithium" code="N0000147892"/>
<Mention id="M613" type="Precipitant" span="437 21" str="macrolide antibiotics" code="N0000175431"/>
<Mention id="M616" type="Precipitant" span="366 14" str="phenothiazines" code="N0000175746"/>
<Mention id="M619" type="Precipitant" span="382 25" str="tricyclic antidepressants" code="N0000029148"/>
<Interaction id="I244" type="Pharmacodynamic interaction" trigger="M618" precipitant="M587" effect="M620"/>
<Interaction id="I245" type="Pharmacodynamic interaction" trigger="M618" precipitant="M590" effect="M620"/>
<Interaction id="I246" type="Pharmacokinetic interaction" trigger="M598" precipitant="M593" effect="C54356"/>
<Interaction id="I247" type="Pharmacokinetic interaction" trigger="M598" precipitant="M595" effect="C54355"/>
<Interaction id="I248" type="Pharmacokinetic interaction" trigger="M598" precipitant="M597" effect="C54356"/>
<Interaction id="I249" type="Pharmacokinetic interaction" trigger="M598" precipitant="M599" effect="C54355"/>
<Interaction id="I250" type="Pharmacodynamic interaction" trigger="M618" precipitant="M601" effect="M620"/>
<Interaction id="I251" type="Pharmacodynamic interaction" trigger="M618" precipitant="M604" effect="M620"/>
<Interaction id="I252" type="Pharmacodynamic interaction" trigger="M618" precipitant="M607" effect="M620"/>
<Interaction id="I253" type="Pharmacodynamic interaction" trigger="M618" precipitant="M610" effect="M620"/>
<Interaction id="I254" type="Pharmacodynamic interaction" trigger="M618" precipitant="M613" effect="M620"/>
<Interaction id="I255" type="Pharmacodynamic interaction" trigger="M618" precipitant="M616" effect="M620"/>
<Interaction id="I256" type="Pharmacodynamic interaction" trigger="M618" precipitant="M619" effect="M620"/>
</Sentence>
<Sentence id="431" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Amiodarone is a substrate for CYP3A and CYP2C8, so inhibitors and inducers affect amiodarone exposure (7) Amiodarone inhibits p-glycoprotein and CYP1A2, CYP2C9, CYP2D6, and CYP3A, increasing exposure to other drugs (7) Drugs prolonging the QT interval: Co-administration of drugs prolonging the QT interval (such as class I and III antiarrhythmics, lithium, certain phenothiazines, tricyclic antidepressants, certain fluoroquinolone and macrolide antibiotics, azole antifungals, halogenated inhalation anesthetic agents) increases the risk of Torsade de Pointes.</SentenceText>
<Mention id="M653" type="Trigger" span="521 18" str="increases the risk"/>
<Mention id="M622" type="Precipitant" span="332 15" str="antiarrhythmics" code="N0000029121"/>
<Mention id="M655" type="SpecificInteraction" span="543 18" str="Torsade de Pointes" code="31722008: Torsades de pointes (disorder)"/>
<Mention id="M625" type="Precipitant" span="460 17" str="azole antifungals" code="N0000175487"/>
<Mention id="M633" type="Trigger" span="75 6;93 8" str="affect | exposure"/>
<Mention id="M628" type="Precipitant" span="40 6;66 8" str="CYP2C8 | inducers" code="n0000187063"/>
<Mention id="M630" type="Precipitant" span="40 6;51 10" str="CYP2C8 | inhibitors" code="n0000187062"/>
<Mention id="M632" type="Precipitant" span="30 5;66 8" str="CYP3A | inducers" code="n0000190118"/>
<Mention id="M634" type="Precipitant" span="30 5;51 10" str="CYP3A | inhibitors" code="n0000191001"/>
<Mention id="M636" type="Precipitant" span="274 32" str="drugs prolonging the QT interval" code="NO MAP"/>
<Mention id="M639" type="Precipitant" span="417 15;447 11" str="fluoroquinolone | antibiotics" code="N0000011190"/>
<Mention id="M642" type="Precipitant" span="479 40" str="halogenated inhalation anesthetic agents" code="N0000029139"/>
<Mention id="M645" type="Precipitant" span="349 7" str="lithium" code="N0000147892"/>
<Mention id="M648" type="Precipitant" span="437 21" str="macrolide antibiotics" code="N0000175431"/>
<Mention id="M651" type="Precipitant" span="366 14" str="phenothiazines" code="N0000175746"/>
<Mention id="M654" type="Precipitant" span="382 25" str="tricyclic antidepressants" code="N0000029148"/>
<Interaction id="I257" type="Pharmacodynamic interaction" trigger="M653" precipitant="M622" effect="M655"/>
<Interaction id="I258" type="Pharmacodynamic interaction" trigger="M653" precipitant="M625" effect="M655"/>
<Interaction id="I259" type="Pharmacokinetic interaction" trigger="M633" precipitant="M628" effect="C54356"/>
<Interaction id="I260" type="Pharmacokinetic interaction" trigger="M633" precipitant="M630" effect="C54355"/>
<Interaction id="I261" type="Pharmacokinetic interaction" trigger="M633" precipitant="M632" effect="C54356"/>
<Interaction id="I262" type="Pharmacokinetic interaction" trigger="M633" precipitant="M634" effect="C54355"/>
<Interaction id="I263" type="Pharmacodynamic interaction" trigger="M653" precipitant="M636" effect="M655"/>
<Interaction id="I264" type="Pharmacodynamic interaction" trigger="M653" precipitant="M639" effect="M655"/>
<Interaction id="I265" type="Pharmacodynamic interaction" trigger="M653" precipitant="M642" effect="M655"/>
<Interaction id="I266" type="Pharmacodynamic interaction" trigger="M653" precipitant="M645" effect="M655"/>
<Interaction id="I267" type="Pharmacodynamic interaction" trigger="M653" precipitant="M648" effect="M655"/>
<Interaction id="I268" type="Pharmacodynamic interaction" trigger="M653" precipitant="M651" effect="M655"/>
<Interaction id="I269" type="Pharmacodynamic interaction" trigger="M653" precipitant="M654" effect="M655"/>
</Sentence>
<Sentence id="432" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Amiodarone is metabolized to the active metabolite desethylamiodarone ( DEA ) by the cytochrome P450 ( CYP450 ) enzyme group , specifically CYP3A and CYP2C8 .</SentenceText>
</Sentence>
<Sentence id="433" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Antiarrhythmics : The metabolism of quinidine , procainamide , flecainide can be inhibited by amiodarone .</SentenceText>
<Mention id="M660" type="Trigger" span="22 10;81 9" str="metabolism | inhibited"/>
<Mention id="M657" type="Precipitant" span="63 10" str="flecainide" code="N0000006966"/>
<Mention id="M659" type="Precipitant" span="48 12" str="procainamide" code="N0000005813"/>
<Mention id="M661" type="Precipitant" span="36 9" str="quinidine" code="N0000007728"/>
<Interaction id="I270" type="Pharmacokinetic interaction" trigger="M660" precipitant="M657" effect="C54357"/>
<Interaction id="I271" type="Pharmacokinetic interaction" trigger="M660" precipitant="M659" effect="C54357"/>
<Interaction id="I272" type="Pharmacokinetic interaction" trigger="M660" precipitant="M661" effect="C54357"/>
</Sentence>
<Sentence id="433" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Antiarrhythmics : The metabolism of quinidine , procainamide , flecainide can be inhibited by amiodarone .</SentenceText>
<Mention id="M666" type="Trigger" span="22 10;81 9" str="metabolism | inhibited"/>
<Mention id="M663" type="Precipitant" span="63 10" str="flecainide" code="N0000006966"/>
<Mention id="M665" type="Precipitant" span="48 12" str="procainamide" code="N0000005813"/>
<Mention id="M667" type="Precipitant" span="36 9" str="quinidine" code="N0000007728"/>
<Interaction id="I273" type="Pharmacokinetic interaction" trigger="M666" precipitant="M663" effect="C54357"/>
<Interaction id="I274" type="Pharmacokinetic interaction" trigger="M666" precipitant="M665" effect="C54357"/>
<Interaction id="I275" type="Pharmacokinetic interaction" trigger="M666" precipitant="M667" effect="C54357"/>
</Sentence>
<Sentence id="433" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Antiarrhythmics : The metabolism of quinidine , procainamide , flecainide can be inhibited by amiodarone .</SentenceText>
<Mention id="M672" type="Trigger" span="22 10;81 9" str="metabolism | inhibited"/>
<Mention id="M669" type="Precipitant" span="63 10" str="flecainide" code="N0000006966"/>
<Mention id="M671" type="Precipitant" span="48 12" str="procainamide" code="N0000005813"/>
<Mention id="M673" type="Precipitant" span="36 9" str="quinidine" code="N0000007728"/>
<Interaction id="I276" type="Pharmacokinetic interaction" trigger="M672" precipitant="M669" effect="C54357"/>
<Interaction id="I277" type="Pharmacokinetic interaction" trigger="M672" precipitant="M671" effect="C54357"/>
<Interaction id="I278" type="Pharmacokinetic interaction" trigger="M672" precipitant="M673" effect="C54357"/>
</Sentence>
<Sentence id="434" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Anticoagulants : Potentiation of warfarin - type ( CYP2C9 and CYP3A substrate ) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding .</SentenceText>
<Mention id="M679" type="Trigger" span="17 12" str="Potentiation "/>
<Mention id="M680" type="Trigger" span="166 9" str=" result in"/>
<Mention id="M676" type="Precipitant" span="51 6;68 9" str="CYP2C9 | substrate" code="NO MAP"/>
<Mention id="M686" type="SpecificInteraction" span="17 12;80 22" str="Potentiation | anticoagulant response " code="64779008: Blood coagulation disorder (disorder)"/>
<Mention id="M687" type="SpecificInteraction" span="193 8" str=" bleeding" code=" 131148009: Bleeding (finding)"/>
<Mention id="M681" type="Precipitant" span="62 15" str="CYP3A substrate" code="NO MAP"/>
<Mention id="M684" type="Trigger" span="17 15;94 8" str="Potentiation of | response"/>
<Mention id="M685" type="Precipitant" span="33 8" str="warfarin" code="N0000006403"/>
<Interaction id="I279" type="Pharmacodynamic interaction" trigger="M679;M680" precipitant="M676" effect="M686;M687"/>
<Interaction id="I280" type="Pharmacodynamic interaction" trigger="M679;M680" precipitant="M681" effect="M686;M687"/>
<Interaction id="I281" type="Pharmacodynamic interaction" trigger="M684" precipitant="M685" effect="M686;M687"/>
</Sentence>
<Sentence id="434" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Anticoagulants : Potentiation of warfarin - type ( CYP2C9 and CYP3A substrate ) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding .</SentenceText>
<Mention id="M693" type="Trigger" span="17 12" str="Potentiation "/>
<Mention id="M694" type="Trigger" span="166 9" str=" result in"/>
<Mention id="M690" type="Precipitant" span="51 6;68 9" str="CYP2C9 | substrate" code="NO MAP"/>
<Mention id="M700" type="SpecificInteraction" span="17 12;80 22" str="Potentiation | anticoagulant response " code="64779008: Blood coagulation disorder (disorder)"/>
<Mention id="M701" type="SpecificInteraction" span="193 8" str=" bleeding" code=" 131148009: Bleeding (finding)"/>
<Mention id="M695" type="Precipitant" span="62 15" str="CYP3A substrate" code="NO MAP"/>
<Mention id="M698" type="Trigger" span="17 15;94 8" str="Potentiation of | response"/>
<Mention id="M699" type="Precipitant" span="33 8" str="warfarin" code="N0000006403"/>
<Interaction id="I282" type="Pharmacodynamic interaction" trigger="M693;M694" precipitant="M690" effect="M700;M701"/>
<Interaction id="I283" type="Pharmacodynamic interaction" trigger="M693;M694" precipitant="M695" effect="M700;M701"/>
<Interaction id="I284" type="Pharmacodynamic interaction" trigger="M698" precipitant="M699" effect="M700;M701"/>
</Sentence>
<Sentence id="434" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Anticoagulants : Potentiation of warfarin - type ( CYP2C9 and CYP3A substrate ) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding .</SentenceText>
<Mention id="M707" type="Trigger" span="17 12" str="Potentiation "/>
<Mention id="M708" type="Trigger" span="166 9" str=" result in"/>
<Mention id="M704" type="Precipitant" span="51 6;68 9" str="CYP2C9 | substrate" code="NO MAP"/>
<Mention id="M714" type="SpecificInteraction" span="17 12;80 22" str="Potentiation | anticoagulant response " code="64779008: Blood coagulation disorder (disorder)"/>
<Mention id="M715" type="SpecificInteraction" span="193 8" str=" bleeding" code=" 131148009: Bleeding (finding)"/>
<Mention id="M709" type="Precipitant" span="62 15" str="CYP3A substrate" code="NO MAP"/>
<Mention id="M712" type="Trigger" span="17 15;94 8" str="Potentiation of | response"/>
<Mention id="M713" type="Precipitant" span="33 8" str="warfarin" code="N0000006403"/>
<Interaction id="I285" type="Pharmacodynamic interaction" trigger="M707;M708" precipitant="M704" effect="M714;M715"/>
<Interaction id="I286" type="Pharmacodynamic interaction" trigger="M707;M708" precipitant="M709" effect="M714;M715"/>
<Interaction id="I287" type="Pharmacodynamic interaction" trigger="M712" precipitant="M713" effect="M714;M715"/>
</Sentence>
<Sentence id="435" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Anticoagulants: Potentiation of warfarin-type (CYP2C9 and CYP3A substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.</SentenceText>
<Mention id="M716" type="Trigger" span="16 15;89 8" str="Potentiation of | response"/>
<Mention id="M717" type="Precipitant" span="32 8" str="warfarin" code="N0000006403"/>
<Mention id="M718" type="SpecificInteraction" span="16 12;75 22" str="Potentiation | anticoagulant response " code="64779008: Blood coagulation disorder (disorder)"/>
<Mention id="M719" type="SpecificInteraction" span="188 8" str=" bleeding" code=" 131148009: Bleeding (finding)"/>
<Interaction id="I288" type="Pharmacodynamic interaction" trigger="M716" precipitant="M717" effect="M718;M719"/>
</Sentence>
<Sentence id="436" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Bradycardia generally occurred within hours to days, but in some cases up to 2 weeks after initiating antiviral treatment.</SentenceText>
</Sentence>
<Sentence id="437" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Bradycardia generally resolved after discontinuation of antiviral treatment.</SentenceText>
</Sentence>
<Sentence id="438" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Cyclosporine ( CYP3A substrate ) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine , despite reduction in dose of cyclosporine .</SentenceText>
<Mention id="M723" type="Trigger" span="171 12" str="resulting in"/>
<Mention id="M727" type="Precipitant" span="0 12" str="Cyclosporine" code="N0000007346"/>
<Mention id="M725" type="SpecificInteraction" span="184 19" str="elevated creatinine" code="166717003: Serum creatinine raised (finding)"/>
<Mention id="M729" type="Precipitant" span="15 15" str="CYP3A substrate" code="NO MAP"/>
<Mention id="M728" type="Trigger" span="124 30" str="elevated plasma concentrations"/>
<Interaction id="I289" type="Pharmacodynamic interaction" trigger="M723" precipitant="M727" effect="M725"/>
<Interaction id="I290" type="Pharmacodynamic interaction" trigger="M723" precipitant="M729" effect="M725"/>
<Interaction id="I291" type="Pharmacokinetic interaction" trigger="M728" precipitant="M727" effect="C54357"/>
<Interaction id="I292" type="Pharmacokinetic interaction" trigger="M728" precipitant="M729" effect="C54357"/>
</Sentence>
<Sentence id="438" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Cyclosporine ( CYP3A substrate ) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine , despite reduction in dose of cyclosporine .</SentenceText>
<Mention id="M733" type="Trigger" span="171 12" str="resulting in"/>
<Mention id="M737" type="Precipitant" span="0 12" str="Cyclosporine" code="N0000007346"/>
<Mention id="M735" type="SpecificInteraction" span="184 19" str="elevated creatinine" code="166717003: Serum creatinine raised (finding)"/>
<Mention id="M739" type="Precipitant" span="15 15" str="CYP3A substrate" code="NO MAP"/>
<Mention id="M738" type="Trigger" span="124 30" str="elevated plasma concentrations"/>
<Interaction id="I293" type="Pharmacodynamic interaction" trigger="M733" precipitant="M737" effect="M735"/>
<Interaction id="I294" type="Pharmacodynamic interaction" trigger="M733" precipitant="M739" effect="M735"/>
<Interaction id="I295" type="Pharmacokinetic interaction" trigger="M738" precipitant="M737" effect="C54357"/>
<Interaction id="I296" type="Pharmacokinetic interaction" trigger="M738" precipitant="M739" effect="C54357"/>
</Sentence>
<Sentence id="438" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Cyclosporine ( CYP3A substrate ) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine , despite reduction in dose of cyclosporine .</SentenceText>
<Mention id="M743" type="Trigger" span="171 12" str="resulting in"/>
<Mention id="M747" type="Precipitant" span="0 12" str="Cyclosporine" code="N0000007346"/>
<Mention id="M745" type="SpecificInteraction" span="184 19" str="elevated creatinine" code="166717003: Serum creatinine raised (finding)"/>
<Mention id="M749" type="Precipitant" span="15 15" str="CYP3A substrate" code="NO MAP"/>
<Mention id="M748" type="Trigger" span="124 30" str="elevated plasma concentrations"/>
<Interaction id="I297" type="Pharmacodynamic interaction" trigger="M743" precipitant="M747" effect="M745"/>
<Interaction id="I298" type="Pharmacodynamic interaction" trigger="M743" precipitant="M749" effect="M745"/>
<Interaction id="I299" type="Pharmacokinetic interaction" trigger="M748" precipitant="M747" effect="C54357"/>
<Interaction id="I300" type="Pharmacokinetic interaction" trigger="M748" precipitant="M749" effect="C54357"/>
</Sentence>
<Sentence id="438" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Cyclosporine ( CYP3A substrate ) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine , despite reduction in dose of cyclosporine .</SentenceText>
<Mention id="M753" type="Trigger" span="171 12" str="resulting in"/>
<Mention id="M757" type="Precipitant" span="0 12" str="Cyclosporine" code="N0000007346"/>
<Mention id="M755" type="SpecificInteraction" span="184 19" str="elevated creatinine" code="166717003: Serum creatinine raised (finding)"/>
<Mention id="M759" type="Precipitant" span="15 15" str="CYP3A substrate" code="NO MAP"/>
<Mention id="M758" type="Trigger" span="124 30" str="elevated plasma concentrations"/>
<Interaction id="I301" type="Pharmacodynamic interaction" trigger="M753" precipitant="M757" effect="M755"/>
<Interaction id="I302" type="Pharmacodynamic interaction" trigger="M753" precipitant="M759" effect="M755"/>
<Interaction id="I303" type="Pharmacokinetic interaction" trigger="M758" precipitant="M757" effect="C54357"/>
<Interaction id="I304" type="Pharmacokinetic interaction" trigger="M758" precipitant="M759" effect="C54357"/>
</Sentence>
<Sentence id="439" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Cyclosporine (CYP3A substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.</SentenceText>
<Mention id="M763" type="Trigger" span="169 12" str="resulting in"/>
<Mention id="M767" type="Precipitant" span="0 12" str="Cyclosporine" code="N0000007346"/>
<Mention id="M765" type="SpecificInteraction" span="182 19" str="elevated creatinine" code="166717003: Serum creatinine raised (finding)"/>
<Mention id="M769" type="Precipitant" span="14 15" str="CYP3A substrate" code="NO MAP"/>
<Mention id="M768" type="Trigger" span="122 30" str="elevated plasma concentrations"/>
<Interaction id="I305" type="Pharmacodynamic interaction" trigger="M763" precipitant="M767" effect="M765"/>
<Interaction id="I306" type="Pharmacodynamic interaction" trigger="M763" precipitant="M769" effect="M765"/>
<Interaction id="I307" type="Pharmacokinetic interaction" trigger="M768" precipitant="M767" effect="C54357"/>
<Interaction id="I308" type="Pharmacokinetic interaction" trigger="M768" precipitant="M769" effect="C54357"/>
</Sentence>
<Sentence id="439" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Cyclosporine (CYP3A substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.</SentenceText>
<Mention id="M773" type="Trigger" span="169 12" str="resulting in"/>
<Mention id="M777" type="Precipitant" span="0 12" str="Cyclosporine" code="N0000007346"/>
<Mention id="M775" type="SpecificInteraction" span="182 19" str="elevated creatinine" code="166717003: Serum creatinine raised (finding)"/>
<Mention id="M779" type="Precipitant" span="14 15" str="CYP3A substrate" code="NO MAP"/>
<Mention id="M778" type="Trigger" span="122 30" str="elevated plasma concentrations"/>
<Interaction id="I309" type="Pharmacodynamic interaction" trigger="M773" precipitant="M777" effect="M775"/>
<Interaction id="I310" type="Pharmacodynamic interaction" trigger="M773" precipitant="M779" effect="M775"/>
<Interaction id="I311" type="Pharmacokinetic interaction" trigger="M778" precipitant="M777" effect="C54357"/>
<Interaction id="I312" type="Pharmacokinetic interaction" trigger="M778" precipitant="M779" effect="C54357"/>
</Sentence>
<Sentence id="439" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Cyclosporine (CYP3A substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.</SentenceText>
<Mention id="M783" type="Trigger" span="169 12" str="resulting in"/>
<Mention id="M787" type="Precipitant" span="0 12" str="Cyclosporine" code="N0000007346"/>
<Mention id="M785" type="SpecificInteraction" span="182 19" str="elevated creatinine" code="166717003: Serum creatinine raised (finding)"/>
<Mention id="M789" type="Precipitant" span="14 15" str="CYP3A substrate" code="NO MAP"/>
<Mention id="M788" type="Trigger" span="122 30" str="elevated plasma concentrations"/>
<Interaction id="I313" type="Pharmacodynamic interaction" trigger="M783" precipitant="M787" effect="M785"/>
<Interaction id="I314" type="Pharmacodynamic interaction" trigger="M783" precipitant="M789" effect="M785"/>
<Interaction id="I315" type="Pharmacokinetic interaction" trigger="M788" precipitant="M787" effect="C54357"/>
<Interaction id="I316" type="Pharmacokinetic interaction" trigger="M788" precipitant="M789" effect="C54357"/>
</Sentence>
<Sentence id="439" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Cyclosporine (CYP3A substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.</SentenceText>
<Mention id="M793" type="Trigger" span="169 12" str="resulting in"/>
<Mention id="M797" type="Precipitant" span="0 12" str="Cyclosporine" code="N0000007346"/>
<Mention id="M795" type="SpecificInteraction" span="182 19" str="elevated creatinine" code="166717003: Serum creatinine raised (finding)"/>
<Mention id="M799" type="Precipitant" span="14 15" str="CYP3A substrate" code="NO MAP"/>
<Mention id="M798" type="Trigger" span="122 30" str="elevated plasma concentrations"/>
<Interaction id="I317" type="Pharmacodynamic interaction" trigger="M793" precipitant="M797" effect="M795"/>
<Interaction id="I318" type="Pharmacodynamic interaction" trigger="M793" precipitant="M799" effect="M795"/>
<Interaction id="I319" type="Pharmacokinetic interaction" trigger="M798" precipitant="M797" effect="C54357"/>
<Interaction id="I320" type="Pharmacokinetic interaction" trigger="M798" precipitant="M799" effect="C54357"/>
</Sentence>
<Sentence id="440" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Digoxin : In patients receiving digoxin therapy , administration of oral amiodarone results in an increase in serum digoxin concentration .</SentenceText>
<Mention id="M800" type="Trigger" span="98 17;124 13" str="increase in serum | concentration"/>
<Mention id="M801" type="Precipitant" span="32 7" str="digoxin" code="N0000005903"/>
<Interaction id="I321" type="Pharmacokinetic interaction" trigger="M800" precipitant="M801" effect="C54357"/>
</Sentence>
<Sentence id="441" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Drugs that slow heart rate : Concomitant use of drugs with depressant effects on the sinus and AV node ( e.g. , digoxin , beta blockers , verapamil , diltiazem , ivabradine , clonidine ) can potentiate the electrophysiologic and hemodynamic effects of amiodarone , resulting in bradycardia , sinus arrest , and AV block .</SentenceText>
<Mention id="M826" type="Trigger" span="191 10;70 7" str="potentiate | effects"/>
<Mention id="M831" type="Precipitant" span="122 13" str="beta blockers" code="N0000175556"/>
<Mention id="M828" type="SpecificInteraction" span="206 18;70 7" str="electrophysiologic | effects " code="NO MAP"/>
<Mention id="M829" type="SpecificInteraction" span="229 19" str=" hemodynamic effects" code=""/>
<Mention id="M836" type="Precipitant" span="175 9" str="clonidine" code="N0000006505"/>
<Mention id="M841" type="Precipitant" span="112 7" str="digoxin" code="N0000005903"/>
<Mention id="M846" type="Precipitant" span="150 9" str="diltiazem" code="N0000006682"/>
<Mention id="M851" type="Precipitant" span="48 54" str="drugs with depressant effects on the sinus and AV node" code="NO MAP"/>
<Mention id="M856" type="Precipitant" span="162 10" str="ivabradine" code="N0000191553"/>
<Mention id="M861" type="Precipitant" span="138 9" str="verapamil" code="N0000007093"/>
<Mention id="M860" type="Trigger" span="265 12" str="resulting in"/>
<Mention id="M862" type="SpecificInteraction" span="278 11" str="bradycardia " code="48867003: Bradycardia (finding)"/>
<Mention id="M863" type="SpecificInteraction" span="292 12" str=" sinus arrest " code=" 5609005: Sinus arrest (disorder)"/>
<Mention id="M864" type="SpecificInteraction" span="311 8" str=" AV block" code=" 233917008: Atrioventricular block (disorder)"/>
<Interaction id="I322" type="Pharmacodynamic interaction" trigger="M826" precipitant="M831" effect="M828;M829"/>
<Interaction id="I323" type="Pharmacodynamic interaction" trigger="M826" precipitant="M836" effect="M828;M829"/>
<Interaction id="I324" type="Pharmacodynamic interaction" trigger="M826" precipitant="M841" effect="M828;M829"/>
<Interaction id="I325" type="Pharmacodynamic interaction" trigger="M826" precipitant="M846" effect="M828;M829"/>
<Interaction id="I326" type="Pharmacodynamic interaction" trigger="M826" precipitant="M851" effect="M828;M829"/>
<Interaction id="I327" type="Pharmacodynamic interaction" trigger="M826" precipitant="M856" effect="M828;M829"/>
<Interaction id="I328" type="Pharmacodynamic interaction" trigger="M826" precipitant="M861" effect="M828;M829"/>
<Interaction id="I329" type="Pharmacodynamic interaction" trigger="M860" precipitant="M831" effect="M862;M863;M864"/>
<Interaction id="I330" type="Pharmacodynamic interaction" trigger="M860" precipitant="M836" effect="M862;M863;M864"/>
<Interaction id="I331" type="Pharmacodynamic interaction" trigger="M860" precipitant="M841" effect="M862;M863;M864"/>
<Interaction id="I332" type="Pharmacodynamic interaction" trigger="M860" precipitant="M846" effect="M862;M863;M864"/>
<Interaction id="I333" type="Pharmacodynamic interaction" trigger="M860" precipitant="M851" effect="M862;M863;M864"/>
<Interaction id="I334" type="Pharmacodynamic interaction" trigger="M860" precipitant="M856" effect="M862;M863;M864"/>
<Interaction id="I335" type="Pharmacodynamic interaction" trigger="M860" precipitant="M861" effect="M862;M863;M864"/>
</Sentence>
<Sentence id="441" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Drugs that slow heart rate : Concomitant use of drugs with depressant effects on the sinus and AV node ( e.g. , digoxin , beta blockers , verapamil , diltiazem , ivabradine , clonidine ) can potentiate the electrophysiologic and hemodynamic effects of amiodarone , resulting in bradycardia , sinus arrest , and AV block .</SentenceText>
<Mention id="M889" type="Trigger" span="191 10;70 7" str="potentiate | effects"/>
<Mention id="M894" type="Precipitant" span="122 13" str="beta blockers" code="N0000175556"/>
<Mention id="M891" type="SpecificInteraction" span="206 18;70 7" str="electrophysiologic | effects " code="NO MAP"/>
<Mention id="M892" type="SpecificInteraction" span="229 19" str=" hemodynamic effects" code=""/>
<Mention id="M899" type="Precipitant" span="175 9" str="clonidine" code="N0000006505"/>
<Mention id="M904" type="Precipitant" span="112 7" str="digoxin" code="N0000005903"/>
<Mention id="M909" type="Precipitant" span="150 9" str="diltiazem" code="N0000006682"/>
<Mention id="M914" type="Precipitant" span="48 54" str="drugs with depressant effects on the sinus and AV node" code="NO MAP"/>
<Mention id="M919" type="Precipitant" span="162 10" str="ivabradine" code="N0000191553"/>
<Mention id="M924" type="Precipitant" span="138 9" str="verapamil" code="N0000007093"/>
<Mention id="M923" type="Trigger" span="265 12" str="resulting in"/>
<Mention id="M925" type="SpecificInteraction" span="278 11" str="bradycardia " code="48867003: Bradycardia (finding)"/>
<Mention id="M926" type="SpecificInteraction" span="292 12" str=" sinus arrest " code=" 5609005: Sinus arrest (disorder)"/>
<Mention id="M927" type="SpecificInteraction" span="311 8" str=" AV block" code=" 233917008: Atrioventricular block (disorder)"/>
<Interaction id="I336" type="Pharmacodynamic interaction" trigger="M889" precipitant="M894" effect="M891;M892"/>
<Interaction id="I337" type="Pharmacodynamic interaction" trigger="M889" precipitant="M899" effect="M891;M892"/>
<Interaction id="I338" type="Pharmacodynamic interaction" trigger="M889" precipitant="M904" effect="M891;M892"/>
<Interaction id="I339" type="Pharmacodynamic interaction" trigger="M889" precipitant="M909" effect="M891;M892"/>
<Interaction id="I340" type="Pharmacodynamic interaction" trigger="M889" precipitant="M914" effect="M891;M892"/>
<Interaction id="I341" type="Pharmacodynamic interaction" trigger="M889" precipitant="M919" effect="M891;M892"/>
<Interaction id="I342" type="Pharmacodynamic interaction" trigger="M889" precipitant="M924" effect="M891;M892"/>
<Interaction id="I343" type="Pharmacodynamic interaction" trigger="M923" precipitant="M894" effect="M925;M926;M927"/>
<Interaction id="I344" type="Pharmacodynamic interaction" trigger="M923" precipitant="M899" effect="M925;M926;M927"/>
<Interaction id="I345" type="Pharmacodynamic interaction" trigger="M923" precipitant="M904" effect="M925;M926;M927"/>
<Interaction id="I346" type="Pharmacodynamic interaction" trigger="M923" precipitant="M909" effect="M925;M926;M927"/>
<Interaction id="I347" type="Pharmacodynamic interaction" trigger="M923" precipitant="M914" effect="M925;M926;M927"/>
<Interaction id="I348" type="Pharmacodynamic interaction" trigger="M923" precipitant="M919" effect="M925;M926;M927"/>
<Interaction id="I349" type="Pharmacodynamic interaction" trigger="M923" precipitant="M924" effect="M925;M926;M927"/>
</Sentence>
<Sentence id="441" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Drugs that slow heart rate : Concomitant use of drugs with depressant effects on the sinus and AV node ( e.g. , digoxin , beta blockers , verapamil , diltiazem , ivabradine , clonidine ) can potentiate the electrophysiologic and hemodynamic effects of amiodarone , resulting in bradycardia , sinus arrest , and AV block .</SentenceText>
<Mention id="M952" type="Trigger" span="191 10;70 7" str="potentiate | effects"/>
<Mention id="M957" type="Precipitant" span="122 13" str="beta blockers" code="N0000175556"/>
<Mention id="M954" type="SpecificInteraction" span="206 18;70 7" str="electrophysiologic | effects " code="NO MAP"/>
<Mention id="M955" type="SpecificInteraction" span="229 19" str=" hemodynamic effects" code=""/>
<Mention id="M962" type="Precipitant" span="175 9" str="clonidine" code="N0000006505"/>
<Mention id="M967" type="Precipitant" span="112 7" str="digoxin" code="N0000005903"/>
<Mention id="M972" type="Precipitant" span="150 9" str="diltiazem" code="N0000006682"/>
<Mention id="M977" type="Precipitant" span="48 54" str="drugs with depressant effects on the sinus and AV node" code="NO MAP"/>
<Mention id="M982" type="Precipitant" span="162 10" str="ivabradine" code="N0000191553"/>
<Mention id="M987" type="Precipitant" span="138 9" str="verapamil" code="N0000007093"/>
<Mention id="M986" type="Trigger" span="265 12" str="resulting in"/>
<Mention id="M988" type="SpecificInteraction" span="278 11" str="bradycardia " code="48867003: Bradycardia (finding)"/>
<Mention id="M989" type="SpecificInteraction" span="292 12" str=" sinus arrest " code=" 5609005: Sinus arrest (disorder)"/>
<Mention id="M990" type="SpecificInteraction" span="311 8" str=" AV block" code=" 233917008: Atrioventricular block (disorder)"/>
<Interaction id="I350" type="Pharmacodynamic interaction" trigger="M952" precipitant="M957" effect="M954;M955"/>
<Interaction id="I351" type="Pharmacodynamic interaction" trigger="M952" precipitant="M962" effect="M954;M955"/>
<Interaction id="I352" type="Pharmacodynamic interaction" trigger="M952" precipitant="M967" effect="M954;M955"/>
<Interaction id="I353" type="Pharmacodynamic interaction" trigger="M952" precipitant="M972" effect="M954;M955"/>
<Interaction id="I354" type="Pharmacodynamic interaction" trigger="M952" precipitant="M977" effect="M954;M955"/>
<Interaction id="I355" type="Pharmacodynamic interaction" trigger="M952" precipitant="M982" effect="M954;M955"/>
<Interaction id="I356" type="Pharmacodynamic interaction" trigger="M952" precipitant="M987" effect="M954;M955"/>
<Interaction id="I357" type="Pharmacodynamic interaction" trigger="M986" precipitant="M957" effect="M988;M989;M990"/>
<Interaction id="I358" type="Pharmacodynamic interaction" trigger="M986" precipitant="M962" effect="M988;M989;M990"/>
<Interaction id="I359" type="Pharmacodynamic interaction" trigger="M986" precipitant="M967" effect="M988;M989;M990"/>
<Interaction id="I360" type="Pharmacodynamic interaction" trigger="M986" precipitant="M972" effect="M988;M989;M990"/>
<Interaction id="I361" type="Pharmacodynamic interaction" trigger="M986" precipitant="M977" effect="M988;M989;M990"/>
<Interaction id="I362" type="Pharmacodynamic interaction" trigger="M986" precipitant="M982" effect="M988;M989;M990"/>
<Interaction id="I363" type="Pharmacodynamic interaction" trigger="M986" precipitant="M987" effect="M988;M989;M990"/>
</Sentence>
<Sentence id="441" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Drugs that slow heart rate : Concomitant use of drugs with depressant effects on the sinus and AV node ( e.g. , digoxin , beta blockers , verapamil , diltiazem , ivabradine , clonidine ) can potentiate the electrophysiologic and hemodynamic effects of amiodarone , resulting in bradycardia , sinus arrest , and AV block .</SentenceText>
<Mention id="M1015" type="Trigger" span="191 10;70 7" str="potentiate | effects"/>
<Mention id="M1020" type="Precipitant" span="122 13" str="beta blockers" code="N0000175556"/>
<Mention id="M1017" type="SpecificInteraction" span="206 18;70 7" str="electrophysiologic | effects " code="NO MAP"/>
<Mention id="M1018" type="SpecificInteraction" span="229 19" str=" hemodynamic effects" code=""/>
<Mention id="M1025" type="Precipitant" span="175 9" str="clonidine" code="N0000006505"/>
<Mention id="M1030" type="Precipitant" span="112 7" str="digoxin" code="N0000005903"/>
<Mention id="M1035" type="Precipitant" span="150 9" str="diltiazem" code="N0000006682"/>
<Mention id="M1040" type="Precipitant" span="48 54" str="drugs with depressant effects on the sinus and AV node" code="NO MAP"/>
<Mention id="M1045" type="Precipitant" span="162 10" str="ivabradine" code="N0000191553"/>
<Mention id="M1050" type="Precipitant" span="138 9" str="verapamil" code="N0000007093"/>
<Mention id="M1049" type="Trigger" span="265 12" str="resulting in"/>
<Mention id="M1051" type="SpecificInteraction" span="278 11" str="bradycardia " code="48867003: Bradycardia (finding)"/>
<Mention id="M1052" type="SpecificInteraction" span="292 12" str=" sinus arrest " code=" 5609005: Sinus arrest (disorder)"/>
<Mention id="M1053" type="SpecificInteraction" span="311 8" str=" AV block" code=" 233917008: Atrioventricular block (disorder)"/>
<Interaction id="I364" type="Pharmacodynamic interaction" trigger="M1015" precipitant="M1020" effect="M1017;M1018"/>
<Interaction id="I365" type="Pharmacodynamic interaction" trigger="M1015" precipitant="M1025" effect="M1017;M1018"/>
<Interaction id="I366" type="Pharmacodynamic interaction" trigger="M1015" precipitant="M1030" effect="M1017;M1018"/>
<Interaction id="I367" type="Pharmacodynamic interaction" trigger="M1015" precipitant="M1035" effect="M1017;M1018"/>
<Interaction id="I368" type="Pharmacodynamic interaction" trigger="M1015" precipitant="M1040" effect="M1017;M1018"/>
<Interaction id="I369" type="Pharmacodynamic interaction" trigger="M1015" precipitant="M1045" effect="M1017;M1018"/>
<Interaction id="I370" type="Pharmacodynamic interaction" trigger="M1015" precipitant="M1050" effect="M1017;M1018"/>
<Interaction id="I371" type="Pharmacodynamic interaction" trigger="M1049" precipitant="M1020" effect="M1051;M1052;M1053"/>
<Interaction id="I372" type="Pharmacodynamic interaction" trigger="M1049" precipitant="M1025" effect="M1051;M1052;M1053"/>
<Interaction id="I373" type="Pharmacodynamic interaction" trigger="M1049" precipitant="M1030" effect="M1051;M1052;M1053"/>
<Interaction id="I374" type="Pharmacodynamic interaction" trigger="M1049" precipitant="M1035" effect="M1051;M1052;M1053"/>
<Interaction id="I375" type="Pharmacodynamic interaction" trigger="M1049" precipitant="M1040" effect="M1051;M1052;M1053"/>
<Interaction id="I376" type="Pharmacodynamic interaction" trigger="M1049" precipitant="M1045" effect="M1051;M1052;M1053"/>
<Interaction id="I377" type="Pharmacodynamic interaction" trigger="M1049" precipitant="M1050" effect="M1051;M1052;M1053"/>
</Sentence>
<Sentence id="441" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Drugs that slow heart rate : Concomitant use of drugs with depressant effects on the sinus and AV node ( e.g. , digoxin , beta blockers , verapamil , diltiazem , ivabradine , clonidine ) can potentiate the electrophysiologic and hemodynamic effects of amiodarone , resulting in bradycardia , sinus arrest , and AV block .</SentenceText>
<Mention id="M1078" type="Trigger" span="191 10;70 7" str="potentiate | effects"/>
<Mention id="M1083" type="Precipitant" span="122 13" str="beta blockers" code="N0000175556"/>
<Mention id="M1080" type="SpecificInteraction" span="206 18;70 7" str="electrophysiologic | effects " code="NO MAP"/>
<Mention id="M1081" type="SpecificInteraction" span="229 19" str=" hemodynamic effects" code=""/>
<Mention id="M1088" type="Precipitant" span="175 9" str="clonidine" code="N0000006505"/>
<Mention id="M1093" type="Precipitant" span="112 7" str="digoxin" code="N0000005903"/>
<Mention id="M1098" type="Precipitant" span="150 9" str="diltiazem" code="N0000006682"/>
<Mention id="M1103" type="Precipitant" span="48 54" str="drugs with depressant effects on the sinus and AV node" code="NO MAP"/>
<Mention id="M1108" type="Precipitant" span="162 10" str="ivabradine" code="N0000191553"/>
<Mention id="M1113" type="Precipitant" span="138 9" str="verapamil" code="N0000007093"/>
<Mention id="M1112" type="Trigger" span="265 12" str="resulting in"/>
<Mention id="M1114" type="SpecificInteraction" span="278 11" str="bradycardia " code="48867003: Bradycardia (finding)"/>
<Mention id="M1115" type="SpecificInteraction" span="292 12" str=" sinus arrest " code=" 5609005: Sinus arrest (disorder)"/>
<Mention id="M1116" type="SpecificInteraction" span="311 8" str=" AV block" code=" 233917008: Atrioventricular block (disorder)"/>
<Interaction id="I378" type="Pharmacodynamic interaction" trigger="M1078" precipitant="M1083" effect="M1080;M1081"/>
<Interaction id="I379" type="Pharmacodynamic interaction" trigger="M1078" precipitant="M1088" effect="M1080;M1081"/>
<Interaction id="I380" type="Pharmacodynamic interaction" trigger="M1078" precipitant="M1093" effect="M1080;M1081"/>
<Interaction id="I381" type="Pharmacodynamic interaction" trigger="M1078" precipitant="M1098" effect="M1080;M1081"/>
<Interaction id="I382" type="Pharmacodynamic interaction" trigger="M1078" precipitant="M1103" effect="M1080;M1081"/>
<Interaction id="I383" type="Pharmacodynamic interaction" trigger="M1078" precipitant="M1108" effect="M1080;M1081"/>
<Interaction id="I384" type="Pharmacodynamic interaction" trigger="M1078" precipitant="M1113" effect="M1080;M1081"/>
<Interaction id="I385" type="Pharmacodynamic interaction" trigger="M1112" precipitant="M1083" effect="M1114;M1115;M1116"/>
<Interaction id="I386" type="Pharmacodynamic interaction" trigger="M1112" precipitant="M1088" effect="M1114;M1115;M1116"/>
<Interaction id="I387" type="Pharmacodynamic interaction" trigger="M1112" precipitant="M1093" effect="M1114;M1115;M1116"/>
<Interaction id="I388" type="Pharmacodynamic interaction" trigger="M1112" precipitant="M1098" effect="M1114;M1115;M1116"/>
<Interaction id="I389" type="Pharmacodynamic interaction" trigger="M1112" precipitant="M1103" effect="M1114;M1115;M1116"/>
<Interaction id="I390" type="Pharmacodynamic interaction" trigger="M1112" precipitant="M1108" effect="M1114;M1115;M1116"/>
<Interaction id="I391" type="Pharmacodynamic interaction" trigger="M1112" precipitant="M1113" effect="M1114;M1115;M1116"/>
</Sentence>
<Sentence id="441" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Drugs that slow heart rate : Concomitant use of drugs with depressant effects on the sinus and AV node ( e.g. , digoxin , beta blockers , verapamil , diltiazem , ivabradine , clonidine ) can potentiate the electrophysiologic and hemodynamic effects of amiodarone , resulting in bradycardia , sinus arrest , and AV block .</SentenceText>
<Mention id="M1141" type="Trigger" span="191 10;70 7" str="potentiate | effects"/>
<Mention id="M1146" type="Precipitant" span="122 13" str="beta blockers" code="N0000175556"/>
<Mention id="M1143" type="SpecificInteraction" span="206 18;70 7" str="electrophysiologic | effects " code="NO MAP"/>
<Mention id="M1144" type="SpecificInteraction" span="229 19" str=" hemodynamic effects" code=""/>
<Mention id="M1151" type="Precipitant" span="175 9" str="clonidine" code="N0000006505"/>
<Mention id="M1156" type="Precipitant" span="112 7" str="digoxin" code="N0000005903"/>
<Mention id="M1161" type="Precipitant" span="150 9" str="diltiazem" code="N0000006682"/>
<Mention id="M1166" type="Precipitant" span="48 54" str="drugs with depressant effects on the sinus and AV node" code="NO MAP"/>
<Mention id="M1171" type="Precipitant" span="162 10" str="ivabradine" code="N0000191553"/>
<Mention id="M1176" type="Precipitant" span="138 9" str="verapamil" code="N0000007093"/>
<Mention id="M1175" type="Trigger" span="265 12" str="resulting in"/>
<Mention id="M1177" type="SpecificInteraction" span="278 11" str="bradycardia " code="48867003: Bradycardia (finding)"/>
<Mention id="M1178" type="SpecificInteraction" span="292 12" str=" sinus arrest " code=" 5609005: Sinus arrest (disorder)"/>
<Mention id="M1179" type="SpecificInteraction" span="311 8" str=" AV block" code=" 233917008: Atrioventricular block (disorder)"/>
<Interaction id="I392" type="Pharmacodynamic interaction" trigger="M1141" precipitant="M1146" effect="M1143;M1144"/>
<Interaction id="I393" type="Pharmacodynamic interaction" trigger="M1141" precipitant="M1151" effect="M1143;M1144"/>
<Interaction id="I394" type="Pharmacodynamic interaction" trigger="M1141" precipitant="M1156" effect="M1143;M1144"/>
<Interaction id="I395" type="Pharmacodynamic interaction" trigger="M1141" precipitant="M1161" effect="M1143;M1144"/>
<Interaction id="I396" type="Pharmacodynamic interaction" trigger="M1141" precipitant="M1166" effect="M1143;M1144"/>
<Interaction id="I397" type="Pharmacodynamic interaction" trigger="M1141" precipitant="M1171" effect="M1143;M1144"/>
<Interaction id="I398" type="Pharmacodynamic interaction" trigger="M1141" precipitant="M1176" effect="M1143;M1144"/>
<Interaction id="I399" type="Pharmacodynamic interaction" trigger="M1175" precipitant="M1146" effect="M1177;M1178;M1179"/>
<Interaction id="I400" type="Pharmacodynamic interaction" trigger="M1175" precipitant="M1151" effect="M1177;M1178;M1179"/>
<Interaction id="I401" type="Pharmacodynamic interaction" trigger="M1175" precipitant="M1156" effect="M1177;M1178;M1179"/>
<Interaction id="I402" type="Pharmacodynamic interaction" trigger="M1175" precipitant="M1161" effect="M1177;M1178;M1179"/>
<Interaction id="I403" type="Pharmacodynamic interaction" trigger="M1175" precipitant="M1166" effect="M1177;M1178;M1179"/>
<Interaction id="I404" type="Pharmacodynamic interaction" trigger="M1175" precipitant="M1171" effect="M1177;M1178;M1179"/>
<Interaction id="I405" type="Pharmacodynamic interaction" trigger="M1175" precipitant="M1176" effect="M1177;M1178;M1179"/>
</Sentence>
<Sentence id="441" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Drugs that slow heart rate : Concomitant use of drugs with depressant effects on the sinus and AV node ( e.g. , digoxin , beta blockers , verapamil , diltiazem , ivabradine , clonidine ) can potentiate the electrophysiologic and hemodynamic effects of amiodarone , resulting in bradycardia , sinus arrest , and AV block .</SentenceText>
<Mention id="M1204" type="Trigger" span="191 10;70 7" str="potentiate | effects"/>
<Mention id="M1209" type="Precipitant" span="122 13" str="beta blockers" code="N0000175556"/>
<Mention id="M1206" type="SpecificInteraction" span="206 18;70 7" str="electrophysiologic | effects " code="NO MAP"/>
<Mention id="M1207" type="SpecificInteraction" span="229 19" str=" hemodynamic effects" code=""/>
<Mention id="M1214" type="Precipitant" span="175 9" str="clonidine" code="N0000006505"/>
<Mention id="M1219" type="Precipitant" span="112 7" str="digoxin" code="N0000005903"/>
<Mention id="M1224" type="Precipitant" span="150 9" str="diltiazem" code="N0000006682"/>
<Mention id="M1229" type="Precipitant" span="48 54" str="drugs with depressant effects on the sinus and AV node" code="NO MAP"/>
<Mention id="M1234" type="Precipitant" span="162 10" str="ivabradine" code="N0000191553"/>
<Mention id="M1239" type="Precipitant" span="138 9" str="verapamil" code="N0000007093"/>
<Mention id="M1238" type="Trigger" span="265 12" str="resulting in"/>
<Mention id="M1240" type="SpecificInteraction" span="278 11" str="bradycardia " code="48867003: Bradycardia (finding)"/>
<Mention id="M1241" type="SpecificInteraction" span="292 12" str=" sinus arrest " code=" 5609005: Sinus arrest (disorder)"/>
<Mention id="M1242" type="SpecificInteraction" span="311 8" str=" AV block" code=" 233917008: Atrioventricular block (disorder)"/>
<Interaction id="I406" type="Pharmacodynamic interaction" trigger="M1204" precipitant="M1209" effect="M1206;M1207"/>
<Interaction id="I407" type="Pharmacodynamic interaction" trigger="M1204" precipitant="M1214" effect="M1206;M1207"/>
<Interaction id="I408" type="Pharmacodynamic interaction" trigger="M1204" precipitant="M1219" effect="M1206;M1207"/>
<Interaction id="I409" type="Pharmacodynamic interaction" trigger="M1204" precipitant="M1224" effect="M1206;M1207"/>
<Interaction id="I410" type="Pharmacodynamic interaction" trigger="M1204" precipitant="M1229" effect="M1206;M1207"/>
<Interaction id="I411" type="Pharmacodynamic interaction" trigger="M1204" precipitant="M1234" effect="M1206;M1207"/>
<Interaction id="I412" type="Pharmacodynamic interaction" trigger="M1204" precipitant="M1239" effect="M1206;M1207"/>
<Interaction id="I413" type="Pharmacodynamic interaction" trigger="M1238" precipitant="M1209" effect="M1240;M1241;M1242"/>
<Interaction id="I414" type="Pharmacodynamic interaction" trigger="M1238" precipitant="M1214" effect="M1240;M1241;M1242"/>
<Interaction id="I415" type="Pharmacodynamic interaction" trigger="M1238" precipitant="M1219" effect="M1240;M1241;M1242"/>
<Interaction id="I416" type="Pharmacodynamic interaction" trigger="M1238" precipitant="M1224" effect="M1240;M1241;M1242"/>
<Interaction id="I417" type="Pharmacodynamic interaction" trigger="M1238" precipitant="M1229" effect="M1240;M1241;M1242"/>
<Interaction id="I418" type="Pharmacodynamic interaction" trigger="M1238" precipitant="M1234" effect="M1240;M1241;M1242"/>
<Interaction id="I419" type="Pharmacodynamic interaction" trigger="M1238" precipitant="M1239" effect="M1240;M1241;M1242"/>
</Sentence>
<Sentence id="441" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Drugs that slow heart rate : Concomitant use of drugs with depressant effects on the sinus and AV node ( e.g. , digoxin , beta blockers , verapamil , diltiazem , ivabradine , clonidine ) can potentiate the electrophysiologic and hemodynamic effects of amiodarone , resulting in bradycardia , sinus arrest , and AV block .</SentenceText>
<Mention id="M1267" type="Trigger" span="191 10;70 7" str="potentiate | effects"/>
<Mention id="M1272" type="Precipitant" span="122 13" str="beta blockers" code="N0000175556"/>
<Mention id="M1269" type="SpecificInteraction" span="206 18;70 7" str="electrophysiologic | effects " code="NO MAP"/>
<Mention id="M1270" type="SpecificInteraction" span="229 19" str=" hemodynamic effects" code=""/>
<Mention id="M1277" type="Precipitant" span="175 9" str="clonidine" code="N0000006505"/>
<Mention id="M1282" type="Precipitant" span="112 7" str="digoxin" code="N0000005903"/>
<Mention id="M1287" type="Precipitant" span="150 9" str="diltiazem" code="N0000006682"/>
<Mention id="M1292" type="Precipitant" span="48 54" str="drugs with depressant effects on the sinus and AV node" code="NO MAP"/>
<Mention id="M1297" type="Precipitant" span="162 10" str="ivabradine" code="N0000191553"/>
<Mention id="M1302" type="Precipitant" span="138 9" str="verapamil" code="N0000007093"/>
<Mention id="M1301" type="Trigger" span="265 12" str="resulting in"/>
<Mention id="M1303" type="SpecificInteraction" span="278 11" str="bradycardia " code="48867003: Bradycardia (finding)"/>
<Mention id="M1304" type="SpecificInteraction" span="292 12" str=" sinus arrest " code=" 5609005: Sinus arrest (disorder)"/>
<Mention id="M1305" type="SpecificInteraction" span="311 8" str=" AV block" code=" 233917008: Atrioventricular block (disorder)"/>
<Interaction id="I420" type="Pharmacodynamic interaction" trigger="M1267" precipitant="M1272" effect="M1269;M1270"/>
<Interaction id="I421" type="Pharmacodynamic interaction" trigger="M1267" precipitant="M1277" effect="M1269;M1270"/>
<Interaction id="I422" type="Pharmacodynamic interaction" trigger="M1267" precipitant="M1282" effect="M1269;M1270"/>
<Interaction id="I423" type="Pharmacodynamic interaction" trigger="M1267" precipitant="M1287" effect="M1269;M1270"/>
<Interaction id="I424" type="Pharmacodynamic interaction" trigger="M1267" precipitant="M1292" effect="M1269;M1270"/>
<Interaction id="I425" type="Pharmacodynamic interaction" trigger="M1267" precipitant="M1297" effect="M1269;M1270"/>
<Interaction id="I426" type="Pharmacodynamic interaction" trigger="M1267" precipitant="M1302" effect="M1269;M1270"/>
<Interaction id="I427" type="Pharmacodynamic interaction" trigger="M1301" precipitant="M1272" effect="M1303;M1304;M1305"/>
<Interaction id="I428" type="Pharmacodynamic interaction" trigger="M1301" precipitant="M1277" effect="M1303;M1304;M1305"/>
<Interaction id="I429" type="Pharmacodynamic interaction" trigger="M1301" precipitant="M1282" effect="M1303;M1304;M1305"/>
<Interaction id="I430" type="Pharmacodynamic interaction" trigger="M1301" precipitant="M1287" effect="M1303;M1304;M1305"/>
<Interaction id="I431" type="Pharmacodynamic interaction" trigger="M1301" precipitant="M1292" effect="M1303;M1304;M1305"/>
<Interaction id="I432" type="Pharmacodynamic interaction" trigger="M1301" precipitant="M1297" effect="M1303;M1304;M1305"/>
<Interaction id="I433" type="Pharmacodynamic interaction" trigger="M1301" precipitant="M1302" effect="M1303;M1304;M1305"/>
</Sentence>
<Sentence id="441" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Drugs that slow heart rate : Concomitant use of drugs with depressant effects on the sinus and AV node ( e.g. , digoxin , beta blockers , verapamil , diltiazem , ivabradine , clonidine ) can potentiate the electrophysiologic and hemodynamic effects of amiodarone , resulting in bradycardia , sinus arrest , and AV block .</SentenceText>
<Mention id="M1330" type="Trigger" span="191 10;70 7" str="potentiate | effects"/>
<Mention id="M1335" type="Precipitant" span="122 13" str="beta blockers" code="N0000175556"/>
<Mention id="M1332" type="SpecificInteraction" span="206 18;70 7" str="electrophysiologic | effects " code="NO MAP"/>
<Mention id="M1333" type="SpecificInteraction" span="229 19" str=" hemodynamic effects" code=""/>
<Mention id="M1340" type="Precipitant" span="175 9" str="clonidine" code="N0000006505"/>
<Mention id="M1345" type="Precipitant" span="112 7" str="digoxin" code="N0000005903"/>
<Mention id="M1350" type="Precipitant" span="150 9" str="diltiazem" code="N0000006682"/>
<Mention id="M1355" type="Precipitant" span="48 54" str="drugs with depressant effects on the sinus and AV node" code="NO MAP"/>
<Mention id="M1360" type="Precipitant" span="162 10" str="ivabradine" code="N0000191553"/>
<Mention id="M1365" type="Precipitant" span="138 9" str="verapamil" code="N0000007093"/>
<Mention id="M1364" type="Trigger" span="265 12" str="resulting in"/>
<Mention id="M1366" type="SpecificInteraction" span="278 11" str="bradycardia " code="48867003: Bradycardia (finding)"/>
<Mention id="M1367" type="SpecificInteraction" span="292 12" str=" sinus arrest " code=" 5609005: Sinus arrest (disorder)"/>
<Mention id="M1368" type="SpecificInteraction" span="311 8" str=" AV block" code=" 233917008: Atrioventricular block (disorder)"/>
<Interaction id="I434" type="Pharmacodynamic interaction" trigger="M1330" precipitant="M1335" effect="M1332;M1333"/>
<Interaction id="I435" type="Pharmacodynamic interaction" trigger="M1330" precipitant="M1340" effect="M1332;M1333"/>
<Interaction id="I436" type="Pharmacodynamic interaction" trigger="M1330" precipitant="M1345" effect="M1332;M1333"/>
<Interaction id="I437" type="Pharmacodynamic interaction" trigger="M1330" precipitant="M1350" effect="M1332;M1333"/>
<Interaction id="I438" type="Pharmacodynamic interaction" trigger="M1330" precipitant="M1355" effect="M1332;M1333"/>
<Interaction id="I439" type="Pharmacodynamic interaction" trigger="M1330" precipitant="M1360" effect="M1332;M1333"/>
<Interaction id="I440" type="Pharmacodynamic interaction" trigger="M1330" precipitant="M1365" effect="M1332;M1333"/>
<Interaction id="I441" type="Pharmacodynamic interaction" trigger="M1364" precipitant="M1335" effect="M1366;M1367;M1368"/>
<Interaction id="I442" type="Pharmacodynamic interaction" trigger="M1364" precipitant="M1340" effect="M1366;M1367;M1368"/>
<Interaction id="I443" type="Pharmacodynamic interaction" trigger="M1364" precipitant="M1345" effect="M1366;M1367;M1368"/>
<Interaction id="I444" type="Pharmacodynamic interaction" trigger="M1364" precipitant="M1350" effect="M1366;M1367;M1368"/>
<Interaction id="I445" type="Pharmacodynamic interaction" trigger="M1364" precipitant="M1355" effect="M1366;M1367;M1368"/>
<Interaction id="I446" type="Pharmacodynamic interaction" trigger="M1364" precipitant="M1360" effect="M1366;M1367;M1368"/>
<Interaction id="I447" type="Pharmacodynamic interaction" trigger="M1364" precipitant="M1365" effect="M1366;M1367;M1368"/>
</Sentence>
<Sentence id="441" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Drugs that slow heart rate : Concomitant use of drugs with depressant effects on the sinus and AV node ( e.g. , digoxin , beta blockers , verapamil , diltiazem , ivabradine , clonidine ) can potentiate the electrophysiologic and hemodynamic effects of amiodarone , resulting in bradycardia , sinus arrest , and AV block .</SentenceText>
<Mention id="M1393" type="Trigger" span="191 10;70 7" str="potentiate | effects"/>
<Mention id="M1398" type="Precipitant" span="122 13" str="beta blockers" code="N0000175556"/>
<Mention id="M1395" type="SpecificInteraction" span="206 18;70 7" str="electrophysiologic | effects " code="NO MAP"/>
<Mention id="M1396" type="SpecificInteraction" span="229 19" str=" hemodynamic effects" code=""/>
<Mention id="M1403" type="Precipitant" span="175 9" str="clonidine" code="N0000006505"/>
<Mention id="M1408" type="Precipitant" span="112 7" str="digoxin" code="N0000005903"/>
<Mention id="M1413" type="Precipitant" span="150 9" str="diltiazem" code="N0000006682"/>
<Mention id="M1418" type="Precipitant" span="48 54" str="drugs with depressant effects on the sinus and AV node" code="NO MAP"/>
<Mention id="M1423" type="Precipitant" span="162 10" str="ivabradine" code="N0000191553"/>
<Mention id="M1428" type="Precipitant" span="138 9" str="verapamil" code="N0000007093"/>
<Mention id="M1427" type="Trigger" span="265 12" str="resulting in"/>
<Mention id="M1429" type="SpecificInteraction" span="278 11" str="bradycardia " code="48867003: Bradycardia (finding)"/>
<Mention id="M1430" type="SpecificInteraction" span="292 12" str=" sinus arrest " code=" 5609005: Sinus arrest (disorder)"/>
<Mention id="M1431" type="SpecificInteraction" span="311 8" str=" AV block" code=" 233917008: Atrioventricular block (disorder)"/>
<Interaction id="I448" type="Pharmacodynamic interaction" trigger="M1393" precipitant="M1398" effect="M1395;M1396"/>
<Interaction id="I449" type="Pharmacodynamic interaction" trigger="M1393" precipitant="M1403" effect="M1395;M1396"/>
<Interaction id="I450" type="Pharmacodynamic interaction" trigger="M1393" precipitant="M1408" effect="M1395;M1396"/>
<Interaction id="I451" type="Pharmacodynamic interaction" trigger="M1393" precipitant="M1413" effect="M1395;M1396"/>
<Interaction id="I452" type="Pharmacodynamic interaction" trigger="M1393" precipitant="M1418" effect="M1395;M1396"/>
<Interaction id="I453" type="Pharmacodynamic interaction" trigger="M1393" precipitant="M1423" effect="M1395;M1396"/>
<Interaction id="I454" type="Pharmacodynamic interaction" trigger="M1393" precipitant="M1428" effect="M1395;M1396"/>
<Interaction id="I455" type="Pharmacodynamic interaction" trigger="M1427" precipitant="M1398" effect="M1429;M1430;M1431"/>
<Interaction id="I456" type="Pharmacodynamic interaction" trigger="M1427" precipitant="M1403" effect="M1429;M1430;M1431"/>
<Interaction id="I457" type="Pharmacodynamic interaction" trigger="M1427" precipitant="M1408" effect="M1429;M1430;M1431"/>
<Interaction id="I458" type="Pharmacodynamic interaction" trigger="M1427" precipitant="M1413" effect="M1429;M1430;M1431"/>
<Interaction id="I459" type="Pharmacodynamic interaction" trigger="M1427" precipitant="M1418" effect="M1429;M1430;M1431"/>
<Interaction id="I460" type="Pharmacodynamic interaction" trigger="M1427" precipitant="M1423" effect="M1429;M1430;M1431"/>
<Interaction id="I461" type="Pharmacodynamic interaction" trigger="M1427" precipitant="M1428" effect="M1429;M1430;M1431"/>
</Sentence>
<Sentence id="441" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Drugs that slow heart rate : Concomitant use of drugs with depressant effects on the sinus and AV node ( e.g. , digoxin , beta blockers , verapamil , diltiazem , ivabradine , clonidine ) can potentiate the electrophysiologic and hemodynamic effects of amiodarone , resulting in bradycardia , sinus arrest , and AV block .</SentenceText>
<Mention id="M1456" type="Trigger" span="191 10;70 7" str="potentiate | effects"/>
<Mention id="M1461" type="Precipitant" span="122 13" str="beta blockers" code="N0000175556"/>
<Mention id="M1458" type="SpecificInteraction" span="206 18;70 7" str="electrophysiologic | effects " code="NO MAP"/>
<Mention id="M1459" type="SpecificInteraction" span="229 19" str=" hemodynamic effects" code=""/>
<Mention id="M1466" type="Precipitant" span="175 9" str="clonidine" code="N0000006505"/>
<Mention id="M1471" type="Precipitant" span="112 7" str="digoxin" code="N0000005903"/>
<Mention id="M1476" type="Precipitant" span="150 9" str="diltiazem" code="N0000006682"/>
<Mention id="M1481" type="Precipitant" span="48 54" str="drugs with depressant effects on the sinus and AV node" code="NO MAP"/>
<Mention id="M1486" type="Precipitant" span="162 10" str="ivabradine" code="N0000191553"/>
<Mention id="M1491" type="Precipitant" span="138 9" str="verapamil" code="N0000007093"/>
<Mention id="M1490" type="Trigger" span="265 12" str="resulting in"/>
<Mention id="M1492" type="SpecificInteraction" span="278 11" str="bradycardia " code="48867003: Bradycardia (finding)"/>
<Mention id="M1493" type="SpecificInteraction" span="292 12" str=" sinus arrest " code=" 5609005: Sinus arrest (disorder)"/>
<Mention id="M1494" type="SpecificInteraction" span="311 8" str=" AV block" code=" 233917008: Atrioventricular block (disorder)"/>
<Interaction id="I462" type="Pharmacodynamic interaction" trigger="M1456" precipitant="M1461" effect="M1458;M1459"/>
<Interaction id="I463" type="Pharmacodynamic interaction" trigger="M1456" precipitant="M1466" effect="M1458;M1459"/>
<Interaction id="I464" type="Pharmacodynamic interaction" trigger="M1456" precipitant="M1471" effect="M1458;M1459"/>
<Interaction id="I465" type="Pharmacodynamic interaction" trigger="M1456" precipitant="M1476" effect="M1458;M1459"/>
<Interaction id="I466" type="Pharmacodynamic interaction" trigger="M1456" precipitant="M1481" effect="M1458;M1459"/>
<Interaction id="I467" type="Pharmacodynamic interaction" trigger="M1456" precipitant="M1486" effect="M1458;M1459"/>
<Interaction id="I468" type="Pharmacodynamic interaction" trigger="M1456" precipitant="M1491" effect="M1458;M1459"/>
<Interaction id="I469" type="Pharmacodynamic interaction" trigger="M1490" precipitant="M1461" effect="M1492;M1493;M1494"/>
<Interaction id="I470" type="Pharmacodynamic interaction" trigger="M1490" precipitant="M1466" effect="M1492;M1493;M1494"/>
<Interaction id="I471" type="Pharmacodynamic interaction" trigger="M1490" precipitant="M1471" effect="M1492;M1493;M1494"/>
<Interaction id="I472" type="Pharmacodynamic interaction" trigger="M1490" precipitant="M1476" effect="M1492;M1493;M1494"/>
<Interaction id="I473" type="Pharmacodynamic interaction" trigger="M1490" precipitant="M1481" effect="M1492;M1493;M1494"/>
<Interaction id="I474" type="Pharmacodynamic interaction" trigger="M1490" precipitant="M1486" effect="M1492;M1493;M1494"/>
<Interaction id="I475" type="Pharmacodynamic interaction" trigger="M1490" precipitant="M1491" effect="M1492;M1493;M1494"/>
</Sentence>
<Sentence id="441" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Drugs that slow heart rate : Concomitant use of drugs with depressant effects on the sinus and AV node ( e.g. , digoxin , beta blockers , verapamil , diltiazem , ivabradine , clonidine ) can potentiate the electrophysiologic and hemodynamic effects of amiodarone , resulting in bradycardia , sinus arrest , and AV block .</SentenceText>
<Mention id="M1519" type="Trigger" span="191 10;70 7" str="potentiate | effects"/>
<Mention id="M1524" type="Precipitant" span="122 13" str="beta blockers" code="N0000175556"/>
<Mention id="M1521" type="SpecificInteraction" span="206 18;70 7" str="electrophysiologic | effects " code="NO MAP"/>
<Mention id="M1522" type="SpecificInteraction" span="229 19" str=" hemodynamic effects" code=""/>
<Mention id="M1529" type="Precipitant" span="175 9" str="clonidine" code="N0000006505"/>
<Mention id="M1534" type="Precipitant" span="112 7" str="digoxin" code="N0000005903"/>
<Mention id="M1539" type="Precipitant" span="150 9" str="diltiazem" code="N0000006682"/>
<Mention id="M1544" type="Precipitant" span="48 54" str="drugs with depressant effects on the sinus and AV node" code="NO MAP"/>
<Mention id="M1549" type="Precipitant" span="162 10" str="ivabradine" code="N0000191553"/>
<Mention id="M1554" type="Precipitant" span="138 9" str="verapamil" code="N0000007093"/>
<Mention id="M1553" type="Trigger" span="265 12" str="resulting in"/>
<Mention id="M1555" type="SpecificInteraction" span="278 11" str="bradycardia " code="48867003: Bradycardia (finding)"/>
<Mention id="M1556" type="SpecificInteraction" span="292 12" str=" sinus arrest " code=" 5609005: Sinus arrest (disorder)"/>
<Mention id="M1557" type="SpecificInteraction" span="311 8" str=" AV block" code=" 233917008: Atrioventricular block (disorder)"/>
<Interaction id="I476" type="Pharmacodynamic interaction" trigger="M1519" precipitant="M1524" effect="M1521;M1522"/>
<Interaction id="I477" type="Pharmacodynamic interaction" trigger="M1519" precipitant="M1529" effect="M1521;M1522"/>
<Interaction id="I478" type="Pharmacodynamic interaction" trigger="M1519" precipitant="M1534" effect="M1521;M1522"/>
<Interaction id="I479" type="Pharmacodynamic interaction" trigger="M1519" precipitant="M1539" effect="M1521;M1522"/>
<Interaction id="I480" type="Pharmacodynamic interaction" trigger="M1519" precipitant="M1544" effect="M1521;M1522"/>
<Interaction id="I481" type="Pharmacodynamic interaction" trigger="M1519" precipitant="M1549" effect="M1521;M1522"/>
<Interaction id="I482" type="Pharmacodynamic interaction" trigger="M1519" precipitant="M1554" effect="M1521;M1522"/>
<Interaction id="I483" type="Pharmacodynamic interaction" trigger="M1553" precipitant="M1524" effect="M1555;M1556;M1557"/>
<Interaction id="I484" type="Pharmacodynamic interaction" trigger="M1553" precipitant="M1529" effect="M1555;M1556;M1557"/>
<Interaction id="I485" type="Pharmacodynamic interaction" trigger="M1553" precipitant="M1534" effect="M1555;M1556;M1557"/>
<Interaction id="I486" type="Pharmacodynamic interaction" trigger="M1553" precipitant="M1539" effect="M1555;M1556;M1557"/>
<Interaction id="I487" type="Pharmacodynamic interaction" trigger="M1553" precipitant="M1544" effect="M1555;M1556;M1557"/>
<Interaction id="I488" type="Pharmacodynamic interaction" trigger="M1553" precipitant="M1549" effect="M1555;M1556;M1557"/>
<Interaction id="I489" type="Pharmacodynamic interaction" trigger="M1553" precipitant="M1554" effect="M1555;M1556;M1557"/>
</Sentence>
<Sentence id="441" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Drugs that slow heart rate : Concomitant use of drugs with depressant effects on the sinus and AV node ( e.g. , digoxin , beta blockers , verapamil , diltiazem , ivabradine , clonidine ) can potentiate the electrophysiologic and hemodynamic effects of amiodarone , resulting in bradycardia , sinus arrest , and AV block .</SentenceText>
<Mention id="M1582" type="Trigger" span="191 10;70 7" str="potentiate | effects"/>
<Mention id="M1587" type="Precipitant" span="122 13" str="beta blockers" code="N0000175556"/>
<Mention id="M1584" type="SpecificInteraction" span="206 18;70 7" str="electrophysiologic | effects " code="NO MAP"/>
<Mention id="M1585" type="SpecificInteraction" span="229 19" str=" hemodynamic effects" code=""/>
<Mention id="M1592" type="Precipitant" span="175 9" str="clonidine" code="N0000006505"/>
<Mention id="M1597" type="Precipitant" span="112 7" str="digoxin" code="N0000005903"/>
<Mention id="M1602" type="Precipitant" span="150 9" str="diltiazem" code="N0000006682"/>
<Mention id="M1607" type="Precipitant" span="48 54" str="drugs with depressant effects on the sinus and AV node" code="NO MAP"/>
<Mention id="M1612" type="Precipitant" span="162 10" str="ivabradine" code="N0000191553"/>
<Mention id="M1617" type="Precipitant" span="138 9" str="verapamil" code="N0000007093"/>
<Mention id="M1616" type="Trigger" span="265 12" str="resulting in"/>
<Mention id="M1618" type="SpecificInteraction" span="278 11" str="bradycardia " code="48867003: Bradycardia (finding)"/>
<Mention id="M1619" type="SpecificInteraction" span="292 12" str=" sinus arrest " code=" 5609005: Sinus arrest (disorder)"/>
<Mention id="M1620" type="SpecificInteraction" span="311 8" str=" AV block" code=" 233917008: Atrioventricular block (disorder)"/>
<Interaction id="I490" type="Pharmacodynamic interaction" trigger="M1582" precipitant="M1587" effect="M1584;M1585"/>
<Interaction id="I491" type="Pharmacodynamic interaction" trigger="M1582" precipitant="M1592" effect="M1584;M1585"/>
<Interaction id="I492" type="Pharmacodynamic interaction" trigger="M1582" precipitant="M1597" effect="M1584;M1585"/>
<Interaction id="I493" type="Pharmacodynamic interaction" trigger="M1582" precipitant="M1602" effect="M1584;M1585"/>
<Interaction id="I494" type="Pharmacodynamic interaction" trigger="M1582" precipitant="M1607" effect="M1584;M1585"/>
<Interaction id="I495" type="Pharmacodynamic interaction" trigger="M1582" precipitant="M1612" effect="M1584;M1585"/>
<Interaction id="I496" type="Pharmacodynamic interaction" trigger="M1582" precipitant="M1617" effect="M1584;M1585"/>
<Interaction id="I497" type="Pharmacodynamic interaction" trigger="M1616" precipitant="M1587" effect="M1618;M1619;M1620"/>
<Interaction id="I498" type="Pharmacodynamic interaction" trigger="M1616" precipitant="M1592" effect="M1618;M1619;M1620"/>
<Interaction id="I499" type="Pharmacodynamic interaction" trigger="M1616" precipitant="M1597" effect="M1618;M1619;M1620"/>
<Interaction id="I500" type="Pharmacodynamic interaction" trigger="M1616" precipitant="M1602" effect="M1618;M1619;M1620"/>
<Interaction id="I501" type="Pharmacodynamic interaction" trigger="M1616" precipitant="M1607" effect="M1618;M1619;M1620"/>
<Interaction id="I502" type="Pharmacodynamic interaction" trigger="M1616" precipitant="M1612" effect="M1618;M1619;M1620"/>
<Interaction id="I503" type="Pharmacodynamic interaction" trigger="M1616" precipitant="M1617" effect="M1618;M1619;M1620"/>
</Sentence>
<Sentence id="441" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Drugs that slow heart rate : Concomitant use of drugs with depressant effects on the sinus and AV node ( e.g. , digoxin , beta blockers , verapamil , diltiazem , ivabradine , clonidine ) can potentiate the electrophysiologic and hemodynamic effects of amiodarone , resulting in bradycardia , sinus arrest , and AV block .</SentenceText>
<Mention id="M1645" type="Trigger" span="191 10;70 7" str="potentiate | effects"/>
<Mention id="M1650" type="Precipitant" span="122 13" str="beta blockers" code="N0000175556"/>
<Mention id="M1647" type="SpecificInteraction" span="206 18;70 7" str="electrophysiologic | effects " code="NO MAP"/>
<Mention id="M1648" type="SpecificInteraction" span="229 19" str=" hemodynamic effects" code=""/>
<Mention id="M1655" type="Precipitant" span="175 9" str="clonidine" code="N0000006505"/>
<Mention id="M1660" type="Precipitant" span="112 7" str="digoxin" code="N0000005903"/>
<Mention id="M1665" type="Precipitant" span="150 9" str="diltiazem" code="N0000006682"/>
<Mention id="M1670" type="Precipitant" span="48 54" str="drugs with depressant effects on the sinus and AV node" code="NO MAP"/>
<Mention id="M1675" type="Precipitant" span="162 10" str="ivabradine" code="N0000191553"/>
<Mention id="M1680" type="Precipitant" span="138 9" str="verapamil" code="N0000007093"/>
<Mention id="M1679" type="Trigger" span="265 12" str="resulting in"/>
<Mention id="M1681" type="SpecificInteraction" span="278 11" str="bradycardia " code="48867003: Bradycardia (finding)"/>
<Mention id="M1682" type="SpecificInteraction" span="292 12" str=" sinus arrest " code=" 5609005: Sinus arrest (disorder)"/>
<Mention id="M1683" type="SpecificInteraction" span="311 8" str=" AV block" code=" 233917008: Atrioventricular block (disorder)"/>
<Interaction id="I504" type="Pharmacodynamic interaction" trigger="M1645" precipitant="M1650" effect="M1647;M1648"/>
<Interaction id="I505" type="Pharmacodynamic interaction" trigger="M1645" precipitant="M1655" effect="M1647;M1648"/>
<Interaction id="I506" type="Pharmacodynamic interaction" trigger="M1645" precipitant="M1660" effect="M1647;M1648"/>
<Interaction id="I507" type="Pharmacodynamic interaction" trigger="M1645" precipitant="M1665" effect="M1647;M1648"/>
<Interaction id="I508" type="Pharmacodynamic interaction" trigger="M1645" precipitant="M1670" effect="M1647;M1648"/>
<Interaction id="I509" type="Pharmacodynamic interaction" trigger="M1645" precipitant="M1675" effect="M1647;M1648"/>
<Interaction id="I510" type="Pharmacodynamic interaction" trigger="M1645" precipitant="M1680" effect="M1647;M1648"/>
<Interaction id="I511" type="Pharmacodynamic interaction" trigger="M1679" precipitant="M1650" effect="M1681;M1682;M1683"/>
<Interaction id="I512" type="Pharmacodynamic interaction" trigger="M1679" precipitant="M1655" effect="M1681;M1682;M1683"/>
<Interaction id="I513" type="Pharmacodynamic interaction" trigger="M1679" precipitant="M1660" effect="M1681;M1682;M1683"/>
<Interaction id="I514" type="Pharmacodynamic interaction" trigger="M1679" precipitant="M1665" effect="M1681;M1682;M1683"/>
<Interaction id="I515" type="Pharmacodynamic interaction" trigger="M1679" precipitant="M1670" effect="M1681;M1682;M1683"/>
<Interaction id="I516" type="Pharmacodynamic interaction" trigger="M1679" precipitant="M1675" effect="M1681;M1682;M1683"/>
<Interaction id="I517" type="Pharmacodynamic interaction" trigger="M1679" precipitant="M1680" effect="M1681;M1682;M1683"/>
</Sentence>
<Sentence id="442" LabelDrug="Nexterone" section="34073-7">
<SentenceText>During transfer to oral amiodarone, reduce the dose levels of previously administered agents by 30 to 50% several days after the addition of oral amiodarone.</SentenceText>
<Mention id="M1684" type="Trigger" span="36 15" str="reduce the dose"/>
<Mention id="M1685" type="Precipitant" span="24 10" str="amiodarone" code="N0000005761"/>
<Interaction id="I518" type="Pharmacokinetic interaction" trigger="M1684" precipitant="M1685" effect="C54355"/>
</Sentence>
<Sentence id="443" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Effect of amiodarone on other drugs Amiodarone and DEA are inhibitors of P-glycoprotein and certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6 and CYP3A [see Clinical Pharmacology (12.3)].</SentenceText>
</Sentence>
<Sentence id="444" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Effect of other drugs on amiodarone Amiodarone is metabolized to the active metabolite desethylamiodarone (DEA) by the cytochrome P450 (CYP450) enzyme group, specifically CYP3A and CYP2C8.</SentenceText>
</Sentence>
<Sentence id="445" LabelDrug="Nexterone" section="34073-7">
<SentenceText>HMG-CoA Reductase Inhibitors : Limit the dose of simvastatin in patients on amiodarone to 20 mg daily .</SentenceText>
<Mention id="M1688" type="Trigger" span="31 14" str="Limit the dose"/>
<Mention id="M1687" type="Precipitant" span="0 28" str="HMG-CoA Reductase Inhibitors" code="n0000175589"/>
<Mention id="M1689" type="Precipitant" span="49 11" str="simvastatin" code="N0000005842"/>
<Interaction id="I519" type="Unspecified interaction" trigger="M1688" precipitant="M1687"/>
<Interaction id="I520" type="Unspecified interaction" trigger="M1688" precipitant="M1689"/>
</Sentence>
<Sentence id="445" LabelDrug="Nexterone" section="34073-7">
<SentenceText>HMG-CoA Reductase Inhibitors : Limit the dose of simvastatin in patients on amiodarone to 20 mg daily .</SentenceText>
<Mention id="M1692" type="Trigger" span="31 14" str="Limit the dose"/>
<Mention id="M1691" type="Precipitant" span="0 28" str="HMG-CoA Reductase Inhibitors" code="n0000175589"/>
<Mention id="M1693" type="Precipitant" span="49 11" str="simvastatin" code="N0000005842"/>
<Interaction id="I521" type="Unspecified interaction" trigger="M1692" precipitant="M1691"/>
<Interaction id="I522" type="Unspecified interaction" trigger="M1692" precipitant="M1693"/>
</Sentence>
<Sentence id="446" LabelDrug="Nexterone" section="34073-7">
<SentenceText>If digitalis treatment is continued, monitor serum levels closely and observe patients for clinical evidence of toxicity [see Clinical Pharmacology (12.3)].</SentenceText>
</Sentence>
<Sentence id="447" LabelDrug="Nexterone" section="34073-7">
<SentenceText>In general, avoid concomitant use of drugs that prolong the QT interval [see Warnings and Precautions (5.4)].</SentenceText>
<Mention id="M1694" type="Trigger" span="12 5" str="avoid"/>
<Mention id="M1695" type="Precipitant" span="37 34" str="drugs that prolong the QT interval" code="NO MAP"/>
<Interaction id="I523" type="Unspecified interaction" trigger="M1694" precipitant="M1695"/>
</Sentence>
<Sentence id="448" LabelDrug="Nexterone" section="34073-7">
<SentenceText>In general, initiate any added antiarrhythmic drug at a lower than usual dose and monitor the patient carefully.</SentenceText>
<Mention id="M1696" type="Trigger" span="82 7" str="monitor"/>
<Mention id="M1697" type="Precipitant" span="31 19" str="antiarrhythmic drug" code="N0000029121"/>
<Interaction id="I524" type="Unspecified interaction" trigger="M1696" precipitant="M1697"/>
</Sentence>
<Sentence id="449" LabelDrug="Nexterone" section="34073-7">
<SentenceText>In view of the long and variable half-life of amiodarone, potential for drug interactions exists not only with concomitant medication but also with drugs administered after discontinuation of amiodarone [see Clinical Pharmacology (12.3)].</SentenceText>
</Sentence>
<Sentence id="450" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Increased steady-state levels of phenytoin during concomitant therapy with amiodarone have been reported.</SentenceText>
<Mention id="M1698" type="Trigger" span="0 29" str="Increased steady-state levels"/>
<Mention id="M1699" type="Precipitant" span="33 9" str="phenytoin" code="N0000006023"/>
<Interaction id="I525" type="Pharmacokinetic interaction" trigger="M1698" precipitant="M1699" effect="C54611"/>
</Sentence>
<Sentence id="451" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Limit the daily dose of lovastatin to 40 mg. Lower starting and maintenance doses of other CYP3A4 substrates (e.g., atorvastatin) may be required as amiodarone may increase the plasma concentration of these drugs.</SentenceText>
<Mention id="M1703" type="Trigger" span="45 5;76 5" str="Lower | doses "/>
<Mention id="M1704" type="Trigger" span="164 33" str=" increase the plasma concentration"/>
<Mention id="M1702" type="Precipitant" span="116 12" str="atorvastatin" code="N0000022046"/>
<Mention id="M1705" type="Precipitant" span="91 17" str="CYP3A4 substrates" code="NO MAP"/>
<Mention id="M1706" type="Trigger" span="0 20" str="Limit the daily dose"/>
<Mention id="M1707" type="Precipitant" span="24 10" str="lovastatin" code="N0000007106"/>
<Interaction id="I526" type="Pharmacokinetic interaction" trigger="M1703;M1704" precipitant="M1702" effect="C54357"/>
<Interaction id="I527" type="Pharmacokinetic interaction" trigger="M1703;M1704" precipitant="M1705" effect="C54357"/>
<Interaction id="I528" type="Pharmacokinetic interaction" trigger="M1706" precipitant="M1707" effect="C54357"/>
</Sentence>
<Sentence id="451" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Limit the daily dose of lovastatin to 40 mg. Lower starting and maintenance doses of other CYP3A4 substrates (e.g., atorvastatin) may be required as amiodarone may increase the plasma concentration of these drugs.</SentenceText>
<Mention id="M1711" type="Trigger" span="45 5;76 5" str="Lower | doses "/>
<Mention id="M1712" type="Trigger" span="164 33" str=" increase the plasma concentration"/>
<Mention id="M1710" type="Precipitant" span="116 12" str="atorvastatin" code="N0000022046"/>
<Mention id="M1713" type="Precipitant" span="91 17" str="CYP3A4 substrates" code="NO MAP"/>
<Mention id="M1714" type="Trigger" span="0 20" str="Limit the daily dose"/>
<Mention id="M1715" type="Precipitant" span="24 10" str="lovastatin" code="N0000007106"/>
<Interaction id="I529" type="Pharmacokinetic interaction" trigger="M1711;M1712" precipitant="M1710" effect="C54357"/>
<Interaction id="I530" type="Pharmacokinetic interaction" trigger="M1711;M1712" precipitant="M1713" effect="C54357"/>
<Interaction id="I531" type="Pharmacokinetic interaction" trigger="M1714" precipitant="M1715" effect="C54357"/>
</Sentence>
<Sentence id="451" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Limit the daily dose of lovastatin to 40 mg. Lower starting and maintenance doses of other CYP3A4 substrates (e.g., atorvastatin) may be required as amiodarone may increase the plasma concentration of these drugs.</SentenceText>
<Mention id="M1719" type="Trigger" span="45 5;76 5" str="Lower | doses "/>
<Mention id="M1720" type="Trigger" span="164 33" str=" increase the plasma concentration"/>
<Mention id="M1718" type="Precipitant" span="116 12" str="atorvastatin" code="N0000022046"/>
<Mention id="M1721" type="Precipitant" span="91 17" str="CYP3A4 substrates" code="NO MAP"/>
<Mention id="M1722" type="Trigger" span="0 20" str="Limit the daily dose"/>
<Mention id="M1723" type="Precipitant" span="24 10" str="lovastatin" code="N0000007106"/>
<Interaction id="I532" type="Pharmacokinetic interaction" trigger="M1719;M1720" precipitant="M1718" effect="C54357"/>
<Interaction id="I533" type="Pharmacokinetic interaction" trigger="M1719;M1720" precipitant="M1721" effect="C54357"/>
<Interaction id="I534" type="Pharmacokinetic interaction" trigger="M1722" precipitant="M1723" effect="C54357"/>
</Sentence>
<Sentence id="452" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Lower starting and maintenance doses of other CYP3A4 substrates ( e.g. , atorvastatin ) may be required as amiodarone may increase the plasma concentration of these drugs .</SentenceText>
<Mention id="M1726" type="Trigger" span="118 37" str="may increase the plasma concentration"/>
<Mention id="M1725" type="Precipitant" span="73 12" str="atorvastatin" code="N0000022046"/>
<Mention id="M1727" type="Precipitant" span="46 17" str="CYP3A4 substrates" code="NO MAP"/>
<Interaction id="I535" type="Pharmacokinetic interaction" trigger="M1726" precipitant="M1725" effect="C54357"/>
<Interaction id="I536" type="Pharmacokinetic interaction" trigger="M1726" precipitant="M1727" effect="C54357"/>
</Sentence>
<Sentence id="452" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Lower starting and maintenance doses of other CYP3A4 substrates ( e.g. , atorvastatin ) may be required as amiodarone may increase the plasma concentration of these drugs .</SentenceText>
<Mention id="M1730" type="Trigger" span="118 37" str="may increase the plasma concentration"/>
<Mention id="M1729" type="Precipitant" span="73 12" str="atorvastatin" code="N0000022046"/>
<Mention id="M1731" type="Precipitant" span="46 17" str="CYP3A4 substrates" code="NO MAP"/>
<Interaction id="I537" type="Pharmacokinetic interaction" trigger="M1730" precipitant="M1729" effect="C54357"/>
<Interaction id="I538" type="Pharmacokinetic interaction" trigger="M1730" precipitant="M1731" effect="C54357"/>
</Sentence>
<Sentence id="453" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Monitor cyclosporine drug levels and renal function in patients taking both drugs.</SentenceText>
<Mention id="M1732" type="Trigger" span="0 7;52 29" str="Monitor | in patients taking both drugs"/>
<Mention id="M1733" type="Precipitant" span="8 12" str="cyclosporine" code="N0000007346"/>
<Interaction id="I539" type="Unspecified interaction" trigger="M1732" precipitant="M1733"/>
</Sentence>
<Sentence id="454" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Monitor heart rate in patients on amiodarone and concomitant drugs that slow heart rate.</SentenceText>
<Mention id="M1737" type="Trigger" span="0 7" str="Monitor"/>
<Mention id="M1735" type="Precipitant" span="34 10" str="amiodarone" code="N0000005761"/>
<Mention id="M1739" type="SpecificInteraction" span="72 15" str="slow heart rate" code="48867003: Bradycardia (finding)"/>
<Mention id="M1738" type="Precipitant" span="61 26" str="drugs that slow heart rate" code="NO MAP"/>
<Interaction id="I540" type="Pharmacodynamic interaction" trigger="M1737" precipitant="M1735" effect="M1739"/>
<Interaction id="I541" type="Pharmacodynamic interaction" trigger="M1737" precipitant="M1738" effect="M1739"/>
</Sentence>
<Sentence id="454" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Monitor heart rate in patients on amiodarone and concomitant drugs that slow heart rate.</SentenceText>
<Mention id="M1743" type="Trigger" span="0 7" str="Monitor"/>
<Mention id="M1741" type="Precipitant" span="34 10" str="amiodarone" code="N0000005761"/>
<Mention id="M1745" type="SpecificInteraction" span="72 15" str="slow heart rate" code="48867003: Bradycardia (finding)"/>
<Mention id="M1744" type="Precipitant" span="61 26" str="drugs that slow heart rate" code="NO MAP"/>
<Interaction id="I542" type="Pharmacodynamic interaction" trigger="M1743" precipitant="M1741" effect="M1745"/>
<Interaction id="I543" type="Pharmacodynamic interaction" trigger="M1743" precipitant="M1744" effect="M1745"/>
</Sentence>
<Sentence id="455" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Monitor heart rate in patients taking or recently discontinuing amiodarone when starting antiviral treatment .</SentenceText>
<Mention id="M1746" type="Trigger" span="0 7;75 33" str="Monitor | when starting antiviral treatment"/>
<Mention id="M1747" type="Precipitant" span="89 9" str="antiviral" code="N0000029089"/>
<Interaction id="I544" type="Unspecified interaction" trigger="M1746" precipitant="M1747"/>
</Sentence>
<Sentence id="456" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Monitor phenytoin levels in patients taking both drugs.</SentenceText>
</Sentence>
<Sentence id="457" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Patients should avoid grapefruit juice beverages while taking amiodarone because exposure to amiodarone is significantly increased [see Clinical Pharmacology (12.3)].</SentenceText>
<Mention id="M1748" type="Trigger" span="81 8;121 9" str="exposure | increased"/>
<Mention id="M1749" type="Precipitant" span="22 16" str="grapefruit juice" code="n0000164879"/>
<Interaction id="I545" type="Pharmacokinetic interaction" trigger="M1748" precipitant="M1749" effect="C54355"/>
</Sentence>
<Sentence id="458" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Postmarketing cases of symptomatic bradycardia , some requiring pacemaker insertion and at least one fatal , have been reported when ledipasvir/sofosbuvir or sofosbuvir with simeprevir were initiated in patients on amiodarone .</SentenceText>
<Mention id="M1758" type="SpecificInteraction" span="35 11" str="bradycardia" code="48867003: Bradycardia (finding)"/>
<Mention id="M1751" type="Precipitant" span="133 10" str="ledipasvir" code="N0000191095"/>
<Mention id="M1754" type="Precipitant" span="174 10" str="simeprevir" code="N0000189533"/>
<Mention id="M1757" type="Precipitant" span="144 10" str="sofosbuvir" code="N0000189539"/>
<Interaction id="I546" type="Pharmacodynamic interaction" trigger="M1758" precipitant="M1751" effect="M1758"/>
<Interaction id="I547" type="Pharmacodynamic interaction" trigger="M1758" precipitant="M1754" effect="M1758"/>
<Interaction id="I548" type="Pharmacodynamic interaction" trigger="M1758" precipitant="M1757" effect="M1758"/>
</Sentence>
<Sentence id="458" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Postmarketing cases of symptomatic bradycardia , some requiring pacemaker insertion and at least one fatal , have been reported when ledipasvir/sofosbuvir or sofosbuvir with simeprevir were initiated in patients on amiodarone .</SentenceText>
<Mention id="M1767" type="SpecificInteraction" span="35 11" str="bradycardia" code="48867003: Bradycardia (finding)"/>
<Mention id="M1760" type="Precipitant" span="133 10" str="ledipasvir" code="N0000191095"/>
<Mention id="M1763" type="Precipitant" span="174 10" str="simeprevir" code="N0000189533"/>
<Mention id="M1766" type="Precipitant" span="144 10" str="sofosbuvir" code="N0000189539"/>
<Interaction id="I549" type="Pharmacodynamic interaction" trigger="M1767" precipitant="M1760" effect="M1767"/>
<Interaction id="I550" type="Pharmacodynamic interaction" trigger="M1767" precipitant="M1763" effect="M1767"/>
<Interaction id="I551" type="Pharmacodynamic interaction" trigger="M1767" precipitant="M1766" effect="M1767"/>
</Sentence>
<Sentence id="458" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Postmarketing cases of symptomatic bradycardia , some requiring pacemaker insertion and at least one fatal , have been reported when ledipasvir/sofosbuvir or sofosbuvir with simeprevir were initiated in patients on amiodarone .</SentenceText>
<Mention id="M1776" type="SpecificInteraction" span="35 11" str="bradycardia" code="48867003: Bradycardia (finding)"/>
<Mention id="M1769" type="Precipitant" span="133 10" str="ledipasvir" code="N0000191095"/>
<Mention id="M1772" type="Precipitant" span="174 10" str="simeprevir" code="N0000189533"/>
<Mention id="M1775" type="Precipitant" span="144 10" str="sofosbuvir" code="N0000189539"/>
<Interaction id="I552" type="Pharmacodynamic interaction" trigger="M1776" precipitant="M1769" effect="M1776"/>
<Interaction id="I553" type="Pharmacodynamic interaction" trigger="M1776" precipitant="M1772" effect="M1776"/>
<Interaction id="I554" type="Pharmacodynamic interaction" trigger="M1776" precipitant="M1775" effect="M1776"/>
</Sentence>
<Sentence id="459" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Reduce dose of digoxin by half or discontinue digoxin.</SentenceText>
<Mention id="M1777" type="Trigger" span="0 11;31 14" str="Reduce dose | or discontinue"/>
<Mention id="M1778" type="Precipitant" span="15 7" str="digoxin" code="N0000005903"/>
<Interaction id="I555" type="Unspecified interaction" trigger="M1777" precipitant="M1778"/>
</Sentence>
<Sentence id="460" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Review the continued need for the other antiarrhythmic agent after the effects of amiodarone have been established , and attempt discontinuation see Clinical Pharmacology ( 12.3 ) .</SentenceText>
</Sentence>
<Sentence id="461" LabelDrug="Nexterone" section="34073-7">
<SentenceText>Since the concomitant administration of warfarin with amiodarone increases the INR by 100 % after 3 to 4 days , reduce the dose of the anticoagulant by one-third to one-half , and monitor INR closely .</SentenceText>
<Mention id="M1779" type="Trigger" span="112 15" str="reduce the dose"/>
<Mention id="M1780" type="Precipitant" span="40 8" str="warfarin" code="N0000006403"/>
<Mention id="M1781" type="SpecificInteraction" span="65 17" str="increases the INR" code="313341008:  International Normalized Ratio raised (finding)"/>
<Interaction id="I556" type="Pharmacodynamic interaction" trigger="M1779" precipitant="M1780" effect="M1781"/>
</Sentence>
<Sentence id="462" LabelDrug="Nexterone" section="34073-7">
<SentenceText>The mechanism for this effect is unknown.</SentenceText>
</Sentence>
<Sentence id="463" LabelDrug="Nexterone" section="43685-7">
<SentenceText>Amiodarone inhibits peripheral conversion of thyroxine ( T4 ) to triiodothyronine ( T3 ) and may cause increased T4 levels , decreased T3 levels , and increased levels of inactive reverse T3 ( rT3 ) in clinically euthyroid patients .</SentenceText>
<Mention id="M1782" type="Trigger" span="125 9;116 6" str="decreased | levels"/>
<Mention id="M1783" type="Precipitant" span="65 23" str="triiodothyronine ( T3 )" code="06LU7C9H1V"/>
<Mention id="M1784" type="Trigger" span="103 9;116 6" str="increased | levels"/>
<Mention id="M1785" type="Precipitant" span="45 16" str="thyroxine ( T4 )" code="N0000007632"/>
<Interaction id="I557" type="Pharmacokinetic interaction" trigger="M1782" precipitant="M1783" effect="C54358"/>
<Interaction id="I558" type="Pharmacokinetic interaction" trigger="M1784" precipitant="M1785" effect="C54357"/>
</Sentence>
<Sentence id="463" LabelDrug="Nexterone" section="43685-7">
<SentenceText>Amiodarone inhibits peripheral conversion of thyroxine ( T4 ) to triiodothyronine ( T3 ) and may cause increased T4 levels , decreased T3 levels , and increased levels of inactive reverse T3 ( rT3 ) in clinically euthyroid patients .</SentenceText>
<Mention id="M1786" type="Trigger" span="125 9;116 6" str="decreased | levels"/>
<Mention id="M1787" type="Precipitant" span="65 23" str="triiodothyronine ( T3 )" code="06LU7C9H1V"/>
<Mention id="M1788" type="Trigger" span="103 9;116 6" str="increased | levels"/>
<Mention id="M1789" type="Precipitant" span="45 16" str="thyroxine ( T4 )" code="N0000007632"/>
<Interaction id="I559" type="Pharmacokinetic interaction" trigger="M1786" precipitant="M1787" effect="C54358"/>
<Interaction id="I560" type="Pharmacokinetic interaction" trigger="M1788" precipitant="M1789" effect="C54357"/>
</Sentence>
<Sentence id="464" LabelDrug="Nexterone" section="43685-7">
<SentenceText>Amiodarone is also a potential source of large amounts of inorganic iodine and can cause either hypothyroidism or hyperthyroidism .</SentenceText>
</Sentence>
<Sentence id="465" LabelDrug="Nexterone" section="43685-7">
<SentenceText>Because of the long half-life of amiodarone and its metabolite desethylamiodarone , the potential for adverse reactions or interactions , as well as observed adverse effects , can persist following amiodarone withdrawal .</SentenceText>
</Sentence>
<Sentence id="466" LabelDrug="Nexterone" section="43685-7">
<SentenceText>Like all antiarrhythmic agents , NEXTERONE may cause a worsening of existing arrhythmias or precipitate a new arrhythmia , sometimes leading to fatal outcomes see Adverse Reactions ( 6.2 ) .</SentenceText>
</Sentence>
<Sentence id="467" LabelDrug="Nexterone" section="43685-7">
<SentenceText>Manage hypothyroidism by reducing the dose of or discontinuing NEXTERONE and considering the need for thyroid hormone supplement .</SentenceText>
</Sentence>
<Sentence id="468" LabelDrug="Nexterone" section="43685-7">
<SentenceText>Perform close perioperative monitoring in patients undergoing general anesthesia who are on amiodarone therapy as they may be more sensitive to the myocardial depressant and conduction defects of halogenated inhalational anesthetics .</SentenceText>
<Mention id="M1790" type="Trigger" span="126 14" str="more sensitive"/>
<Mention id="M1791" type="Precipitant" span="196 36" str="halogenated inhalational anesthetics" code="NO MAP"/>
<Mention id="M1792" type="SpecificInteraction" span="148 21" str="myocardial depressant " code="NO MAP"/>
<Mention id="M1793" type="SpecificInteraction" span="174 18" str=" conduction defects" code=""/>
<Interaction id="I561" type="Pharmacodynamic interaction" trigger="M1790" precipitant="M1791" effect="M1792;M1793"/>
</Sentence>
<Sentence id="469" LabelDrug="Nexterone" section="43685-7">
<SentenceText>Reserve the combination of amiodarone with other antiarrhythmic therapies that prolong the QTc to patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent .</SentenceText>
</Sentence>
<Sentence id="470" LabelDrug="Nexterone" section="43685-7">
<SentenceText>Since NEXTERONE contains dextrose , patients with allergy to corn or corn products are at risk for allergic reaction .</SentenceText>
</Sentence>
</Sentences>
<LabelInteractions><LabelInteraction type="Pharmacodynamic interaction" precipitant="azole antifungals" precipitantCode="N0000175487" effect="31722008: Torsades de pointes (disorder)"/>
<LabelInteraction type="Unspecified interaction" precipitant="azole antifungals" precipitantCode="N0000175487"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="fluoroquinolone | antibiotics" precipitantCode="N0000011190" effect="31722008: Torsades de pointes (disorder)"/>
<LabelInteraction type="Unspecified interaction" precipitant="fluoroquinolone | antibiotics" precipitantCode="N0000011190"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="grapefruit juice" precipitantCode="n0000164879" effect="C54355"/>
<LabelInteraction type="Unspecified interaction" precipitant="grapefruit juice" precipitantCode="n0000164879"/>
<LabelInteraction type="Unspecified interaction" precipitant="inducers of cyp450 enzymes" precipitantCode="n0000185505"/>
<LabelInteraction type="Unspecified interaction" precipitant="inhibitors | of cyp450 enzymes" precipitantCode="n0000182136"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="macrolide antibiotics" precipitantCode="N0000175431" effect="31722008: Torsades de pointes (disorder)"/>
<LabelInteraction type="Unspecified interaction" precipitant="macrolide antibiotics" precipitantCode="N0000175431"/>
<LabelInteraction type="Unspecified interaction" precipitant="p-glycoprotein" precipitantCode="n0000011430"/>
<LabelInteraction type="Unspecified interaction" precipitant="protease inhibitors" precipitantCode="N0000000076"/>
<LabelInteraction type="Unspecified interaction" precipitant="st.   john s wort" precipitantCode="N0000022261"/>
<LabelInteraction type="Unspecified interaction" precipitant="substrates | of cyp450 enzymes" precipitantCode="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="antiarrhythmics" precipitantCode="N0000029121" effect="31722008: Torsades de pointes (disorder)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="cyp2c8 | inducers" precipitantCode="n0000187063" effect="C54356"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="cyp2c8 | inhibitors" precipitantCode="n0000187062" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="cyp3a | inducers" precipitantCode="n0000190118" effect="C54356"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="cyp3a | inhibitors" precipitantCode="n0000191001" effect="C54355"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="drugs prolonging the qt interval" precipitantCode="NO MAP" effect="31722008: Torsades de pointes (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="halogenated inhalation anesthetic agents" precipitantCode="N0000029139" effect="31722008: Torsades de pointes (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="lithium" precipitantCode="N0000147892" effect="31722008: Torsades de pointes (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="phenothiazines" precipitantCode="N0000175746" effect="31722008: Torsades de pointes (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="tricyclic antidepressants" precipitantCode="N0000029148" effect="31722008: Torsades de pointes (disorder)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="flecainide" precipitantCode="N0000006966" effect="C54357"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="procainamide" precipitantCode="N0000005813" effect="C54357"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="quinidine" precipitantCode="N0000007728" effect="C54357"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="cyp2c9 | substrate" precipitantCode="NO MAP" effect=" 131148009: Bleeding (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="cyp2c9 | substrate" precipitantCode="NO MAP" effect="64779008: Blood coagulation disorder (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="cyp3a substrate" precipitantCode="NO MAP" effect=" 131148009: Bleeding (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="cyp3a substrate" precipitantCode="NO MAP" effect="166717003: Serum creatinine raised (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="cyp3a substrate" precipitantCode="NO MAP" effect="64779008: Blood coagulation disorder (disorder)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="cyp3a substrate" precipitantCode="NO MAP" effect="C54357"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="warfarin" precipitantCode="N0000006403" effect=" 131148009: Bleeding (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="warfarin" precipitantCode="N0000006403" effect="313341008:  International Normalized Ratio raised (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="warfarin" precipitantCode="N0000006403" effect="64779008: Blood coagulation disorder (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="cyclosporine" precipitantCode="N0000007346" effect="166717003: Serum creatinine raised (finding)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="cyclosporine" precipitantCode="N0000007346" effect="C54357"/>
<LabelInteraction type="Unspecified interaction" precipitant="cyclosporine" precipitantCode="N0000007346"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="digoxin" precipitantCode="N0000005903" effect=" 233917008: Atrioventricular block (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="digoxin" precipitantCode="N0000005903" effect=" 5609005: Sinus arrest (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="digoxin" precipitantCode="N0000005903" effect="48867003: Bradycardia (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="digoxin" precipitantCode="N0000005903" effect="NO MAP"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="digoxin" precipitantCode="N0000005903" effect="C54357"/>
<LabelInteraction type="Unspecified interaction" precipitant="digoxin" precipitantCode="N0000005903"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="beta blockers" precipitantCode="N0000175556" effect=" 233917008: Atrioventricular block (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="beta blockers" precipitantCode="N0000175556" effect=" 5609005: Sinus arrest (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="beta blockers" precipitantCode="N0000175556" effect="48867003: Bradycardia (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="beta blockers" precipitantCode="N0000175556" effect="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="clonidine" precipitantCode="N0000006505" effect=" 233917008: Atrioventricular block (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="clonidine" precipitantCode="N0000006505" effect=" 5609005: Sinus arrest (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="clonidine" precipitantCode="N0000006505" effect="48867003: Bradycardia (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="clonidine" precipitantCode="N0000006505" effect="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="diltiazem" precipitantCode="N0000006682" effect=" 233917008: Atrioventricular block (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="diltiazem" precipitantCode="N0000006682" effect=" 5609005: Sinus arrest (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="diltiazem" precipitantCode="N0000006682" effect="48867003: Bradycardia (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="diltiazem" precipitantCode="N0000006682" effect="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="drugs with depressant effects on the sinus and av node" precipitantCode="NO MAP" effect=" 233917008: Atrioventricular block (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="drugs with depressant effects on the sinus and av node" precipitantCode="NO MAP" effect=" 5609005: Sinus arrest (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="drugs with depressant effects on the sinus and av node" precipitantCode="NO MAP" effect="48867003: Bradycardia (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="drugs with depressant effects on the sinus and av node" precipitantCode="NO MAP" effect="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="ivabradine" precipitantCode="N0000191553" effect=" 233917008: Atrioventricular block (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="ivabradine" precipitantCode="N0000191553" effect=" 5609005: Sinus arrest (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="ivabradine" precipitantCode="N0000191553" effect="48867003: Bradycardia (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="ivabradine" precipitantCode="N0000191553" effect="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="verapamil" precipitantCode="N0000007093" effect=" 233917008: Atrioventricular block (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="verapamil" precipitantCode="N0000007093" effect=" 5609005: Sinus arrest (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="verapamil" precipitantCode="N0000007093" effect="48867003: Bradycardia (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="verapamil" precipitantCode="N0000007093" effect="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="amiodarone" precipitantCode="N0000005761" effect="48867003: Bradycardia (finding)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="amiodarone" precipitantCode="N0000005761" effect="C54355"/>
<LabelInteraction type="Unspecified interaction" precipitant="hmg-coa reductase inhibitors" precipitantCode="n0000175589"/>
<LabelInteraction type="Unspecified interaction" precipitant="simvastatin" precipitantCode="N0000005842"/>
<LabelInteraction type="Unspecified interaction" precipitant="drugs that prolong the qt interval" precipitantCode="NO MAP"/>
<LabelInteraction type="Unspecified interaction" precipitant="antiarrhythmic drug" precipitantCode="N0000029121"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="phenytoin" precipitantCode="N0000006023" effect="C54611"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="atorvastatin" precipitantCode="N0000022046" effect="C54357"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="cyp3a4 substrates" precipitantCode="NO MAP" effect="C54357"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="lovastatin" precipitantCode="N0000007106" effect="C54357"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="drugs that slow heart rate" precipitantCode="NO MAP" effect="48867003: Bradycardia (finding)"/>
<LabelInteraction type="Unspecified interaction" precipitant="antiviral" precipitantCode="N0000029089"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="ledipasvir" precipitantCode="N0000191095" effect="48867003: Bradycardia (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="simeprevir" precipitantCode="N0000189533" effect="48867003: Bradycardia (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="sofosbuvir" precipitantCode="N0000189539" effect="48867003: Bradycardia (finding)"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="triiodothyronine ( t3 )" precipitantCode="06LU7C9H1V" effect="C54358"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="thyroxine ( t4 )" precipitantCode="N0000007632" effect="C54357"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="halogenated inhalational anesthetics" precipitantCode="NO MAP" effect="NO MAP"/>

</LabelInteractions></Label>